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Abstract  
It is well-established that in vitro differentiation of Embryonic Stem Cells (ESCs) 
can recapitulate embryonic development. In this project a novel, step-wise, 
serum-free differentiation system was developed using specific recombinant 
growth factors for investigating the differentiation of mESCs, through formation 
of a primitive streak-like population expressing Brachyury and specification of a 
subpopulation of mesodermal progenitors expressing both paraxial and lateral 
plate mesoderm markers. These cells subsequently differentiated efficiently in 
monolayer cultures to chondrocyte and osteoblast lineages marked by cell 
morphology, Alcian blue/ALP staining as well as by chondrocyte and osteoblast-
specific gene expression. 
The role of the Rho kinase (ROCK) pathway in cartilage and bone cell 
differentiation is controversial.  Exposure of ESC cultures to the ROCK inhibitor, 
Y-27632, at mesoderm enrichment and/or monolayer differentiation phases 
revealed that continuous exposure to Y27632 modulated differentiation in a 
developmental phase-dependent manner, with up to a 7-fold and 2-fold 
increase in chondrogenesis and osteogenesis, respectively.  In contrast, 
temporal exposure of Y27632 favoured chondrogenic over osteogenic 
differentiation. This was confirmed by qPCR analysis of chondrocyte (Sox9, 
Sox5, Acan, Coll II, Col X) and osteoblast (Runx2, Osx, ALP, BSP, OC)-specific 
gene expression. Furthermore, temporal exposure to FGF2 and BMP4 together 
with phase-specific addition of Y-27632 enhanced differentiation/expansion of 
hypertrophic chondrocytes and mineralising osteoblasts. Finally, renal capsule 
grafting studies showed that the mesoderm-derived ESCs mimicked 
endochondral ossification, which was enhanced by Y27632 treatment. 
This study established a novel ESC model system, which generated defined, 
manipulatable and expandable chondro-osteoprogenitor populations that will 
provide insights into the molecular basis of bone/cartilage development.  
Moreover, a phase-dependent inhibition of ROCK signalling modulated early 
chondro-osteoprogenitor lineage commitment and enhanced cartilage and bone 
formation. These studies provide a novel targetable pathway for generating 
specific populations for potential bone and cartilage tissue repair and 
replacement. 
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Abbreviations  
ATDC5          Chondrogenic cell line  
 
BMP              Bone morphogenic protein 
 
Bry                Brachyury 
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Abbreviations (cont’d) 
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Gata-1        GATA-binding factor 1 
 
Nkx2.5        Homeobox protein Nkx-2.5 
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Tbx18         T-box18 
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Tbx6           T-box 6 
 
Meox1        Mesenchyme homeobox 1 
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Prrx1          Paired related homeobox 1 
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1.1 Part A 
1.2 Embryonic development of cartilage and bone  
 
Skeletogenesis in higher vertebrates is a process which involves the distinctive 
development of cartilage, bone and joint tissues (Olsen et al. 2000).  Both 
cartilage and bone tissues are characterised by distinct cellular and extracellular 
matrix components (Yang 2013).  However, the process of embryonic 
development of cartilage and bone has similarities, which involves three 
phases: first, the migration of osteogenic/chondrogenic precursors to the site of 
future skeletogenesis; second, the mesenchymal–epithelial interactions that 
leads to condensation (or aggregation) of the mesenchymal cells and finally the 
third phase of mesenchymal cells differentiation into either the chondrogenic or 
osteogenic lineages (Olsen et al. 2000; Lefebvre & Bhattaram 2010;Yang 
2013).  
 
The osteogenic/chondrogenic precursor cells (or skeletogenic cells) arise from 
mesenchymal-type stem cells (MSCs) (Olsen et al. 2000; Lefebvre & Bhattaram 
2010)  that are formed from embryonic cells known as neural crest or 
mesoderm cells  (Gilbert, 2000; Keller & Nieden, 2011; Olsen et al., 2000).  The 
majority of the skeleton is formed of mesoderm-derived cartilage and bone.  
Mesodermal cartilage and bone develop from paraxial mesoderm and lateral 
plate mesoderm.  Paraxial mesoderm gives rise to vertebrae, ribs, while lateral 
plate mesoderm, gives rise to limb joint and growth plate bones (Keller & 
Nieden 2011) as will be discussed further in the next section 1.3.   On the other 
hand, the craniofacial skeleton largely develops from neural crest cells ( Jiang 
et al. 2002; Santagati & Rijli 2003; Morriss-Kay & Wilkie 2005; Keller & Nieden 
2011) (Fig.1.1).  The next section will describe the embryonic development of 
both paraxial mesoderm and lateral plate mesoderm development.  
Introduction: part A 











Figure 1.1: A schematic diagram showing the development of sclerotome and 
limb bud mesenchyme cells, which are the skeletal precursors of cartilage and 
bone tissues. 
A) A cross-section of a gastrulating mouse embryo (after gastrulation at day 8 of 
development) showing the 3 germ layers; ectoderm (blue), mesoderm (red), 
and endoderm (orange). B) A cross section of the embryo showing the 
mesoderm derivatives in a gastrulating embryo. In addition, the migration of 
neural crest cells, following neuralectoderm formation, the origin of craniofacial 
bone (modified from Gilbert 2000). 
 
1.3 Embryonic development of mesoderm-derived cartilage and 
bone  
 
Embryogenesis involves a process called gastrulation during which the 
formation of three germ layers occurs; ectoderm, mesoderm and endoderm and 
form the body plane.  The beginning of gastrulation is marked by the formation 
of the primitive streak (PS) at E6 of mouse development (Tam & Behringer 
1997; Arnold & Robertson 2009).  The PS is a transient structure, located at the 
posterior part of the embryo, through which epiblast cells ingress and migrate, 
and differentiate to mesoderm and endoderm (Gilbert 2000).  Ectodermal cells 
are located in the anterior part of the embryo and do not migrate through the PS 
(Tam & Beddington 1987).  The significance of the formation of the PS and the 
3 germ layers have been implemented in the in vitro differentiation of ESC, and 
this issue will be further discussed in section 1.10.1. 
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1.3.1 Mesoderm  
Mesoderm is the middle germ layer that occupies an intermediate position 
between the ectoderm and endoderm germ layers (Gilbert 2000).  The 
mesoderm is divided into 4 regions; axial mesoderm (chordal), paraxial 
mesoderm, which forms along side the notochord “axial mesoderm”, (somatic 
dorsal), intermediate mesoderm, and lateral plate mesoderm (away from the 
notochord) (Gilbert 2000).  As mentioned in the previous section, MSCs 
undergo a stage of condensation then differentiate to either cartilage or bone, 
which is predetermined by a stage of skeletal patterning and positional 
identification of the axial and appendicular skeleton (Olsen et al. 2000;Yang 
2013) (Fig.1.2).   
1.3.2 Paraxial mesoderm  
 
Axial bone and ribs (most of the axial skeleton) develop from paraxial 
mesoderm, which gives rise to somites (precursors of vertebrae) in a process 
called somitogenesis (Gilbert 2000).  The anterior part of paraxial mesoderm 
(un-segmented mesoderm is known as ”presomitic mesoderm (PSM)”), which 
develops into somites (segmented mesoderm) (Kulesa & Fraser 2002a; Tam & 
Tan 1992).  The segmentation of the somites occurs on both sides of the neural 
tube.  Later on, mesenchymal somites differentiate into dermomyotomes and 
sclerotomes (Aulehla & Pourquié 2010).  Each somite is comprised of two parts; 
rostal (anterior) and caudal (posterior) which are determined prior to somite 
development (Saga & Takeda 2001).  The mechanism of differentiation occurs 
under the control of various signalling pathways (Aulehla & Pourquié 2010).  
Somite formation is regulated in part by the transcription factors paraxis (Tcf15) 
and Tbx18, at which stage their expression coincides with paraxial mesoderm 
induction (Burgess et al. 1996; Bussen et al. 2004).  Tbx6 is required for PSM 
specification (Chapman & Papaioannou 1998) while Msgn1 is required for pre-
somitic mesoderm maturation.  Later on, specification of the sclerotome from 
somites is marked by the expression of Meox1 (Rodrigo 2003; Rodrigo et al. 
2004; Mankoo et al. 2003), Pax1 (Dietrich et al. 1993; Rodrigo 2003) and 
Nkx3.2 (also known as Bapx1) (Tribioli et al. 1997; Tribioli & Lufkin 1999; 
Hartmann 2009) (Fig.1.2). 
Introduction: part A 
- 23 - 
 
1.3.3 Lateral plate mesoderm  
 
The lateral plate mesoderm gives rise to craniofacial skeletal structures, the 
limb skeletal elements (appendicular skeleton), the sternum (part of the axial 
skeleton), and non-skeletal structures such as the hematopoietic and 
cardiovascular tissues (Lawson et al. 1991; Kinder et al. 1999; Olsen et al. 
2000). The lateral plate mesoderm consists of dorsal somatic and ventral 
splanchnic layers. It lines the paraxial mesoderm as two mesenchymal sheets 
separated by the coelom (Fig. 1.1A). The splanchnic layer surrounds the 
endodermal gut tube and forms smooth muscle and connective tissue of the 
digestive organs. Both Mesp1 (Saga et al. 1996; Saga et al. 1999; Takahashi et 
al. 2005) and Foxf1a (Mahlapuu et al. 2001; Ormestad et al. 2004) are two of 
the characteristic markers of lateral plate mesoderm (Fig. 1.2).  Appendicular 
bone develops from limb mesenchyme, originating from somatic lateral plate 
mesoderm (Aulehla & Pourquié 2010; Olsen et al. 2000; Yamaguchi et al. 
1993). During limb bud development, mesenchymal cells are controlled by the 
apical ectodermal ridge (AER)–FGF reciprocal signalling.  The mechanism of 
patterning and differentiation occurs under the control of various signalling 
pathways: Wnt, BMP and FGF (Aulehla & Pourquié 2010; Yu & Ornitz 2008).   
Prx1 has been demonstrated, by using a Prx1-cre transgene, to mark limb bud 
mesenchymal cells, which are undifferentiated and later on give rise to a 
subpopulation of Sox9-expressing cells.  Prx1 is also expressed in the 
periosteum later in development (Martin & Olson 2000)  (Fig.1.2). 
In conclusion, mesoderm-derived cartilage and bone tissue development arise 
from either paraxial or lateral plate mesoderm formation depending on 
predetermined stage of skeletal patterning and positional identification.  Various 
signalling pathways control the process of mesenchymal progenitor cells of both 
cartilage and bone lineages. This process is also marked by expression of 
several gene markers.  These signalling pathways and gene markers will be of 
eminent importance for studying the in vitro ESC-derived chondrocyte and 
osteoblast differentiation, thus recapitulating embryonic development as will be 
discussed in sections 1.5 and 1.6. 
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Figure 1.2: A schematic diagram showing selected transcriptional regulation of   
sclerotome and limb bud mesenchyme cells development, which are the 
skeletal precursors of cartilage and bone cells. 
A) A 7.5 mouse GFP-Bry embryo expressing GPF in the primitive streak (PS), 
with the anterior (ant), middle (mid), and posterior (post) regions of the PS 
shown in white boxes (Gadue et al. 2006).  B) Bry, Pdgfrα, and Flk-1 are 
expressed during early/multipotent mesoderm differentiation. C) Tcf15, Tbx18, 
Meox1, Pax1 and Nkx3.2 are expressed during paraxial mesoderm (PAM) 
differentiation, while Mesp1, Foxf1a and Prx1 are expressed during lateral plate 
mesoderm (LPM) formation and differentiation (modified from Gilbert 2000).   
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1.4 Process of bone formation (osteogenesis) 
 
Once mesenchymal cells reach the required location in the skeleton (i.e. axial or 
appendicular skeleton tissue), the process of cartilage and bone differentiation 
occurs, whereby mesenchymal cell condensation occur and common osteo-
chondroprogenitor cells differentiate toward either the chondrocyte or osteoblast 
lineages via one of the two processes of bone ossification; intramembranous or 
endochondral ossification according to the positional identity of the future bone 
which occurs along with the specific skeletal patterning process (Hall & Miyake 
2000; Yang 2013). In the intramembranous process mesenchymal cells 
differentiate directly to bone. While in in the endochondral process 
mesenchymal progenitor cells differentiate into chondrocyte (in a process called 
chondrogenesis), forming a cartilaginous template.  Cells surrounding the 
template are called the perichondrium, which later changes identity sequentially 
to be called the periosteum and gives rise to osteoblast precursors. 
Concurrently, osteogenesis occurs, whereby blood vessel invasion and 
osteoblast precursors replace the calcified cartilage matrix and lay down bone 
matrix, which becomes mineralised (Komori 2010; Hartmann 2009; Lefebvre & 
Bhattaram 2010) (Fig. 1.3).  
1.4.1 Chondrogenesis 
 
During chondrogenesis, characteristic changes occur at each stage of cartilage 
differentiation during the longitudinal growth of bone. Cartilage tissue consists of 
chondrocytes and characteristic extracellular matrix. Chondrocytes are 
characterised by a round or polygonal morphology, which express the “Sox trio” 
(Sox9, Sox5 and Sox6) and secrete extracellular matrix rich in collagen type II 
(hereafter, as Col II) and aggrecan (hereafter, as Acan), transcriptional 
regulation will be discussed in section1.5.  Then chondrocytes proliferate and 
expand for elongation and lengthening of bone after which they undergo 
hypertrophy and mineralisation prior to bone formation to replace the cartilage 
matrix. Hypertrophic chondrocytes are characterised as enlarged chondrocyte 
cells and secret collagen type X (hereafter, as Col X) (Wezeman 1998), express 
matrix metalloproteinase 13 (MMP13), ALP, Runx2 and Ihh (Komori 2010; 
Pitsillides & Beier 2011; Raggatt & Partridge 2010; Hartmann 2009) (Fig. 1.3).   
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1.4.2 Osteogenesis  
 
During osteogenesis, characteristic changes occur at each stage of bone 
differentiation.  In general, bone tissue consists of cells, an organic and an 
inorganic (hydroxylapatite) extracellular matrix.  The cellular component is 
composed of 3 cell types: osteoblasts (bone-forming cells), osteocytes 
(engulfed osteoblast in mineralised bone matrix) and osteoclasts (bone-
resorbing cells).  Osteoblasts, in particular, are characterised by a cuboidal 
morphology, which express Runx2, Osterix (herein Osx) and secrete 
extracellular matrix proteins rich in collagen type I (herein Col I), ALP, and as 
osteoblasts mature they upregulate the expression of other proteins such as 
Bone Sialoprotein (BSP) and Osteocalcin (OC) (Malaval et al. 1999; Aubin and 
Triffitt 2002; Boskey & Robey 2013; Olsen et al. 2000; Hartmann 2009; Goldring 
2012). Osteogenesis is a multistep process that is controlled by a cascade of 
molecular events, which will be discussed in the next section.  Any defects in 
the process of cartilage or bone formation leads to altered development of 
cartilage and bone tissues which may result in skeletal deformation and growth 
retardation (Pitsillides & Beier 2011; Woods et al. 2007) (Fig. 1.3).    
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Figure 1.3: A diagram showing intramembranous and endochondral ossification  
A) Intramembranous ossification occurs in craniofacial skeleton (flat bones of 
the skull) and lateral halves of the clavicle bone. Bone formation occurs by 
mesenchymal stem cell condensation and direct differentiation into osteoblasts 
(bone forming cells), which lay down bone matrix without a cartilage template 
stage.  B) Endochondral ossification occurs in the axial and appendicular 
skeleton; long bones and vertebrae. A cartilage template (anlagen) precedes 
the bone formation stage (mature osteoblast), during which cells mature from 
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1.5 Transcriptional control in cartilage and bone; lineage 
specification and differentiation  
 
The commitment and differentiation to cartilage and bone lineages is regulated 
by characteristic changes in molecular activity and gene expression as well as 
in cell shape and ECM synthesis (Hall & Miyake 2000; Hartmann 2009; Raggatt 
& Partridge 2010; Keller & Nieden 2011).  The transcriptional regulation that 
controls chondrogenesis (cartilage formation) and osteogenesis (bone 
formation) were identified based on the phenotypic changes seen in human 
diseases and in knockout or genetically manipulated mice (Akiyama et al. 2002; 




Sox9 expression is essential for the commitment to the chondrogenic lineage 
and the formation of mesenchymal condensations (Bi et al. 1999).  It is 
expressed in chondroprogenitors and chondrocytes and not in hypertrophic 
cartilage (Akiyama et al. 2002) or mature osteoblasts (Akiyama et al. 2005).  
Furthermore, conditional targeting of Sox9 genes using the Cre recombinase-
loxP recombination system (Prx1-Cre transgene) demonstrated that the Sox9-
expressing cells originate from an undifferentiated limb bud population during 
limb bud development in the embryo, suggesting that Sox9 is required for 
mesenchymal condensation. In addition, using the Col2a1-Cre transgene, 
inactivation of Sox9 at, and after mesenchymal condensation, stopped the 
differentiation of condensed mesenchymal cells at the condensation stage and 
impaired chondrocyte proliferation and maturation (Akiyama et al. 2005). 
1.5.2 L-Sox5 and Sox6 
 
In cooperation with Sox9, L-Sox5, a large isoform of Sox5 (hereafter, referred to 
as Sox5), and Sox6, also regulate chondrogenesis (Lefebvre et al. 1998; Smits 
et al. 2001).  The expression of both Sox5 and 6 is downstream of Sox9 
expression.  Inactivation of Sox5 and 6 does not prevent chondrogenic 
differentiation, however, causes a reduction in the expression of Col2a1, Col9a2 
and Col11a2 (Smits et al. 2001).  Sox5 and Sox6 are expressed along with 
Sox9 in all pre-cartilaginous condensations and cartilage elements, however, 
their presence is not observed in mesenchymal condensations (Akiyama et al. 
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2005; Akiyama 2008). Sox5 and Sox6 cooperate together with Sox9 to activate 
the Col2a1 enhancer (Lefebvre et al. 1998). 
The combined expression of Sox5, Sox6 and Sox9 (the SOX Trio) is the master 
regulator in the chondrogenic differentiation process. Overexpression of Sox9, 
Sox5 and Sox6 in cultured cells has been shown to induce chondrogenesis 
(Ikeda et al. 2004). In addition, transgenic mice in which Sox9 was ectopically 
expressed in limb bud mesenchyme using the Prx1 promoter exhibited ectopic 
cartilage formation in association with the induction of ectopic Sox5 and Sox6 
expression without any patterning defects in limb bud development (Akiyama et 
al. 2005). 
Sox9 expressing cells are not only progenitors for cartilage but also for bone 
differentiation during the process of endochondral bone formation (Akiyama et 
al. 2005). Sox9 expressing cells showed, by using Sox9-Cre;R26R mice, to be 
common progenitor cells for not only chondrogenic, but also for Runx2 
expressing osteogenic progenitors hence indicating a bi-potential progenitor 
population stage. This observation has also been confirmed in 
Osxflox/LacZ;Sox9-Cre mice. Interestingly, Sox9 is also expressed in the 
embryonic development of other lineages than cartilage (Cheung & Briscoe 
2003; Blache et al. 2004; Vidal et al. 2005). 
1.5.3 Runx2 
 
The Runx2 transcription factor (the runt family) is required for osteogenesis 
initiation for both endochondral and intramembranous bone formation.  Mice 
lacking Runx2 do not develop osteoblasts and fail to form hypertrophic 
chondrocytes leading to a cartilaginous skeleton, which does not mineralise 
(Komori et al. 1997; Otto et al. 1997; Ducy et al. 1999). Ducy et al. (1999) 
established that overexpression of Runx2 in non-osteoblastic fibroblasts was 
sufficient enough to induce the expression of osteoblastic markers such as type 
I collagen, bone sialoprotein (BSP), osteocalcin (OC) and osteopontin (OP) 
(Ducy et al. 1999). By interacting with many transcriptional activators and 
repressors and other co-regulatory proteins, Runx2 has been shown to regulate 
the expression of osteoblast-specific markers (Col1, ALP, OPN, osteonectin ON 
and OC) in either a positive or a negative manner (Harada et al. 1999).   
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Runx2 is essential for the proper function of osteoblasts and bone matrix 
formation (Ducy et al. 1999).  
Furthermore, Runx2 is also important in the late stages of chondrocyte 
differentiation and hypertrophy (Inada et al. 1999; Kim et al. 1999; Takeda et al. 
2001). Runx2 overexpression studies showed that under the control of the 
Col2a1 promoter, Runx2 overexpression accelerates chondrocyte maturation 
and Col10a1 (hypertrophic cartilage marker) expression in mice, while the 
dominant-negative Runx2 under the same promoter showed the opposite result 
(Ueta et al. 2001). Runx2 is also expressed in the osteochodroprogenitor 
population, but Sox9 expressing cells precede Runx2 expressing cells, during 
limb bud development in the embryo (Akiyama et al. 2002; Akiyama et al. 
2005).  Similar to Sox9 expression, Runx2 expression is not required at 
maturation stage of osteogenesis (Komori 2010). 
1.5.4 Osterix 
 
Further on in the osteogenic differentiation process, the expression of osterix 
(specificity protein-7 (SP7)) (hereafter, referred to as Osx), is required 
downstream of Runx2 and is in fact a target of Runx2 (Nakashima et al. 2002).  
Osx is a zinc finger transcription factor which has been shown to control the 
continuation of osteogenesis towards matrix deposition and mineralisation in 
both intramembranous and endochondral bones.  Osx is responsible for the 
activation of OC and Col1a1 genes. Runx2-null mice, do not express Osx, but 
show ectopic cartilage formation and express chondrocyte markers, such as 
Sox9 and Col2a1 with no bone formation (Nakashima et al. 2002).  
Furthermore, Osx, is also required in chondrogenenic differentiation whereby 
chondrocyte-specific Osx conditional knockout using Col2a1-Cre resulted 
reduction in chondrogenic markers expression and impaired endochondral bone 
formation (Oh et al. 2012). 
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1.6 Signalling pathways controlling cartilage and bone lineages 
differentiation 
 
Beside the transcriptional control, cartilage and bone differentiation are 
mediated by paracrine signalling pathways such as Bone Morphogenetic 
Proteins (BMPs) and Fibroblast Growth Factors (FGFs). These signalling 
pathways are involved in regulating embryonic development and the 
chondrogenic and osteogenic fate decisions (Hartmann & Tabin 2000; Karsenty 
& Wagner 2002; Lin & Hankenson 2011) and will be further investigated in this 
thesis (Fig 1.4).   
 
1.6.1 BMP signalling  
 
BMPs are members of the TGFβ super-family.  The connection of BMP with 
osteogenesis has been first demonstrated when Urist (1962) proved that BMP 
induced ectopic bone formation in mice.  Based on mutation studies, BMPs 
regulate chondrogenesis and osteogenesis (Bandyopadhyay et al. 2006; Lin & 
Hankenson 2011).  For example, knockout experiments of BMP2 and BMP4 
showed a requirement of BMP2 and BMP4 signalling for maturation and 
completion of osteoblast differentiation whereby osteogenic differentiation is 
terminated by the loss of BMP2 and BMP4 ligands (Bandyopadhyay et al. 
2006).  Furthermore, BMP signalling has been also demonstrated to direct MSC 
commitment towards the osteogenic lineage over the myogenic and adipogenic 
lineages (Gimble et al. 1995; Hogan 1996; Lin & Hankenson 2011).  BMP 
signalling showed in vitro to target Runx2 whereby BMP2 upregulated Runx2 
and ALP expression in human bone marrow cells (Gori et al. 1999). 
 
1.6.2 FGF signalling  
 
The FGF gene family is composed of 23 members that bind to FGF tyrosine 
kinase receptor isoforms (Fgfr). The FGF-family polypeptides play a critical role 
in regulating bone formation (Marie et al. 2012; Long & Ornitz 2013a).  FGF1 
and FGF2 were the first FGF ligands to be purified and defined as mitogenic 
factors of fibroblasts grown in culture (Gospodarowicz & Moran 1975).  Mice 
lacking FGF (2,18, and 23) have demonstrated skeletal phenotypes (Degnin et 
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al. 2010).  FGF signalling is required in limb bud development whereby FGF2 
beads showed to replace function of AER (Fallon et al. 1994; Taylor et al. 
1994).   
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Figure 1.4: A differentiation scheme showing key transcriptional factors and 
signalling pathways controlling the different stages of bone and cartilage 
specification and differentiation/maturation.  
Differentiation of Mesenchymal cells (MSCs) to chondro-osteoprogenitor cells 
which commit to either osteoblast or chondrocyte lineages under the control of 
cartilage and bone specific transcriptional factors (Sox9, 5, and 6, and Runx2 
and Osx. respectively. In addition, paracrine signaling pathways  (BMP, FGF) 
control MSC differentiation.  Each stage of differentiation shows the expression 
of cartilage and bone specific phenotypic genes. Collagen type I (Col I), Alkaline 
phosphatase (ALP), Bone Sialoprotein (BSP) and Osteocalcin (OC), Dentin 
matrix acidic phosphoprotien 1 (DMP1)) for osteogenic lineage, and Collagen 
type II (Col II), aggrecan (Acan) and Collagen type X (Col X), Runx2, osterix 
(Osx), BSP, metalloproteinase (MMP13)) for chondrogenic lineage.   (Modified 
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1.7  ESC differentiation to cartilage and bone  
 
Stem cells are responsible for the development of an organism and the 
maintenance of organs and tissues throughout life.  They have the ability to 
renew themselves (self-renewal) and to produce daughter cells with the 
potential to differentiate into different cell types with restricted properties (Blau 
et al. 2001; Smith 2006; Murry & Keller 2008).  In this thesis, I will describe two 
general types of stem cells; adult and embryonic stem cells. While the latter will 
be the basis of this project as will be discussed in the later sections.  
 
1.7.1 Adult (Somatic) stem cells 
 
Adult stem cells are committed stem cells found in many organs and 
differentiated tissues.  They have a limited capacity for self-renewal and 
proliferative potential. They can be multi-potent, but their capacity is normally 
limited to cell types in the organ of origin (Smith 2006).  The most studied Adult 
Stem Cells that is relevant to this thesis are Mesenchymal Stem Cells (MSCs), 
described below. 
 
1.7.2 Mesenchymal stem cell (MSCs) 
 
The work of Friedenstein and Owen in the 1960’s led to the discovery of non-
hematopoietic stem cells in the bone marrow, and these were designated bone 
marrow stromal stem cells (BMSC) (Friedenstein et al. 1978; Owen & 
Friedenstein 1988).  These cells are clonogenic, multipotent and have the 
capacity to differentiate in vitro and in vivo into mesenchymal tissues, such as 
osteoblasts, chondrocytes and adipocytes.  These were later termed as MSCs 
or skeletal stem cells and were suggested to differentiate to a wide range of cell 
types cardiomyocytes, neurons, and astrocytes in vitro and in vivo (Friedenstein 
et al. 1978; Bianco et al. 1998; Pittenger 1999; Y. Jiang et al. 2002; Bianco et 
al. 2008; Caplan 2010; Salem & Thiemermann 2010).  Although MSCs are 
found in tissues other than bone marrow, such as adipose tissue, muscle, 
periosteum, dental tissues and perivascular mesenchymal cells (pericytes) 
(Sacchetti et al. 2007; Hipp & Atala 2008; RodriguezLozano et al. 2011).  
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They are all generally considered to be a rare, heterogeneous stem cell 
population, with a limited capacity for self-renewal and demonstrated to lose 
clonal mulitpotency (Bianco et al. 1998; Jiang et al. 2002).  In addition, MSCs 
lack unique surface markers, making it difficult to distinguish progenitor cells 
from specific cell types and thus track their differentiation.  
However, some specific cell surface antigens expression have been used as 
minimum criteria to isolate MSCs, as defined by the International Society for 
Cellular Therapy (Dominici et al. 2006):  CD29, CD44, CD56, CD73, CD90, 
CD105, CD271 and MSCA-1, as well as  In addition, Stro-1 to characterise 
osteoprogenitor cells (Gronthos et al. 2003; Dominici et al. 2006; Battula et al. 
2009; Abdallah & Kassem 2007). These markers are characterised based on 
plastic “adherence selection“ (Dominici et al. 2006; Salem and Thiemermann 
2013).  However, there are obstacles regarding methods of culturing and 
heterogeneity of populations (Salem & Thiemermann 2010).  
 
1.7.3 Embryonic Stem Cells (ESCs) 
 
ESCs have an unlimited capacity for self-renewal and are pluripotent (Evans & 
Kaufman 1981).  The term pluripotency means that these particular cells have 
the capacity to differentiate to form all germ layers and differentiate to all tissue 
cell types, which has been demonstrated both in vitro and in vivo using 
chimaeric mice by Bradley et al. 1984 (Smith 1992; Gadue et al. 2005; Murry & 
Keller 2008).  ESCs originate from the inner cell mass (ICM), which is a 
transient structure in the pre-implantation embryo stage called the blastocyst 
stage (spherical embryo). The ICM is defined as “Pluripotent tissue inside the 
blastocyst that gives rise to the embryo proper and yolk sac tissue.”  It was first 
isolated from mice (Evans & Kaufman 1981; Evans 2011).  Following their 
isolation in mice, ESCs were then isolated from human embryos (Thomson 
1998) and other species (Wobus & Boheler 2005; Wobus & Boheler 2009).  
Murine ESCs were shown to retain normal chromosomal karyotypes even with 
multiple passaging, and do not undergo senescence compared to somatic stem 
cells whereby studies suggest the involvement of maintained telomerase, which 
is a reverse transcriptase that elongates the ends of the DNA (Günes & 
Rudolph 2013). 
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Pluripotent stem cells can be used for gene targeting (Smith 1992) through 
genetically manipulating cells in vitro, which has been proven by over-
expression and knockout mice, and producing chimaeric mice to trace a specific 
gene in vivo (Irion et al. 2008).  In addition, stem cell studies are used to aid in 
the screening and testing of chemical products before they are tested on 
humans (Keller 2005; Irion et al. 2009).  In terms of tissue regeneration, ESCs 
provide unlimited, principally a bulk production of a homogeneous cell source 
hence overcoming the limitations of MSCs.  On the other hand, the 
disadvantage of ESCs as a model system relies on their ability to form teratoma 
in vivo and the challenge is the ability to control and direct the differentiation of 
ESCs towards a specific cell lineage.  The latter will be discussed further in 
sections 1.10. 
 
1.7.4 Induced Pluripotent Stem cells (iPSCs) 
 
iPSC reprogramming is a method of engineering or reversing the state of a 
differentiated somatic cells to an undifferentiated ESC-like state without the use 
of an embryo.  The first iPSCs were generated in 2006 when Takahashi and 
Yamanaka reported reprogramming of a mouse fibroblast by transient retroviral 
transduction of cells with four embryonic transcription factors (Yamanaka et al. 
2008).  iPSC lines have been established from diseased patient cells, such as 
Duchenne Muscular Dystrophy or Amyotrophic lateral sclerosis (ALS), therefore 
allowing for studying disease in vitro and recapitulating development of  a 
specific cell type/tissue in a dish (Dimos et al. 2008; Park et al. 2008).  The 
behaviour of iPSCs resembles ESCs, in that they are pluripotent, they express 
pluripotency markers and cause teratoma formation.  The unique character of 
iPSCs is that they convey the potential of providing patient - specific cell-based 
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In summary, ESCs are attractive cell source for advancing in vitro differentiation 
techniques for directed and controlled differentiation under appropriate 
conditions.  This will permit the study of early cell precursors in order to 
understand specific cell-type lineage commitment (Gadue et al. 2005; Murry & 
Keller 2008).  For this project, ESCs will be used specifically to look into 
chondro-osteoprogenitor progenitor differentiation, as will be discussed further 
in  sections 1.10.2. 
  
1.8 Mouse ESCs 
 
In this project the focus will be on mouse ESCs.  Morphologically, mouse ESCs 
grow in colonies of small cells with a high nucleus to cytoplasmic ratio (Smith 
1992). SSEA-1 (Solter & Knowles 1978) and alkaline phosphatase are 
characteristic mESC surface markers. Mouse ESCs without feeder cells are 
maintained in an undifferentiated state (as found in the blastocyst) using 
leukemia inhibitory factor (LIF) in a serum-free cultures (Williams et al. 1988; 
Ying et al. 2008).  
1.8.1 In vitro ESC differentiation methods 
 
There are three methods which have been established to initiate ESCs 
differentiation (Keller 1995; Murry & Keller 2008) (i) Embryoid Body formation, 
(ii) co-culture with stromal cells rich with suitable factors, and finally (iii) direct 
culturing of cells on defined matrices such as collagen type IV (Nishikawa et al. 
2007). 
 
The most common method used is the Embryoid Body formation.  Embryoid 
Bodies (EBs) are 3D structures of ESC aggregates in culture.  This method 
allows for the creation of a gastrulation phase in vitro (formation of the three 
germ layers), mimicking the peri-implantation embryo environment, where 
interactions between various cell types facilitate inductive events and accessing 
progenitor cells that are not yet committed to any specific cell lineage (Murry & 
Keller 2008).  There are two techniques for EB formation in non-adherent 
cultures:  First, ESCs are plated in a static suspension method using a liquid 
medium or methylcellulose in a Petri dish. This method prevents the adhesion 
of ESCs to the surface and allows them to aggregate and form EB structures. 
The second method, is using a three-step method, where cells are seeded on a 
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dish lid as “hanging drops” and then condensed by gravitational force so 
forming uniform EBs which are then transferred to a liquid culture (Keller 1995; 
Murry & Keller 2008).  In this project, EB formation using the static suspension 
technique was selected in order to expose ESCs to mesoderm induction/and 
enrichment growth factors during differentiation. This point will be further 
explained in details in chapter 2 and 3 details.     
 
1.9 ESC differentiation to cartilage and bone via EB culture method 
 
Early studies to understand cartilage and bone differentiation processes have 
been carried out on primary cells, tumour cells and mesenchymal cell lines 
(Bellows et al. 1990; Erlebacher et al. 1995; Bellows et al. 2003).  These culture 
models were composed of heterogeneous populations of differentiated and 
undifferentiated cells and represented relatively late stages of development 
(Bellows et al. 1990; Duplomb et al. 2007).  Later on, researchers have used 
ESC in vitro culture models in order to understand bone and cartilage 
differentiation from the earliest stages of embryonic development to terminal 
differentiation stages by differentiating ESCs to EBs first then culturing the 
created cells in chondrogenic or osteogenic (Buttery et al. 2001; Hegert 2002; 
Kramer et al. 2000; Kramer et al. 2003; zur Nieden et al. 2003; Kawaguchi et al. 
2005b; zur Nieden et al. 2005).    
For osteogenic differentiation, the first cocktail used by Buttery et al (2001) 
consisted of ascorbic acid, β-glycerophosphate and dexamethasone and proved 
to mineralise osteoblast nodules.  The osteogenic media was later on modified 
by many laboratories by the addition of inducing factors to enhance the 
differentiation such as compactin (Phillips et al. 2001), retinoic acid, (Phillips et 
al. 2001; Kawaguchi et al. 2005), 1,25alpha (OH)2 vitamin D3 (VitD3) (zur 
Nieden et al. 2003; zur Nieden et al. 2007), BMP2/4 (Kawaguchi et al. 2005) 
and conditioned medium from the human hepatocarcinoma cell line HepG2 
(Hwang et al. 2006). Theses studies examined osteoblast differentiation by 
mineralisation of bone nodules and bone-specific markers expression.  For 
chondrogenic differentiation, the inducing factors investigated were, for 
example; TGFβ1/3 and BMP2/4/7, IGF-1 and ascorbic acid (Kramer et al. 2000; 
C. Hegert 2002; zur Nieden et al. 2005; Y. Hwang et al. 2007). The examination 
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of chondrogenic media was evaluated by gene expression of chondrogenic 
genes and Alcian blue staining.  
The majority of the studies demonstrated the in vitro potential of ESC to 
differentiate towards the chondrogenic and osteogenic lineages. However, the 
reports relied on the presence of serum in the culture conditions, which may 
lead to an uncontrolled differentiation of ESC and the generation of 
heterogeneous cell populations.  The presence of fetal calf serum (FCS) in the 
culture medium offered a source of unknown essential cell nutrient (agonist) 
growth factors as well as inhibitor factors (antagonist).  Moreover, a batch-to-
batch variability led to variable cell differentiation results. Furthermore, the 
uncontrolled EB-based differentiation of ESCs induces spontaneous mesoderm 
along the side with cell types from the other germ layers, which could result in 
an inefficient differentiation of ESCs to chondro-osteoprogenitor population and 
incomplete differentiation and commitment of cells to the required cell type 
lineage (Keller 2005; Nostro et al. 2011; Nakayama & Umeda 2011). These 
factors therefore make it difficult to produce a reproducible and controllable 
differentiation system model for stem cell differentiation to bone and cartilage. 
In conclusion, these studies indicate the importance and requirement for 
controlled, directed stem cell differentiation model systems, using a serum free 
and a chemically defined (signalling molecules) differentiation environment to 
enrich for novel chondro-osteoprogenitor population, as will be discussed in the 
next sections.  
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1.10 ESC differentiation to cartilage and bone differentiation via 
recapitulation of primitive streak/mesoderm formation  
 
In the last few years, researchers have been focusing on approaches to direct 
the differentiation of ESCs to a more homogenous population of chondro-
osteoprogenitor cells by the manipulation of signalling pathways and purification 
methods to enrich for mesoderm progenitor populations, thus following a 
developmental approach, whereby recapitulating mesoderm development and 
differentiation to mesoderm progenitors allow the access to precursors of both 
cartilage and bone lineages as mentioned in section 1.3 (Murry & Keller 2008; 
Kitagawa & Era 2010; Keller & Nieden 2011; Nakayama & Umeda 2011)  (Fig. 
1.5).  
 
During embryonic development, the formation of mesoderm is controlled 
spatially and temporally via specific signalling mechanisms including the TGF-β 
superfamily (TGF-β, BMP, Nodal), FGF, and Wnt signalling pathways 
(Nishikawa et al. 2007; Irion et al. 2009). Initial studies on mesoderm 
induction/differentiation have been done using Xenopus and Zebrafish embryos.  
This basic process is conserved in all vertebrates (Kimelman 2006).  Studies of 
both loss- and gain-of-function in mice reported that Nodal (Conlon et al. 1994; 
Schier & Shen 2000), BMP4 (Hogan 1996) and Wnt (Yamaguchi 2001) are key 
pathways in directing this process.    
 
Mesoderm differentiation follows the stage of primitive streak differentiation - as 
mentioned in section 1.3 - Gadue et al. (2006) established using a mESC 
culture model that the activation of activin/Nodal, BMP and Wnt signalling 
pathways are required to recapitulate a primitive-like (PS) cell population in 
vitro.  The differentiation of the primitive streak-like cell population could later on 
be directed towards sub-mesodermal (Lindsley et al. 2006; Gadue et al. 2006; 
Gouon-Evans et al. 2006; Nostro et al. 2011) as well as endodermal (Gouon-
Evans et al. 2006) populations under the control of a specific combination of 
these signalling factors, i.e. concentration and time.  Therefore, through 
manipulation of the above signalling pathways, it is possible to differentiate 
ESCs to MSC-like, specifically chondro-osteoprogenitor populations in vitro 
(Keller 2005; Murry & Keller 2008).  
 
Introduction: part A 
- 41 - 
 
1.10.1 Directed ESC differentiation to primitive streak/mesoderm lineage 
 
It has been proven in Xenopus that the concentration gradient of the signalling 
molecules influences the subpopulation of the germ layer generated (Green et 
al. 1992; Fukui & Asashima 1994; Kubo et al. 2004).  Higher concentrations of 
Activin A direct cells towards endodermal lineages while low concentrations 
direct cells towards mesodermal lineages (Okabayashi & Asashima 2003).  
Activin A acts as a substitute for Nodal, it acts through the same receptor as 
Nodal (Gadue et al. 2006).  In contrast, a BMP concentration gradient 
demonstrated an opposite effect (Sumi et al. 2008; Nostro et al. 2011) as been 
demonstrated in mice (McMahon et al. 1998) (Fig. 1.5).    
 
To trace early mesoderm developmental stages in the ESC culture model, a 
reporter ESC line such as GFP-Bry and subsequent gene expression have 
been used to trace PS/mesoderm from EB formation in vitro (Fehling 2003; 
Gadue et al. 2006).  Craft et al (2013) utilised the GFP-Bry cell line to monitor 
mesoderm differentiation in mESC cultures.  Brachyury (a conserved T box 
transcription factor) is expressed throughout the primitive streak (Smith et al. 
1991) and early mesoderm  (Wilkinson 1990; Herrmann & Kispert 1994; 
Yamaguchi et al. 1999; Kubo et al. 2004). Umeda et al (2012) utilised Mixl-1-
GFP hESCs to differentiate chondrogenic progenitors from a mesoderm 
progenitors. Mixl-1 is also expressed in the PS and early mesoderm.  It is a 
common marker for mesoderm and endoderm (Pearce & Evans 1999; Hart et 
al. 2002).   
 
Furthermore, several studies revealed that the manipulation of different 
signalling pathways at specific developmental stages may direct the early 
stages of mesoderm induction and distinguish it from PS formation (Murry & 
Keller 2008; Nostro et al. 2008).  Surface markers such as the receptor kinase 
Flk-1 and Pdgfrα (Kataoka et al. 1997; Ema et al. 2006; Murry & Keller 2008; 
Nostro et al. 2011) have been used to further purify intermediate mesoderm 
progenitor populations (Kitagawa & Era 2010).    
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In vitro ESC fate analysis showed that Flk1-positive cells differentiate into lateral 
plate mesoderm derivatives (Nishikawa et al. 1998; Yamashita et al. 2000; 
Wang 2006; Kattman et al. 2006) whereas Pdgfrα differentiates towards 
paraxial mesoderm derivatives  (Nakayama et al. 2003; Sakurai et al. 2006), 
which recapitulates normal embryonic development.  Pdgfrα and Flk-1 have 
been used for purification of chondro-osteoprogenitor populations as will be 
discussed in the next section.  However, more specific markers are required 
besides Pdgfrα and Flk-1 for further characterisation and purification of 
chondro-osteoprogenitor populations, such as a Pax-1 sclerotome marker for 
mature paraxial mesoderm or a Prx-1 positive limb mesenchyme for mature 
later plate mesoderm (Nakayama & Umeda 2011). 
 
In conclusion, using ESCs in vitro as a model for recapitulating PS and lineage 
commitment provides an opportunity to generate enriched, functional cell types 
under defined culture conditions via recapitulating the gastrulation phase and 
demonstrate mesoderm gene expression in vitro. 
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Figure 1.5: A scheme showing differentiation of ESCs using the Embryoid Body 
model system to recapitulate embryonic development of mesoderm and 
endoderm in vitro.  
A scheme showing the differentiation of ESC to EBs after the removal of LIF.   A 
primitive streak (PS)-like population expressing Brachyury (Bry-positive) is 
generated recapitulating the embryonic development of the PS in vivo (inset 
showing a mouse embryo (E7.25) with GFP-Bry positive PS regions, ant, mid, 
post.  BMP, Activin A, and Wnt signalling pathways induce and enrich for 
mesoderm and endoderm differentiation. The manipulation of these signalling 
pathways temporally as well as by concentration directs the differentiation of 
PS-like cells to either anterior or posterior regions of the PS, providing efficient 
and reproducible control of the differentiation of specific cell types required 
(modified from Keller 2005 and Gadue et al 2006). 
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1.10.2 Directed ESC-derived mesoderm differentiation towards cartilage 
and bone lineages 
 
As opposed to spontaneous ESC-derived mesoderm differentiation to 
chondrogenic and osteogenic pathways, recently ESC differentiation has 
demonstrated mesoderm differentiation in a defined medium to generate 
controlled and purified populations of a specific cell type. This is by 
recapitulating primitive streak formation then mesoderm formation (Nishikawa et 
al. 2007; Murry & Keller 2008; Kitagawa & Era 2010). The following studies 
were discussed in here mainly in the context of mESCs studies with only some 
related hESC studies. 
1.10.3 Paraxial and lateral plate recapitulation and differentiation  
 
Several studies defined culture conditions for directing the differentiation of 
mESCs towards paraxial/lateral plate mesoderm and chondrocyte development 
(Nakayama et al. 2003; Sakurai et al. 2006; Tanaka et al. 2009; Craft et al. 
2013).  The following studies highlighted the importance of signalling factors; 
timing and interaction between growth factors as well as the purification 
methods for enriching specific mesoderm progenitor populations.   Nakayama et 
al. (2003) were the first to use Pdgfrα and Flk-1 as markers for purifying 
mesoderm intermediate populations, which later showed to acquire 
chondroprogenitor potential.   
Tanaka et al. (2009) proved the generation of (Pdgfrα+) population with 
chondrogenic potential in a serum free culture condition.  The mesoderm 
induction was through the activation of Activin/Nodal and Wnt signalling with the 
inhibition of BMP.   Interestingly, Umeda et al (2012) demonstrated same 
results in hESC culture, suggesting that the mesoderm induction protocol used 
was efficient for paraxial mesoderm-derived chondrogenic differentiation.  
Furthermore, several studies proposed the differentiation of both cartilage and 
bone cells using the same mesoderm progenitor population.  Sakurai et al 
(2006) established that a Pdgfrα+ population has both an osteogenic and 
chondrogenic potential.  
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However, these Pdgfrα+ populations could originate from either: (1) (Pdgfrα+/ 
Flk-1+) (bi-potential potential paraxial and lateral plate mesoderm population) 
(2) (Pdgfrα+/ Flk-1-) which consists mainly of paraxial mesoderm population), 
but not from (Flk-1+/Pdgfrα-) which consists mainly of paraxial mesoderm 
population evident by gene expression of osteogenic and vascular gene 
markers. Furthermore, Sakurai et al (2009) proved in a serum free culture 
conditions that the induction by continuous BMP4 signalling formed cartilage 
and bone both in vitro and in vivo, in quadriceps femoris muscles of 
immunodeficient mice.  
1.10.4 Three phase differentiation 
 
Very recently, using mESCs, Craft et al., (2013) demonstrated paraxial 
mesoderm derived chondrocyte potential using a stage-specific manipulation of 
the same signalling cocktail utilised in the Tanaka et al. (2009) study, in a 
serum-free culture (i.e. inhibition of BMP with the activation of Activin/Nodal and 
Wnt signalling). The mesoderm induction generated a Pdgfrα+ population more 
efficiently than cultures containing BMP.  This 3-stage signalling manipulation 
that Craft et al. (2013) utilised has been applied in hESCs in a similar approach 
and demonstrated to generate ~74-97% of Sox9-expressing cells, thus 
increasing the efficiency of the chondrogenic differentiation (Oldershaw et al. 
2010). 
In conclusion, several studies proved the generation of chondrogenic and 
osteogenic progenitor populations using a developmental approach whereby 
ESCs recapitulate embryonic development of mesoderm followed by cartilage 
and bone differentiation.  However, there is still controversy for which cocktail of 
signalling pathways is best for the generation of mesodermal progenitor 
subpopulation, that might provide improved chondrogenic/osteogenic 
progenitors for differentiation.  Nevertheless, the development of a stage-
specific, manipulative system for mesoderm differentiation in a serum-free 
condition demonstrates a more controlled method for mesoderm differentiation 
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The later approach will facilitate in addressing developmental questions 
regarding cartilage and bone specification and differentiation.  Therefore, this 
will provide the base for this thesis for further studying of the molecular events 
controlling lineage specification and differentiation towards both cartilage and 
bone lineages, specifically related to ROCK signalling pathway as will be 
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1.11  Part B 
 
1.12 Rho/ROCK signalling pathway 
  
The Rho (Ras homologous) family of signalling molecules is part of the Ras 
superfamily of small guanosine triphosphatases “GTPases” (Wennerberg & Der 
2004; Wennerberg et al. 2005).  The best characterised Rho GTPase signalling 
subfamilies include: Rho “including 3 isoforms: A, B, and C” (RAS homologue 
gene family member), Rac1, and Cdc42 (cell division cycle 42) (Matsui et al. 
1996; Amin et al. 2013).   
 
Rho GTPase signalling is involved in several cellular signal transductions 
pathways to the cell through many cell surface receptors, including 
tyrosine/serine/threonine kinase receptors, G-proteins, and integrins (Assoian & 
Schwartz 2001; Boudreau & Jones 1999; Whitehead et al. 2001; Riento & 
Ridley 2003; Mueller et al. 2005; Heasman & Ridley 2008; Ridley 
2013)(Fig.1.6).  For controlling cellular functions, they behave as a molecular 
switch by cycling between an inactive, GDP-bound state, and an active, GTP-
bound state. This is regulated by guanine nucleotide exchange factors (GEFs) 
and GTPase-activating proteins (GAPs) (Riento & Ridley 2003; Mueller et al. 
2005; Bustelo et al. 2007; Heasman & Ridley 2008; Ridley 2013) (Fig. 1.6). 
 
Rho GTPases are involved in cell motility, proliferation and apoptosis by acting 
on the cytoskeleton and microtubules.  Moreover, they are also involved in cell 
cycle progression and differentiation processes through their effects on gene 
expression (Wennerberg & Der 2004; Heasman & Ridley 2008).   The activation 
of Rho (GTP-bounded) subsequently translocates to specific subcellular 
locations to activate many downstream targets, one of which is Rho-associated 
kinase (ROCK) ( Riento & Ridley 2003; Jaffe & Hall 2005; Heasman & Ridley 
2008; Amano et al. 2010)  (Fig.1.6).  ROCK signalling specifically will be the 
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1.12.1 Rho- associated coiled-coil-forming kinase (ROCK)   
 
ROCK (also known as Rho-kinase/ROK) is an immediate downstream effector 
molecule of the Rho GTPses subfamily of small GTPases and also one of the 
best characterised effectors (Leung et al. 1996; Matsui et al. 1996) (Fig. 1.6). It 
is a serine/threonine protein kinase, which phosphorylates proteins involved in 
many cellular functions (Leung et al. 1996; Nakagawa et al. 1996).  ROCK 
includes two isoforms, ROCK1 (ROKβ/p160ROCK) and ROCK2 (ROKα), each 
encoded by different genes (Nakagawa et al. 1996; Riento & Ridley 2003; 
Mueller et al. 2005; Amano et al. 2010).   Mouse knockouts for ROCK1 and 
ROCK2 were shown to be embryonic lethal due to placental dysfunction and 
growth retardation (Thumkeo et al. 2003; Mueller et al. 2005).   Both ROCK 
isoforms share an overall identity; 65% in the amino acid sequences and 92% in 
the kinase domains, having similar substrate specificity (Riento & Ridley 2003; 
Amano et al. 2010).  Although both ROCK isoforms show similarities and are 
ubiquitously expressed in mouse tissue; however, their mRNA is present at 
higher levels in specific tissues and may show specific functions, thus 
suggesting that they might demonstrate different functions. ROCK2 is 
expressed in higher levels in brain and muscles whereas ROCK1 is present in 
higher levels in non-neuronal tissues, including liver, lung and testis (Leung et 
al. 1996; Nakagawa et al. 1996; Hashimoto et al. 1999; Riento & Ridley 2003; 
Amano et al. 2010).   
 
At present, an understanding of ROCK function is derived mostly from in vitro 
studies.  In vivo studies have reported the involvement of both isoforms in actin 
bundling by the analysis of knockout mice: homozygous ROCK1 (Shimizu et al. 
2005a) and ROCK2 (Thumkeo et al. 2003), which showed that both knockouts 
affect epithelial cell motility as evidenced by eyelid closure and fusion of the 
ventral body wall, due to the formation of omphalocele and open eyes  
(Thumkeo et al. 2003; Shimizu et al. 2005).  ROCK1 or ROCK2 heterozygous 
mice also had omphalocele and open eyes (Thumkeo et al. 2005).   Until now, 
there are no published reports on germline or somatic inducible and tissue-
specific ROCK knockout mouse models (Bustelo et al. 2007; Amin et al. 2013).  
 
ROCK phospholylates targets several proteins and the major targets include: 
myosin light chain phosphatase “MLCP”, myosin light chain “MLC”, LIM kinases 
Introduction: part B 
- 49 - 
”LIMKs”, and collapsing response mediator protein2 “CRMP2”.  ROCK was first 
characterised for its role in RhoA-induced stress fibres and focal adhesion by 
controlling the reorganization of the actin cytoskeleton and regulation of actin 
myosin contractility by the phosphorylation of myosin light chain (MLC) (Amano 
et al. 1996; Leung et al. 1996; Somlyo & Somlyo 2000; Riento & Ridley 2003).  
It promotes the assembly of actomyosin filaments through the phosphorylation 
and deactivation of the myosin binding subunit of myosin phosphatase (MYPT1) 
(Kawano et al. 1999), and direct phosphorylation of myosin light chain (MLC) 
(Amano et al. 1996; Kimura et al. 1996).  
 
ROCK is involved in several cellular functions, such as cell motility, adhesion, 
invasion, cell size, differentiation, apoptosis and regulating MSC lineage 
commitment (Riento & Ridley 2003; Sordella et al. 2003; McBeath et al. 2004; 
Amano et al. 2010) (Fig. 1.6). The inhibition of ROCK has been investigated in 
part by the use of pharmacological inhibitors, one of which is Y27632 (Amin et 
al. 2013). This project will be focusing on the effect of Y27632 on cartilage and 
bone development as will be discussed in the following section.  
 
1.12.2 ROCK inhibitor (Y27632) 
 
The effect of inhibition of RhoA/ROCK signalling has been studied through the 
use of pharmacological inhibitors such as Y27632 (Fig. 1.6).  The 
pharmacological inhibitor of ROCK, Y27632, (+)-(R)-trans-4-(1-ami-noethyl)-N-
(4-pyridyl) cyclohexanecarboxamide dihydrochloride monohydrate was 
discovered by Yoshitomi Pharmaceutical Industries (Ishizaki et al. 2000).  It is 
one of the first identified ROCK inhibitors through its Ca2+ antagonistic effect and 
potential use for hypertension therapy in rats (Uehata et al. 1997) and is an 
extensively tested ROCK inhibitor in vitro  (Mueller et al. 2005; Amin et al. 
2013).  The mechanism of Y27632 relies on targeting the ATP-dependent 
kinase domains of both ROCK isoforms and competitively inhibits the 
phosphorylation of various substrates (Ishizaki et al. 2000; Amin et al. 2013).  
Both ROCK1 and ROCK2 are inhibited by Y27632, with no selectivity, at 
equimolar concentration.  However, Y27632 can also non-specifically inhibit 
other protein kinases, such as protein kinase-related protein (PRK)-2, at equal 
potency and inhibits other protein kinases: protein kinase N, and citron kinase, 
at higher concentrations (Davis 2011; Zhou et al. 2011; Amin et al. 2013).   
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Several reports have described potential therapeutic effects of ROCK inhibitors, 
including Y27632 in cases involving the central nervous (Mueller et al. 2005) 
and cardiovascular systems (including spinal cord injury, vasospasm, 
hypertension, atherosclerosis, and myocardial hypertrophy) (Zhou et al. 2011), 
diabetic nephropathy (Komers 2011), and  cancer invasion and metastasis (Itoh 
et al. 1999; Li et al. 2009; Morgan-Fisher et al. 2013).  In addition, Y27632 
showed promising results in improving arthritis lesions in rodents by preventing 
further articular cartilage degradation (Appleton et al. 2010; Furumatsu et al. 
2013).   
 
In the context of ESC studies, Y27632 has been reported to be beneficial in 
several stages of ESC in vitro (i.e. survival/ culturing, expansion, differentiation) 
and in vivo studies. Y27632 supplemented ESC media acts as a survival factor 
for hESCs, by decreasing dissociation induced apoptosis (anoikis), therefore 
increasing cloning efficiency and scaling up ESC production for industrial use 
(Watanabe et al. 2007).  In addition, Y27632 has been shown to enhance the 
post-thaw survival of embryos, hESCs, iPS, and hMSCs and facilitate 
differentiation (Watanabe et al. 2007; Claassen et al. 2009; Cortes et al. 2009; 
Gauthaman et al. 2010; Lai et al. 2010).  Furthermore, the in vivo studies, 
survival of ESC-derived neural cells was enhanced by Y27632 treatment prior 
to and during injection in mice striatum (Koyanagi & Takahashi 2008).  
Moreover, Y27632 proved that ROCK is required in cell differentiation by 
restoring adipogenic cell differentiation in mice lacking p190-B RhoGAP 
(Sordella et al. 2003).  ROCK dependent effects through use of Y27632, in 
particular in chondrogenic and osteogenic differentiation, have been reported in 
association with RhoA protein analysis, as will be discussed in the subsequent 
sections.   
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Figure 1.6: A scheme showing the Rho/ROCK GTPase signalling pathway.  
The three main classes of Rho GTPase regulators (GAPs, GEFs, and GDIs), 
control the switch between the active and inactive states of Rho.  In a resting 
cell, in the cytosol, Rho is present mostly in the GDP-bound form (RhoGDP) in 
a complex with GDI. Upon stimulation by extracellular signals such as LPA 
(lysophosphatidic acid) and activation of G-protein coupled receptors (GPCR), 
Rho is dissociated from Rho GDI (guanine-nucleotide-dissociation inhibitor) and 
targeted to specific membranes.  At the membrane, GEFs is activated: 
converting RhoGDP to RhoGTP, which interacts with its specific effectors and 
exerts its functions.  RhoA activates down stream effectors such as mammalian 
diaphenous (mDia), PLC, and ROCK (I/II). Once ROCK (I/II) is activated it 
phosphorylates downstream target substrates; MLC: myosin light chain, LIM- 
kinase, and collapsin response mediator protein 2 (CRMP2). Y27632 is a 
pharmacological inhibitor of ROCK signalling (modified from Jaffe & Hall 2005, 
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1.12.3 RhoA/ROCK signalling and chondrogenesis  
 
RhoA GTPase signalling in cartilage development has been an area of research 
focus due to its role in connecting signals from the extracellular matrix to the 
actin cytoskeleton and cellular morphology, thus it may influence other cellular 
activities such as cell cycle progression, gene expression, lineage commitment, 
differentiation, and apoptosis (Wang et al. 2004; Woods et al. 2005; Woods & 
Beier 2006; Kumar & Lassar 2009).   
Chondrocytes display a characteristic cortical actin organization that differs from 
the fibrillar organisation seen in precursor cells or de-differentiated 
chondrocytes (Wang et al 2004).  Inhibition of actin polymerisation using 
mycotoxin (cytochalasin B) was proved by stimulating rounding of chondrocytes 
in monolayer cultures, and regaining of the chondrocyte phenotype as well as 
expression of chondrogenic specific gene markers (Benya et al. 1988; Zanetti & 
Solursh 1984).  In addition, the actin cytoskeleton has been shown to regulate 
chondrocyte differentiation in the growth plate whereby overexpression of actin-
binding protein (adservin) causes rearrangement of the actin cytoskeleton, 
increases cell volume, and upregulates hypertrophic chondrocyte markers 
(Wang et al. 2004).  
Furthermore, the mechanism of the actin cytoskeleton effect on chondrogenesis 
was linked to RhoA signalling.  RhoA signalling has been proven to negatively 
regulate chondrogenesis.   Stimulation of RhoA signalling has been shown to 
cause distribution of actin stress fibres in vitro and deformation of chondrocytes 
to a fibroblast-like phenotype (Woods et al. 2005).    In addition, overexpression 
of RhoA inhibits chondrocyte differentiation (Wang et al. 2004; Woods et al. 
2005; Woods & Beier 2006; Kumar & Lassar 2009).  Furthermore, loss of RhoA 
expression and activity was demonstrated during dedifferentiation of 
chondrocytes in alginate and micromass cultures. These results were proved 
using dominant negative RhoA and Rho antagonist C3 transferase (Kumar & 
Lassar 2009).   
The effect of RhoA on chondrogenesis has been linked to its downstream 
effector ROCK.  Woods et al. (2005) showed in ATDC5 cultures that the 
inhibition of ROCK signalling by using ROCK inhibitor Y27632 stimulated 
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chondrogenesis, as was evident by the increase in glycosaminoglycan 
synthesis and enhancement in mRNA Sox9 expression. Meanwhile, 
overexpression of RhoA in ATDC5 cells showed the opposite results.   These 
results were reproduced in micromass limb bud cultures. The stimulatory effect 
of RhoA/ROCK signalling inhibition on chondrogenesis is linked to cell shape 
and the actin cytoskeleton.  It has been shown that ROCK inhibition produced 
spheres containing cells with chondrocyte-like morphology and exhibited 
reorganisation of the cortical organisation of actin filaments. The actin 
cytoskeleton controlled Sox9 expression whereby both cytochalasin D  (binds 
monomeric actin and inhibits actin cytoskeleton) and colchicine (inhibitor of 
microtubule polymerization) were seen to reduce Sox9 expression (Woods et al. 
2005).  
Mechanistically, Woods et al. (2005) showed that the effect of ROCK inhibition 
on Sox9 expression is through stimulation of Sox9 promoter activity, thus 
suggesting that Sox9 is regulated at the transcriptional level.  Sox9 expression 
is known to be required for the expression of Sox5 and 6 (Smits et al. 2001; 
Akiyama et al. 2002), from which all 3 genes (Sox trio) are required for induction 
of chondrogenesis and expression of chondrogenic specific extra cellular matrix 
markers such as Col II (Lefebvre et al. 2001; Ikeda et al. 2004; Han & Lefebvre 
2008).   Woods & Beier (2006) demonstrated that the upregulation of Sox9 
expression was accompanied by upregulation in the expression of Sox5, Sox6, 
Col II and Acan at the mRNA level (transcript level). In addition, Sox9 
expression was accompanied by an increase in the phosphorylation level of 
Sox9 (Woods & Beier 2006).   
Several other reports demonstrated the stimulatory effect of inhibition of ROCK 
signalling on chondrogenesis. It was found that ROCK inhibition caused super 
induction of Sox9 expression in a monolayer of articular cartilage, thus rescuing 
the phenotype of de-differentiated chondrocytes (Tew & Hardingham 2006).  
Another report suggested that RhoA/ROCK signalling regulated Sox9 
transcriptional activity through actin polymerization mediated by protein kinase 
A phosphorylation of Sox9 (Kumar & Lassar 2009).   Recently, Sox9 has been 
demonstrated to correlate with Mef2c in down regulating Runx2 and Col X, thus 
preventing chondrocyte terminal differentiation to hypertrophic chondrocytes. 
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This may suggest that Rho GTPases may function upstream of Sox9 during 
chondrocyte differentiation (Dy et al. 2012).  
To the contrary, other reports showed an antagonistic effect of RhoA/ROCK on 
chondrogenesis. This was explained by differences in cell culture (i.e. 2D 
versus 3D) model, cell origin, or developmental stage of cells, which might 
influence the effect of RhoA/ROCK signalling on chondrogenic differentiation 
and maturation.  Woods & Beier (2006) reported that the inhibition of 
Rho/ROCK signalling demonstrated an increase in Sox9 expression in 
micromass cultures (Woods et al. 2005), which would be expected to 
upregulate cartilage specific extracellular markers; Col II and Acan.  However, 
there was a decrease in Sox9 expression, which is opposite to the results seen 
in ATDC5 and primary cell monolayer cultures.  This was unexpected since 
Sox9 expression is essential for the activation of the downstream markers Col II 
and Acan (Woods & Beier 2006).  In addition, cytochalasin D down regulated 
the expression of Col II and Acan, confirming the ROCK inhibitor results, and 
jasplakinolide (inducer of actin polymerisation) was shown to recover Sox9 
expression (Woods & Beier 2006).   
Furthermore, inhibition of RhoA/ROCK signalling has also been shown to 
control the maturation of chondrocytes.  Wang et al. (2004) demonstrated in 
both the ATDC5 cell line and in primary chondrocyte micromass cultures that 
overexpression of RhoA in ATDC5 cells enhanced the proliferation of 
chondrocytes and delayed hypertrophy as marked by decreased expression of 
Col X, BSP and MMP13 as well as reduction in the induction of alkaline 
phosphatase activity and mineralisation.  In addition, ROCK inhibition via 
Y27632 enhanced hypertrophy of chondrocytes (Wang et al. 2004).   Therefore, 
the negative control of RhoA/ROCK signalling on hypertrophic differentiation of 
chondrocytes suggests that it might negatively affect osteogenic differentiation 
as well.  This will be further discussed in the next section.   
In conclusion, the majority of studies showed an agonistic effect of ROCK 
signalling on chondrogenesis, although others showed an antagonistic effect. 
As mentioned, this was dependent on many factors, including differences in the 
cell culture model, cell origin, developmental stage of cells, culture condition, 
growth factors and cytokines, all of which might influence the effect of ROCK 
signalling on chondrogenic differentiation and maturation.  The effect of ROCK 
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signalling has not yet been investigated in an ESC culture model, which will 
allow for a more controlled approach to tracing the signalling effect on different 
stages of ESC development during the differentiation process in vitro.   In 
addition, given that ROCK signalling is known to regulate Sox9 expression and 
activity, using an ESC culture model may progress understanding of the exact 
mechanism of ROCK signalling in modulating chondrogenesis, thus leading to 
better understanding of the role of ROCK signalling in cartilage development 
and disease.   Therefore, the next sections will focus on the use of ESCs in an 
approach that recapitulates embryonic developmental of cartilage and bone 
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1.12.4 ROCK signalling and osteogenesis 
 
The influence of the ROCK pathway has also been studied in osteoblast 
differentiation. Interestingly, as has been reported in chondrogenic 
differentiation studies, controversial results were reported, defined by variations 
in culture conditions, such as cell origin, developmental stage of cells as well as 
matrix stiffness, which were shown to influence the way ROCK signalling 
controls osteoblast differentiation and maturation.  
The Rho/ROCK pathway has been demonstrated to be a negative regulator of 
osteoblast differentiation.  Our laboratory demonstrated that Rho/ROCK 
signalling inhibition increased osteogenic differentiation in mouse calvarial cells, 
marked by an increase in bone nodule number and mineralisation, as well as 
upregulation of the ALP and OC gene expression (Harmey et al. 2004).  
Similarly, activation of Rho by Pasteurella Multocida Toxin (PMT) led to a 
decrease in osteoblast differentiation and an increase in proliferation. 
Yoshikawa et al. (2009) also showed that ROCK inhibition using Y27632 
stimulated osteogenesis both in vivo and in vitro, with upregulation of ALP and 
OC expression and increased nodule formation compared to the untreated 
cultures.  The osteogenic effect of ROCK inhibition was further confirmed by 
means of using constitutively-active and dominant-negative ROCK constructs in 
ST2 cells (Yoshikawa et al. 2009).  This stimulatory effect was also reproduced 
with a different ROCK inhibitor, Hydroxyfasudil, using MC3T3-E1 cells 
(Kanazawa et al. 2009) and in human primary osteoblast cultures (Ohnaka et al. 
2001), therefore, confirming the anabolic effect of Rho/ROCK signalling 
inhibition on osteogenesis.  
Mechanistically, several reports suggested a link to BMP signalling for the 
anabolic effect of RhoA/ROCK signalling on osteogenic differentiation.  BMP 
(BMP2 and 4) expression was upregulated simultaneously with the increase in 
ALP and OC expression upon the inhibition of RhoA/ROCK signalling (Harmey 
et al. 2004; Yoshikawa et al. 2009).   Similarly, Hydroxyfasudil upregulated 
BMP2 expression in MC3T3-E1 cultures (Kanazawa et al. 2009).   
In support of the association between BMP signalling with RhoA/ROCK 
signalling several reports have proved this association by the use of other 
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classes of pharmacological inhibitors, that have indirect effects on Rho/ROCK, 
such as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors (Amin et al. 2013).  Ohnaka et al. (2001) demonstrated that the 
enhancement of BMP2 and OCN mRNA expression in osteoblasts induced by 
hydroxyfasudil is also proved by the inhibition of the mevalonate pathway 
(metabolite downstream of HMG-CoA) by pitavastatin (lipophilic statins), which 
suppressed RhoA translocation induced by lysophosphatidic acid.     
Recently, Prowsein et al. (2013) showed that RhoA/ROCK inhibition using 
Y27632 stimulated osteogenesis in rat calvarial osteoblasts cultured on tissue 
culture plastic.  In addition, ROCK inhibition not only stimulated osteogenesis, 
but also effectively speeded up maturation and mineralisation in synergy with 
topography modification using SLA (sandblasted large grit, acid etched) 
topography, suggesting the interaction of RhoA/ROCK signalling with surface 
roughness in controlling differentiation and maturation.  
To the contrary, Meyers et al. (2005) reported that transfecting hMSCs with an 
adenovirus containing constitutively active RhoA inhibited osteogenic 
differentiation in modelled microgravity cultures.  Furthermore, Khatiala et al. 
(2009) demonstrated similar results to the Meyers study.  However, the 
negative effect of RhoA/ROCK inhibition on osteoblast differentiation was also 
linked to ROCK and influenced by hydrogel stiffness.  MC3T3-E1 cells cultured 
in stiff hydrogel matrices showed a reduction in the expression of Runx2, BSP, 
OC and ALP activity as well as osteoblast mineralisation upon inhibition of 
RhoA/ROCK signalling by using dominant negative RhoA, cell-permeable C3 
transferase (C3) and Y27632.  The reduction in Runx2 expression was 
accompanied by a reduction in extracellular signal-regulated kinase (ERK) 
activity, whereas overexpression of constitutively active RhoA showed an 
increase in ERK activation and stimulation of osteogenic differentiation 
(Khatiwala et al. 2009). Therefore, mechanistically, this suggests that ERK and 
Runx2 regulate the osteogenic effect of RhoA/ROCK on osteogenic 
differentiation.  In addition, exerting external forces such as oscillatory fluid flow 
in C3H10T1/2 murine mesenchymal stem cell cultures resulted in activation of 
both RhoA and ROCK, which induced Runx2 expression. This was reduced 
upon application of Y27632, cytochalasin D or jasplakinolide.  In parallel, the 
chondrogenic marker Sox9 and adipogenic marker PPARγ were negatively 
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regulated by RhoA/ROCK and actin cytoskeleton tension (Arnsdorf et al. 2009).  
Furthermore, McBeath et al. (2004) proposed that the effect of RhoA/ROCK  
signalling on osteogenesis may be influenced by the development stage of cells 
and this effect is differentially regulated by cell density and shape using a micro-
pattern approach.  Expressing constitutively active RhoA in un-spread cells led 
to osteogenic fate over adipogenic fate, particularly in the absence of 
osteogenic inducing growth factors or in adipogenic media.  Cells infected with 
adenovirus encoding dominant negative RhoA cells showed an adipogenic fate, 
thus switching cell fate to the adipogenic lineage.  Interestingly, only in spread 
cells was constitutively active RhoA shown to induce osteogenesis, while 
dominant-negative RhoA induced adipogenesis in round cells.     
On the contrary, ROCK seems to control cell fate in respect to cell shape.  
Constitutively-active ROCK induced osteogenesis in round and spread cells, 
suggesting that ROCK is downstream of both cell shape and soluble factors 
(McBeath et al. 2004).  The study identified no alteration in proliferation or 
apoptosis of the cells upon RhoA exposure. This study highlights that the 
developmental stage of cells might play a significant role in influencing the 
response of cells to RhoA/ROCK signalling as well as controlling cell fate.  
Sordella et al. (2003) confirmed the effect of RhoA on cell fate determination in 
the absence of soluble factors.  In addition, the study proposed that RhoA might 
influence cell fate decision into adipocytes and myoblasts in embryonic 
fibroblasts derived from mice deficient in an inactivator of Rho, p190-B 
RhoGAP. This study, however, showed no link to cytoskeleton (Sordella et al., 
2003).  In summary, controversial results have been produced on the role of 
ROCK signalling in osteogenic differentiation, as with chondrogenic 
differentiation.  These opposing reports suggest that studying ROCK signalling 
is a complex process and may be influenced by many different factors, such as 
species differences, cell origin, stage of cell development, as well as the 
involvement of extracellular matrix stiffness.  In addition, ROCK signalling is a 
complex pathway linking external signals to the internal part of the cell, the 
involvement of integrin, cell cytoskeleton, cell shape, cross talk between ROCK 
different targets as well as the effect of upstream proteins such as RhoA and 
other Ras superfamily members, all of which add to the complexity of studying 
the potential role of ROCK in chondrogenic and osteogenic differentiation 
processes.  
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Hypothesis and aims of the study  
 
It is now well-established that ESCs are an attractive cell source for advancing 
in vitro differentiation techniques that recapitulate the embryonic development 
and differentiation of specific cell types.  This occurs through a directed and 
controlled set of experimental conditions that also allow the testing of putative 
novel regulators of differentiation that can eventually be translated further to 
clinical applications.  Based on the current knowledge in the ESC differentiation 
field described in the Introduction, it is clear that the derivation and 
characteristics of the earliest embryonic chondrocyte and osteoblast precursors 
are not well understood.  It is also clear that previous studies exploring the role 
of the ROCK pathway in cartilage and bone development has produced 
controversial findings.  
Therefore, the work in this thesis will take a developmental culture approach 
using mESCs to (1) establish a novel system for studying the ontogeny of 
chondro-osteoprogenitor cells and differentiation to chondrocyte and osteoblast 
lineages, and (2) use this system to unravel the developmental role of ROCK 
signalling on chondrogenesis and osteogenesis.  The specific Aims are 
described below: 
1.  To establish and optimise a step-wise differentiation system of mESCs using 
defined factors, through mesoderm specification, enrichment and commitment 
to cartilage and bone cell lineages, and differentiation to maturity in vitro.  This 
will test the hypothesis that defined combinations and exposure to specific 
developmental factors can produce the optimal mesodermal subpopulations for 
chondro-osteoprogenitor cell differentiation. 
2.  To investigate the role of Rho/ROCK signalling through inhibition of ROCK 
activity at defined stages of lineage development.  This will test the hypothesis 
that ROCK inhibition will have differential effects on chondrogenesis and 
osteogenesis depend on the stage of development and differentiation of early 
stem/progenitor cells versus lineage committed cells.   
3.  To investigate the potential of ESC-derived chondrocytes and osteoblasts 
generated in vitro to differentiate in vivo following xenograft transplantation.  
This will test the hypothesis that in vitro-generated chondrocytes and 
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osteoblasts using the protocols of Aims 1 and 2 can recapitulate developmental 
chondrogenesis and ossification to form functional tissue in vivo. 
I anticipate that after achieving these Aims, that novel insights will be gained 
into the mechanism of cartilage and bone development that may contribute to 
the improvement of regenerative therapies and the treatment of cartilage and 

















Materials and methods  
- 61 - 
 


















 - 62 - 
List of reagents and abbreviations  
 
Alcian blue                                                                           AB 
 
Alkaline phosphatase                                                          ALP 
 
Bone morphogenic protein 4                                               BMP4 
        
Bovine Serum Albumin                                                        BSA 
B27 supplement                                                                  B27  
serum-free supplement 
rat hippocampal and cortical neurons  
 
Dexamethasone                                                                 Dex  
 
1,25-dihydroxyvitamin D3                                                   Vitamin D3 
 
Distrene plasticiser xylene                                                  DPX  
 
Dulbecco's Modified Eagle Medium                                    DMEM 
Ethylenediaminetetraacetic acid                                         EDTA 
Fibroblast growth factor 2 (basic FGF)                               FGF2 
 
Foetal calf serum                                                                FCS 
β-glycerophosphate                                                            β-GP 
Growth/differentiation factor 5                                            GDF5 
  
Hydrochloric acid                                                                HCL 
 
 
Iscove's Modified Dulbecco's Media                                   IMDM 
L-Ascorbic acid                                                                    AA  
leukaemia inhibitory factor                                                  LIF 
 
L-Glutamine                                                                        L-Glut  
Magnesium chloride                                                            MgCl  
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List of reagents and abbreviations  
 
Moloney murine leukemia virus                                          MMLV-RT     
 
Monothioglycerol                                                                 MTG 
 
Chemically defined, serum-free supplement,                     N2-Supplement                                                                                
based on N-1 formula    
(Growth of a rat neuroblastoma cell line 
 in serum-free supplemented medium)             
 
Paraformaldehyde                                                              PFA 
 
Phosphate-Buffered Saline                                                 PBS  
   
Rho-associated protein kinase                                            Y27632 
(ROCK inhibitor) (C14H21N3O.2HCl).                                      
Chemical name: trans-4-[(1R)-1-Aminoethyl]-N-4-pyr  
idinylcyclohexanecarboxamide dihydrochloride 
       
Smoothened (Smo)                                                             SAG  
agonist (Chlorobenzothiophene-containing Hh                             
pathway)  
 
An animal origin-free, recombinant enzyme                TrypLETM 
replacment of porcine trypsin 
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2.1 Cell culture  
 
2.1.1 Mouse Embryonic Stem Cell (mESC) culture  
 
As described in the introduction, mESCs are a useful system to study 
osteoblasts and chondroblasts from early lineage specification and commitment 
to differentiation stages.  For all experiments, the CCE cell line (feeder-free cell 
line) was used (Robertson et al. 1986). Cells were differentiated using a 
modification of a three-phase protocol that has been published previously (Craft 
et al., 2013; Gouon-Evans et al. 2006) with some modification for this project as 
described in chapter 3.  
 
2.1.2  mESC growth and maintenance 
  
Cells were maintained in DMEM media supplemented with 20% batch-tested 
FCS (Summit), leukaemia inhibitory factor (LIF) (103 u/ul) (Chemicon) and 
1.5x10-4 M of monothioglycerol (MTG, Sigma-Aldrich) (designated DMEM-ES 
media).  Cells were plated in a 6-well plate (BD Falcon) coated with 0.1% 
gelatine (in 1% BSA/PBS).  Cells were passaged when they reached near 
confluence (80%) and the medium was changed every other day.   
To freeze down ESCs, cells were spun down at 1200 rpm for 5 minutes at 4°C 
and re-suspended in cold freezing medium (prepared early and kept on ice) at 
approximately 5x106 cells/vial.  Cell suspensions were slowly and gently 
pipetted into ice-cold cryovials (1 or 1.8 ml size) (labelled and stored at -80°C 
prior to freezing). Vials were frozen at -80°C and then transferred to liquid 
nitrogen for long-term storage. 
 
2.1.3  mESC differentiation via generation of Embryoid Bodies (EBs) 
 
To prepare ESCs for differentiation, they were passaged once more in IMDM-
ES+LIF media where DMEM was replaced by IMDM in the medium followed by 
plating of ESCs in SFD medium to start the differentiation process.  This stage 
of differentiation is identified as (0d), which is the start of differentiation (Fig.2.1) 
and will be discussed in details in next section 2.1.3.1. 
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2.1.3.1 Mesoderm induction (phase I: 2-4d) 
 
At 0d of differentiation (start of differentiation), mESCs were trypsinised (0.25% 
trypsin/EDTA, Sigma-Aldrich) and cultured in 60mm dishes (Sterilin) at 7.5x106 
cell/dish in SFD medium.  This stage allowed mESCs to form embryoid bodies 
(EBs). The SFD medium used in the differentiation experiment consisted of N2-
Supplement and B27 (without retinoic acid) (Invitrogen), 10% BSA/PBS (Sigma-
Aldrich), IMDM (Sigma-Aldrich), F12 (Invitrogen), 1% L-glutamine and 1% 
Penicillin/Streptomycin (Sigma-Aldrich). SFD medium was then supplemented 
with 50ug/ml L-ascorbic acid (AA), L-glutamine (5mM) and MTG (3ul/1ml) 
(Sigma-Aldrich) just prior to adding the medium to the cells. This medium will be 
referred to as SFD+supplements (SFD+S).   After 2d of differentiation, EBs 
formed were harvested and dissociated with 0.25% trypsin/EDTA then re-
aggregated in SFD+S consisting of mesoderm-inducing factors: 9 ng/ml Activin 
A (cat. no. 338AC), 25ng/ml Wn3a (cat. no. 1324WN), and 100 ng/ml Noggin 
(cat. no. 1967NG) (R&D) cultured at the same initial cell density for 2 days (Fig. 
2.1).  A one-day mesoderm induction was also tested as shown in next section. 
2.1.4 One day mesoderm induction (phase I: 2-3d) 
 
The mesoderm induction medium used for a 2-day mesoderm induction (from 2-
4d) discussed in the previous section 2.1.3.1, was also used in testing a 1-day 
mesoderm induction period (from 2-3d) for both chondrogenic and osteogenic 
differentiation in phase III.   
 
2.1.4.1  Mesoderm enrichment  (phase II: 4-7d) 
 
 At 4d of differentiation (following a 2-day mesoderm induction), formed EBs 
were dissociated in TrypLE and re-aggregated in a 24-well plate (ultra low 
attachment) (Costar) at 0.25x106 cell/well in a suspension culture. At this time 
only FGF2 (10ng/ml) (cat. no. 234-FSE) (R&D) was added to SFD+S medium 
for mesoderm enrichment (Fig. 2.1). 
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2.1.4.2 Monolayer differentiation (phase III: 7-21d) 
 
At 7d (following 3 days of re-aggregation), re-aggregates were dissociated with 
TrypLE and plated as single cells in a 0.1 % gelatinised, 96-well plate (BD 
Falcon) at a cell density of (10,000 cell/well) in a monolayer culture. The cells 
were cultured in SFD+S consisting of either chondrogenic or osteogenic 
differentiation media as will be described in the next sections.  All cultures were 
incubated in a humidified atmosphere containing 5% CO2 at 37°C. The medium 





Figure 2.1: Step-wise, serum free directed ESC/EB differentiation culture model. 
The start of the differentiation was marked once CCE mESCs had been 
cultured in the absence of LIF for 2 days. At 2d of differentiation, ESCs were 
cultured in SFD+S consisting of mesoderm-inducing factors: 9 ng/ml Activin A, 
25ng/ml Wnt-3a, and 100 ng/ml Noggin for 2 days (phase I: from 2-4d).  At 4d of 
differentiation, formed EBs were cultured in FGF2 (10ng/ml) for 3days (phase II: 
from 4-7d).  At 7d of differentiation, aggregates were plated as single cells in a 
monolayer culture containing differentiation media for 2 weeks (phase III: 7-
21d).  Chondrogenic media details are given in section 2.1.5 and osteogenic 
media details in section 2.1.6. 
 
2.1.5 Chondrogenic differentiation  
 
For chondrogenic differentiation, single cells were cultured in SFD+S media 
consisting of FGF2 (10ng/ml) and recombinant human BMP4 (100ng/ml) (R&D) 
in addition to ascorbic acid and L-glutamine  (Table 2.1). 
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                   Table 2.1: Chondrogenic differentiation media. 
 
2.1.6 Osteogenic differentiation  
 
For osteogenic differentiation, single cells were cultured in SFD+S media 
consisting of FGF2 (10ng/ml), BMP4 (100ng/ml), ascorbic acid, L-glutamine, in 
addition to, Dexamethasone (10-7M) (Sigma-Aldrich) and β-GP (10uM) (Sigma-







                     Table 2.2: Osteogenic differentiation media.  
2.2 Analysis of ROCK inhibition via Y27632 on mESC differentiation  
 
At 4d (following 2 days in mesoderm induction media), formed EBs were 
dissociated and re-aggregated in a 24-well plate (ultra low attachment) at 
0.25x106 cells/well. At this time Y27632 (10uM) (Merck) was added to SFD+S 
media in the presence of FGF2 (Fig. 2.4). At 7d (after 3 days of re-aggregation), 
cells from Y27632 pre-treated and not pre-treated at phase II, were plated in a 
0.1 % gelatinised, 96-well plates at a cell density of 10,000 cells/well. The cells 
were cultured in the presence and absence of Y27632 in either chondrogenic 
(table 2.1) or osteogenic media (table 2.2) for 2 weeks (Fig. 2.2). 
 
 
Reagent Final Conc. Company/cat. no. 
SFD+S (A.A+L-G+MTG) 1ml/ml - 
 Recombinant Human FGF2 10ng/ml R&D/234-FSE 
Recombinant Human BMP4 100ng/ml R&D/314BP 
Reagent Final Conc. Company/cat. no. 
SFD+S (A.A+L-G+MTG) 1ml/ml - 
Recombinant Human FGF2 10ng/ml R&D/234-FSE 
Recombinant Human BMP4 100ng/ml R&D/314BP 
Dexamethasone 10-7  M Sigma-Aldrich/D8893 
β-glycerophosphate 10uM Sigma-Aldrich 
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Figure 2.2: Step-wise, serum free directed ESC/EB differentiation culture model 
showing stage specific addition of Y27632. 
 A schematic diagram showing 3-stage differentiation phases described in 
(figure 2.1).  At 4d of differentiation (phase II), formed EBs were cultured in 
FGF2 (10ng/ml) for 3days in the presence and absence of Y27632 (10uM). At 
7d of differentiation (phase III), cells from Y27632 pre-treated and not pre-
treated at phase II, were plated as single cells in a monolayer culture in the 
presence and absence of Y27632 in either chondrogenic (table 2.1) or 
osteogenic  (table 2.2) media for 2 weeks. 
 
2.3 Modification of the differentiation phase (phase III) protocol  
 
The culture medium used in the differentiation phase (phase III: 7-21d) was 
modified as presented in (chapter 5) and (chapter 7, section B) to investigate 
the in vitro differentiation and maturation potential of chondrogenic and 
osteogenic cells, respectively.   
2.3.1 Culturing cells in FGF2 either alone or in combination with BMP4 in 
the differentiation phase (phase III) 
 
At 4d of differentiation, EBs were cultured in SDF+S containing FGF2 and 
Y27632 for 3-days of the reaggregation period.  At 7d of differentiation, 
aggregates were plated in a 0.1 % gelatinised, 96-well plate at a cell density of 
10,000 cells/well in a monolayer culture in SFD+S in the presence of Y27632 
with either FGF2+BMP4, FGF2 alone or BMP4 alone for 3 weeks (Fig. 2.3A). 
This was also tested in osteogenic media, which consisted of SFD+S in the 
presence of Y27632 with either FGF2+BMP4, FGF2 alone or BMP4 alone, in 
addition to, Dexamethasone and β-GP (Fig. 2.3B).   
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2.3.2 Primary osteoblast cultures  
 
Primary calvarial osteoblasts were isolated as described by Harmey et al. 
(2004) and cultured in differentiation media, which consisted of AA and β-GP, in 
both the presence and absence of batch-tested serum.  The differentiation 
media was then supplemented with FGF2 or a combination of FGF2 and BMP4 







Figure 2.3: A schematic diagram showing the addition of FGF2 alone or in 
combination with BMP4 in chondrogenic or osteogenic media.  
A) A differentiation scheme showing the timing of factors additional to the 
culture media in phases II and III. In phase II, cells were cultured in FGF2 and 
Y27632. Then in phase III, cells were cultured in chondrogenic media 
containing Y27632 in the presence of FGF2 and BMP4 either alone or in 
combination for 3 weeks.  B) A differentiation scheme showing the timing of 
factors additional to the culture media in phase II and III. In phase II, cells were 
cultured in FGF2 and Y27632. Then in phase III, cells were cultured in 
osteogenic media containing Dexamethasone, β-GP and Y27632 in the 
presence of  FGF2 and BMP4 either alone or in combination for 3 weeks.  
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2.3.3 Culturing cells in temporal FGF2 in the differentiation phase (phase 
III) 
 
For testing chondrogenic differentiation in Y27632 and temporal FGF2 
containing media, cells from Y27632 pre-treated and not pre-treated at phase II 
were plated on 7d in SDF+S consisting of FGF2 and BMP4 (100ng/ml) in the 
presence of Y27632. After one week of culture, FGF2 was removed from the 
media and cells were cultured for another week in BMP4 and Y27632 for 
chondrogenic differentiation, or further supplemented with Dexamethasone and 
β-GP for osteogenic differentiation. The temporal FGF2 protocol will be referred 







Figure 2.4: Culturing cells in temporal FGF2 in the differentiation phase (phase 
III). 
 
A differentiation scheme showing the timing of factors additional to the culture 
media in phases II and III.  In phase II, cells were cultured in FGF2 in the 
presence and absence of Y27632. Then in phase III, cells were cultured in 
chondrogenic media containing Y27632, FGF2 and BMP4. At 14d, FGF2 was 
removed from the culture media and cells were cultured in media containing 
Y27632 and BMP4 for another week.  B) A differentiation scheme showing the 
timing of factors additional to the culture media in phases II and III.  In phase II, 
cells were cultured in FGF2 in the presence and absence of Y27632. Then in 
phase III, cells were cultured in osteogenic media containing Y27632, FGF2, 
BMP4, Dexamethasone and β-GP. At 14d, FGF2 was removed from the culture 
media and cells were cultured in media containing Y27632 and BMP4 for 
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2.3.4 Culturing cells in temporal FGF2 and GDF5 in the differentiation 
phase (phase III) 
 
For testing chondrogenic differentiation in media containing GDF5, cells from 
Y27632 pre-treated and not pre-treated at phase II, were plated at 7d in SDF+S 
consisting of FGF2 and GDF5 (30ug/ml) (R &D) in the presence of Y27632. 
After one week of culture, FGF2 was removed from the media and cells were 
cultured for another week. This culture media will be referred to as (Temporal 





Figure 2.5: A schematic diagram showing addition of temporal FGF2 and GDF5 
in phase III.  
A differentiation scheme showing the timing of factors additional to the culture 
media in phases II and III.  In phase II, cells were cultured in FGF2 in the 
presence and absence of Y27632. Then in phase III, cells were cultured in 
FGF2 and GDF5 in the presence of Y27632. FGF2 was removed from the 
culture media and cells were cultured in media containing Y27632 and GDF5 
for another week.  
   
2.3.5 Prolonging the culture period to test mineralisation in the 
differentiation phase (phase III) 
 
The original standard culture period used for osteogenic differentiation in phase 
III was 2 weeks (from 7d to 21d). The culture period was then prolonged for 
another 2 weeks (i.e. from 21d to 35d).  Cells were treated with Y27632 in 
phase II, and subsequently, in phase III, cells were cultured in osteogenic media 
(table 2.2) in addition to Y27632 for 35 days.   
 
Materials and methods 
- 72 - 
 
2.3.6 Culturing cells in osteogenic inducing agents in the differentiation 
phase (phase III) 
 
Cells from Y27632 pre-treated and not pre-treated in phase II were cultured in 
media in phase III in osteogenic media (table 2.2) containing Y27632, in 
addition to one of the following factors; SAG, Wnt3a, VitD3 or β-GP (2mM) for 3 









Figure 2.6: Culturing cells in Y27632 with known osteogenic inducing factors. 
A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.  In phase III, cells were cultured in osteogenic media 
supplemented with one of the following osteogenic factors: β-GP (2mM), VitD3 
(10-8M), SAG (100nM) and Wnt3a (10ng/ml) for 3 weeks. 
 
2.3.7 Culturing cells in differentiation media containing serum  
 
Cells were cultured in phase II in the presence of Y27632, and in phase III cells 
were cultured in osteogenic media (Table 2.1) containing Y27632 for 28d, and 
additionally batch-tested FCS was added at three different concentrations (10%, 
1%, and 0.1%).   
2.3.8 Re-plating differentiated cells in phase IV (21-28d) 
 
Cells Y27632 pre-treated and not pre-treated in phase II were cultured in 
osteogenic media in presence of Y27632 in phase III, for 2 weeks. FGF2 was 
added only for one week (7-14d) and removed afterwards. Cells were then 
dissociated using TrypLE and replated in 0.1 % gelatinised, 48-well plates 
(Corning® Costar®) in osteogenic media containing BMP4, Dexamethasone 
and β-GP in the presence of Y27632 (Fig. 2.7).  
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Figure 2.7:A schematic diagram showing ESC/EB differentiation culture model 
with the re-plating phase  (phase IV).  
A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.  Cells from Y27632 pre-treated and not pre-treated in 
phase II, were cultured in phase III, in osteogenic media containing BMP4, 
Y27632, Dex, and β-GP. At 14d, FGF2 was removed from the culture media 
and cells were cultured in Y27632 BMP4, Dex, and β-GP for another week. At 
21d, the cells were re-plated and cultured in media containing BMP4, Dex, and 
β-GP in the presence and absence of Y27632 for 1 week.  
  
2.4 Kidney capsule in vivo transplantation  
 
At the mesoderm enrichment phase (phase II), cells were cultured in FGF2 in 
the presence and absence of Y27632 and then harvested at 7d for 
transplantation under the kidney capsule of adult immunocompromised (SCID) 
mice, in the form of aggregates or as a single cell suspension in matrigel.  
Matrigel was then transplanted without cells as a control (Fig. 2.8A).   
At the differentiation phase (phase III), cells from Y27632 pre-treated or not pre-
treated were the cultured in phase III in osteogenic media in the presence of 
Y27632.  At 21d of differentiation, monolayers were harvested by mechanically 
scraping the monolayer from the well plate as one piece and surgically placing it 
under the kidney capsule of adult immunocompromised (SCID) mice (Fig. 
2.8B). After that, the kidneys were surgically removed and fixed in 4% 
paraformaldehyde overnight, and then decalcified for 1 day. Kidney samples 
were then processed and embedded in wax for histology 2.5.5.1.  
Transplantations were performed in 2 independent experiments.  All animal 
studies had been reviewed and approved by the Institutional Animal Care and 
Use Committee at King’s College University in accordance with the policy 
regarding the use and care of laboratory animals and all procedures were 
performed according to Home Office guidelines.  
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Figure 2.8: A schematic diagram showing the two time points of in vivo 
transplantation.  
A differentiation scheme showing the timing at which Y27632 was added.   In 
phase II, cells were cultured in FGF2 in the presence and absence of Y27632.  
Then after 3 days in culture (at 7d), cells were harvested and transplanted 
under the kidney capsule of adult immunocompromised (SCID) mice, in the 
form of aggregates or as single cells in matrigel suspension, and harvested 
after 3 weeks.  B) A differentiation scheme showing the timing at which Y27632 
was added.   In phase II, cells were cultured in FGF2 in the presence and 
absence of Y27632.  In phase III, cells were cultured in the presence and 
absence of Y27632 in osteogenic media.  Then, after 2 weeks in culture (at 
21d), cells were harvested and transplanted under the kidney capsule of adult 
immunocompromised mice (SCID), in the form of a monolayer, and harvested 




Materials and methods 
- 75 - 
 
2.5 Data analysis  
2.5.1 Histochemical staining: 
  
The cultured cells were fixed at 21d with 4% paraformaldehyde (PFA) in PBS 
for 15 minutes and washed with distilled water prior to staining to remove any 
residual fixing material.  
 
2.5.2 Alkaline phosphatase staining and quantification 
 
Alkaline phosphatase (ALP) activity of osteoblasts was examined using a salt 
solution prepared from a mixture of 5mg Naphthol AS MX-PO4, 200µl N,N- 
dimethylformamide (DMF) added to 25ml Tris-HCL (0.2M, pH8.3), 25ml distilled 
water and 30mg Fast Red TR . All staining reagents were purchased from 
Sigma-Aldrich (Dorset, UK). The solution was filtered through a 0.45um filter 
(NALGENE 190-2545) and immediately added to fixed cells and left to incubate 
at room temperature until the cells turned red (working time 10 minutes until 
solution start to precipitate). Following incubation, the cells were rinsed with 
distilled H2O and visualised under microscope (Olympus). Plates were also 
scanned using an Epson Perfection 1200 scanner (Herts., UK). Quantification of 
the stained area was done using Image J ® software to quantifying the 
threshold area.  
 
2.5.3 Alcian Blue staining and quantification 
 
To stain acidic proteoglycans in chondrocyte nodule monolayers, a 1% Alcian 
blue solution prepared in 0.1N HCl was used. The cells were washed for 3x 3 
minutes each with 0.1 N HCl and then stained with Alcian Blue for 8 hours or 
left overnight. Monolayers were then washed again with 0.1 N HCL for 3x 3 
minutes per wash followed by a distilled water wash. The stained wells were 
prepared for quantification of staining area as described above for alkaline 
phosphatase staining images, using Image J ® software. When the chondrocyte 
nodules had coalesced, grid count method, a modification of the point-counting 
method was used (Grigoriadis et al 1996). 
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 The Alcian Blue-positive area/nodules which coincided with a grid intersect was 
scored and expressed as a percentage of the total number of intersects.  
For quantification of Alcian Blue staining, which represents GAG synthesis, 
Alcian Blue-stained monolayers were first solubilised using a modification of the 
Mushtag et al (2002) protocol as the follows; after washing the monolayer with 
distilled water , the wells were treated with 200ul of 6M of guanidine HCL to 
extract alcian blue colour for 6 hours on a rotating platform at room 
temperature,  repeated pipetting of guanidine solution to aid in mechanically 
extracting alcian blue colour from 3-D chondrocyte nodules. Then extracted dye 
solution was transferred from each well to a labelled clean well to allow for 
accurate measurements using a plate reader (Thermo, Multiskan Ascent).  
Absorbance was measured at OD of 630nm. The quantifications were then 




To analyse the expression of cartilage markers (Sox9, Col II, Col X) and bone 
markers (Col 1) during ESC differentiation, an indirect immunofluorescence 
technique was used.  The monolayer was stained either in situ or on a slide 
following histological sectioning. Each antigen required specific treatment 
before antibody staining.  Briefly, the monolayer was fixed in 4% PFA in PBS for 
15 minutes and washed with distilled water and then treated according to each 
protein as summarised in Tables 2.3 and 2.4. After that, the monolayer was 
washed 3x with 5-10% gout serum blocking solution at room temperature. 
Primary antibody was diluted in blocking buffer then added at the optimised 
dilutions (Table 2.4) and incubated at 4°C overnight. The monolayer was 
washed with PBS 3x and incubated in secondary antibody for 45 minutes or 1 
hour at room temperature in the dark. Finally, the monolayer was then 
incubated with 4', 6-diamidino-2-phenylindole (DAPI) (1ug/ml) or Hoechst 33342 
(20ug/ml) (Sigma) for 15 min for nuclear staining. To detect Sox9 expression, 
staining was performed on 7d cells on following cytospinning of the cell 
suspension, or on monolayers from 10d cultures (ie. 3days after plating).  Col I 
and Col II stainings were performed on 21d monolayers.  Col X staining was 
performed on 21d monolayers following paraffin histology. 
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The stained monolayers were visualised using a Zeiss microscope 
(Axiovert200)/software Axiovision 4.8 software, or a Nikon microscope Eclipse 
80i. DAPI, FITC and TRITC fluorescence were visualised with DAPI filter 
(excitation 358nm and emission 461 nm), FITC filer (excitation 494 and 




At 7d of differentiation aggregates were dissociated and single cells were 
prepared for cytospin (Shandon Cytospin 3). The cells were centrifuged at 1350 
rpm for 5 min and slides were fixed with 4% PFA for 15 minutes at room 
temperature followed by 0.2% washed with Triton-X100 for 15 min again at 
room temperature.  Then the samples were blocked in 5% goat serum in PBS 
overnight at 4°C as described above prior to immunostaining, and were 
counterstained with 10 ug/ml Hoechst for 5-10 minutes at room temperature. 
The stained cells slides were visualised using Nikon microscopy.  
   
 
   Table 2.3: Reagents used for Collagen type II immunofluorescence staining. 
 
Procedure Reagents Concentration Company/ cat. no. 
Pepsin 10 mg/ml  
Sigma-Aldrich/P-
7000 Pepsin digestion 
solution Hydrochloric 
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2.5.5.1 Tissue processing and histology   
 
The two-week (21d) differentiated monolayers were mechanically scraped 
under a dissecting microscope using a sterile needle to detach the edges of the 
monolayer from the well prior to fixation.   All samples, including cell monolayers 
and kidney tissues were fixed in 4% paraformaldehyde, decalcified in 0.5M 
EDTA where appropriate, dehydrated in increasing concentrations of ethanol, 
then washed with histoclearTM, before being embedded in paraffin and cut at 
5um using microtome (leica, RM2245). Monolayers were processed for 
histology according to the step-wise protocol in Table 2.5.  All sections were 
mounted on poly-lysine coated slides (super frost plus, VWR, 631-0449) then 
de-paraffinised and rehydrated before stained with H&E and Alcian Blue, or 
processed for immunocytochemistry as indicated.   
Haematoxylin & Eosin (H&E) staining was used together with Alcian Blue 
staining to stain the nuclei (purple/blue colour) with Haematoxylin (Solmedia 
HST003) and eosin to stain (Solmedia HST101) cytoplasm of the cell (pink/red 
colour) while Alcian blue to stain chondrcocyte extracellular matrix.  Sections 
were then de-paraffinized with Histo-clearTM 10 minute x2 and rehydrated 
through a series of ethanol washes (100%, 90%, 70% and 50%) 2 
minutes/wash. Sections were then washed for ten minutes in distalled H2O 
followed by submerging sections in Erhlich’s Haematoxylin for 10 minutes.  
Samples were then washed for 10 minutes under running water to remove 
excess haematoxylin. Then sections submerged in acid alcohol for 15 seconds. 
Subsequently, the sections were stained with 0.5% aqueous Eosin for two 
minutes, then washed in distalled H2O and dehydrated through a series of two 
minute ethanol washes (70%, 90% and 2x 100%). Sections were then air-dried 
up to one hour.  After that, slides were mounted using DePex (Solmedia 
REA201) mounting media. Modification of timing was done for monolayer tissue 
sections. Sections were mounted in either aqueous or DePeX mounting media.  
Finally, sections were visualized under Zeizz microscope Axioskop 2 plus/ soft 
ware and pictures taken using AxioCamHRcamera. 
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      Table 2.5: Monolayer tissue processing protocol. 
 
2.5.6 Molecular analysis: Polymerase Chain Reaction (PCR) 
 
Determination of cellular gene expression was done using reverse transcription-
PCR (RT-PCR) at specific time-points during differentiation (Fig. 2.9). A two-
step protocol was used. First, RNA was reverse transcribed to cDNA. Second, 
diluted cDNA was amplified by either quantitative or semi-quantitative RT-PCR 
as described below. All steps up to PCR reaction were carried out using RNase 
and DNase free pipette filter tips; all bench areas were cleaned using an RNase 
and DNase free solution (Sigma-Aldrich). The RNA and DNA work were 






Figure 2.9: Time points at which RNA was extracted and used for PCR and 
gene expression analysis.   
 
Stations Solution Procedure 
1 PBS Wash 3x 
2 70%ethanol Incubate 15 minutes 
3 90% ethanol Incubate 15 minutes 
4 100% ethanol Incubate 15 minutes 3x 
5 histoclear Incubate 15 minutes 
6 Ultraplast wax Incubate 15 minutes 3x 
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2.5.6.1 RNA extraction and quantification 
 
RNA preparation and extraction was performed using the Qiagen RNEasy mini 
and micro kits following manufacturer’s instructions.  Briefly, cells at the 
indicated times were removed and dissociated using either 0.25% trypsin in 
EDTA (for cells from DMEM and IMDM cultures) or TrypLE (from 0d-28d) for 
not more than 5 minutes, then lysed by addition of appropriate volume of RLT 
lysis buffer containing β-mercaptoethanol (β-ME) (10ul/ml) to allow for complete 
release of RNA. Mechanical pipetting was performed until complete lysis of 
monolayer was achieved. The Lysates were stored at -80°C until RNA 
extraction.  
The Lysates were homogenised using a QIAshredder spin column (Qiagen) to 
reduce the viscosity of the lysates and ensure binding of RNA to the silica 
membrane. RNA was isolated from lysate using a RNeasy column purification 
kit (Qiagen) according to the manufacturer’s instructions. A Minikit 
(74104,74106) or Microkit (74004) was used according to cell numbers. The 
Minikit was used to extract RNA from 0d to 7d while the Microkit was used for 
RNA extraction from 14d and 21d cultures. Poly-A RNA was added to lysate 
before homogenising step, as an RNA carrier (4 ng/µl). DNase (nonspecific 
endonuclease) was included in the extraction process to that degrades DNA. 
The concentration of RNA was determined by measuring absorbance at 260nm 
(A260) in a spectrophotometer (NanoDrop 2000C, Thermo), which included 
measuring purity of RNA  (260/280 and 260/230 ratios).  
2.5.6.2 Reverse transcription  (RT) 
 
Reverse transcription was performed in two steps.  First, to melt secondary 
structure of RNA, 1ug of RNA was mixed with random primers (Table 2.6) and 
denatured at 70°C for 5 minutes, then placed on ice for five minutes until 
proceeding with the reaction mix for cDNA synthesis (Table 2.7).  The reaction 
mix contained MMLV-RT Reverse Transcriptase as an RNA-dependent DNA 
polymerase (Table 2.7). The reverse transcription reaction mix was then added 
to the RNA and random primer mix, and was incubated at room temperature for 
10 minutes then in a hot block at 42°C for 1 hour. Then placing samples on ice 
stopped the reaction. Negative control samples were prepared by omitting 
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MMLV-RT in the reaction mix. Then cDNA was diluted 1:5 in nuclease free 

















dNTPs 1mM 1.25ul 1.25ul Promega/C114G 
 buffer 5x 5ul 5ul Promega/M531A 
MMLV-RT 200u/ul 1ul -  Promega/M170A 
Nuclease-
free H2O - 3.75ul (4.75) 
Promega 
Total volume  11ul 11ul - 
 
          Table 2.7: Reverse transcription (RT) reaction mix for cDNA synthesis.  
 
 
2.5.6.3 Primer designing, efficiency and specificity testing 
 
Forward and reverse primers were designed using Primerblast-NCBI with exon-
exon junction spanning to limit amplification to mRNA only. Some primers were 
found in published papers and checked using NCBI Primer-Blast for specificity 
(Table 2.11).  Serial 1:5 dilutions of RNA expressing the gene of interest (E11.5-
14.5 for chondrogenic genes, primary osteoblasts (POB) for osteogenic genes) 
were used to run standard curves for each primer pair. Specificity was 
determent by checking the melting curve for a single peak. This indicates that 
each primer pair amplified a single amplicon (Fig. 2.10). The PCR product was 
then run on a 2% agarose gel to confirm the product size. 
Reagent Volume/reaction (ul) Company/cat.no. 
RNA Up to 12 ul - 
Random primer 20ug 2 Promega/C118A 
RNase-free water Prepared up to 14 - 
Total volume 14 - 
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Figure 2.9: Quantitative PCR amplification data, constructed standard curve, 
and melting curve analysis for primer testing.   
A) A representative image of a qRT-PCR run showing tight grouping of the 
triplicate amplification lines of each of the gene's standards. B) A standard 
curve analysis showing 109% efficiency, R^2=0.998, and slope=-3.11.  C). A 
single peak in the melting curve analysis demonstrates that one specific product 
was amplified. 
 
2.5.6.4 cDNA amplification  and Semi quantitative RT- PCR  
 
Diluted cDNA was used for the PCR reaction and SYBR green was used as a 
fluorescent dye to detect amplified double-stranded DNA specifications. 
Nuclease-free water (non template control) and no reverse transcription was 
used as negative controls, while E11.5-E14.5 and primary mouse calvaria 
osteoblast (POB) cDNAs were used as positive controls for cartilage and bone, 
respectively.  The reaction mix was prepared as shown in Table 2.8, aliquoted 
in 0.2ml PCR tubes followed by 1ul of cDNA.  PCR tubes were later run in a 
PCR machine (MJ Research, PTC200, peltier thermal cycler) using a three-step 
protocol with an annealing temperature at 55-60°C.  The PCR cycles were 
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The generated amplicon was then run on a 1-1.5% agarose gel containing 
ethidium bromide to allow for visualisation of PCR product bands under UV 
light. A DNA ladder 100bp (Fermentas, SM0323) was run in same gel with 
tested samples to confirm PCR product size. The reaction mix was prepared as 
in Table 2.9, aliquoted in transparent q-PCR tubes followed by 1ul of cDNA. 
PCR tubes were run on a Rotor-Gene Q 6000 (Qiagen) machine using a two-
step protocol as follows: 1-Denaturation: 95°C, 3 minutes. 2-Amplification: 
Denaturation 95°C, 5 seconds. Then combined anneling/extension 60°C, 1 
second 3-Melting: Ramp from 65°C to 95°C rising by 1°C/step.).  The PCR 
cycles were repeated 40 times. In most runs, the internal control (Gapdh) as 
well as negative controls (non-template and no reverse transcription) were 
included. Each PCR was performed in triplicates.  The generated amplicon was 
then run on a 1.5-2% agarose gel as described above.  
         










- 32.75 Promega 
Primer F 10um 0.5 See Table 2.10 
Primer R 10uM 0.5 See Table 2.10 
dNTPs 1mM 1 Promega/C114G  
 Buffer  5x 10 Promega/M531A  
MgCl2 25mM 3 Promega/A351B  
GoTaq 5u/ul 0.25 Promega/M830B 
cDNA 1:5 dilution 1 - 
  Total volume =49 - 
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         Table 2.9: Reaction mix for quantitative RT-PCR (qRT-PCR). 
2.5.6.5  PCR data analysis 
 
Analysis of the PCR runs was performed using the Rotor-Gene Q 2.1.0.9 
software. Quantification of gene expression was performed in the exponential 
range of each primer pair to get closer to 100% efficiency of primers and SYBR 
green. Then a comparative CT method was used to quantify changes in the 
expression of gene of interest between the different samples. Data plotted as 
ΔCT = CT (target gene) – CT (endogenous reference gene) whereby Gapdh 
was used as the reference gene.  Primers used for gene expression analysis 
are listed in table 2.10.  
2.5.7 Statistical analysis  
All data were presented as the mean ± standard deviation (SD) from 3 
replicates unless stated otherwise. The statistics used were the student’s t-test 
(paired and unpaired) according to the comparison to test differences between 
to groups. For more than two groups a one-way ANOVA analysis was used with 
Holm-Sidak posthoc test for correcting multiple comparisons (GraphPad 
software, Prism 6) with a significant cut off point at p ≤ 0.05. Data were 
represented as mean ± SD from a representative experiment.  Experiments 
were repeated at least 3 times for verification unless stated otherwise. A cut off 
point at p ≤ 0.05 was considered statistically significant.  
Reagent Volume/reaction (ul) Stock concentration 
Company/ 
cat.no. 
Forward primer 0.5 100uM (1:10 dilution) 
See table 
2.10 
Reverse primer 0.5 100uM (1:10 dilution) 
See table 
2.10 
Brilliant III Ultra-Fast 
SYBER@Green 
QPCR Master Mix 
5 2x Agilent/600882 
cDNA 2-1 1:5 dilution - 
Nuclease-free H2O 
Top up to 
10ul - Promega 
Total volume 10   
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Table 2.10:  List of primer sequences used for PCR analysis. 
 (F: forward, R: reverse, PL: product length). 
Primer 
 
Sequence 5’-3’ Accession  number 
F TTGTCCTCAGTGGGGCGGTT Oct-4 
(Pou5f1) R CACCTTTCCAAAGAGAACGCCCAGG 
NM_001252452.1 





F CGCACGCCAGACTGTGTAT Pdgfrα 
R GTTAAAGACGGCACAGGTCAC 
NM_011058.2 
F CACCTGGCACTCTCCACCTTC Flk1 
(KDR) R GATTTCATCCCACTACCGAAAG 
NM_010612.2 
F AGAAACTGCAGACCAGAAGCTATCA  
Sox17 R GCT CATTGT ATC CAT GAG GTG 
ACA 
NM_011441.4 
F CATTGGCCCCTTGTGAGGCCAGAGA Gata1 R ACCTGATGGAGCTTGAAATAGAGGC NM_008089.2 
F ATGCTGGCCGCCTTCAAGCC Nkx2.5 
 R CTGCAGCGCGCACAGCTCTTT NM_008700.2 
F AAACCACTCCTGCGTTGTGTAAG Tcf15 
(Paraxis) R TGGATGGCTAGATGGGTCCTT NM_009328.2 
F TAGACAGGAATCCATTTGCCAAA Tbx18 R TAGTGATGGCCTCCAGAATGC NM_023814.4 
F AGATGTCAGCCAGCGTTTC Nkx3.2 R  AGGCGTAACGCTGTCATCCT NM_007524.3 
F TGGATTACAGCATGTTGGCTTT Msgn1 
R TCTCCGCTGGACAGACATCTT 
NM_019544.1 
F ATGTACCATCCACGAGAGTTGT Tbx6 
R CCAAATCAGGGTAGCGGTAAC 
NM_011538.2 
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Table 2.10: List of primer sequences used for PCR analysis (F: forward, R: 
reverse, PL: product length) (continued). 
 












F CGGAGAAGCAGCCCTACT Foxf1a 




 R CCCACACTTTCGTCTGCTTGT 
NM_011127.2 
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Table 2.10: List of primer sequences used for PCR analysis (F: forward, R: 
reverse, PL: product length) (continued). 
 





F CCA TGG TGA CAA GCA GAC AG 
Sox5 
R AAC TTT ATT GCC ATC GAC TTC AT 
NM_001243163.1 
F CCAAACACTTTCCAACCGCAGTCA Col II 






F ACCCCAAGGACCTAAAGGAA ColX 




R GGCAGATCCTGCTTTTGAAG NM_008109.2 
F GAA CCG CCG GCT GTG GAT GA Lubricin 
(Prg4) 






F GGAGGCACAAAGAAGCCATACGC Osterix 






F CTTGGTGGTTTTGTATTCGATGAC CoL I (col 
1 a1) 
 R GCGAAGGCAACAGTCGCT 
NM_007742.3 
F GCTACTTTCTTTATAAGCATGCCTACT BSP 
 R GCCTCCCTGGACTGGAAAC 
NM_008318.3 
F CTCACAGATGCCAAGCCCA OC 
(Bglap2) R CCAAGGTAGCGCCGGAGTCT 
NM_001032298.2 
F CCATGGAGAAGGCTGGGG Gapdh 
 R CAAAGTTGTCATGGATGACC 
NM_002046.5 
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Chapter 3 Effect of ROCK inhibition on mesoderm enrichment 
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3.1 Introduction  
 
During embryonic development, mesodermal chondrogenic and osteogenic 
precursor cells (or skeletogenic cells) arise from a common mesenchymal-type 
stem cells (MSCs) (Olsen et al. 2000; Lefebvre & Bhattaram 2010), which 
emerge from paraxial and lateral plate mesoderm depending on the anatomical 
location of cartilage and bone tissue.  Mesoderm is derived from the primitive 
streak during the gastrulation.  The differentiation process of each cartilage and 
bone lineage is controlled by lineage-specific transcription factors and signalling 
pathways that modify their expression as been mentioned in the Introduction 
section 1.5 and 1.6. 
 
The RhoA/ROCK signalling pathway proved to have a role in controlling skeletal 
lineage decisions (Sordella et al. 2003; McBeath et al. 2004) and later 
differentiation stages (Harmey et al. 2004; Woods et al. 2005; Prowse et al. 
2013).  However, reports showed contradictory results owing to the complexity 
of the pathway and other factors related to culture conditions such as the 
culture model used, cell origin and developmental stage of the cells (Harmey et 
al. 2004; McBeath et al. 2004; Woods & Beier 2006).  Thus, the molecular 
mechanism of Rho/ROCK signalling in influencing chondrocyte and/or 
osteoblast commitment is not yet clear.  Therefore, in this chapter, the 3-phase 
differentiation scheme of ESC differentiation described here gives an 
opportunity to investigate the role of this signalling pathway in a chemically 
defined, serum free, step-wise method.   
 
The ESC/EB culture model used in this project relies on the formation of a 
primitive streak-like population, and the induction of a mesoderm population.  
Gadue et al. (2006) established, using ESC in vitro culture, that the activation of 
Activin/Nodal and Wnt signalling is required for primitive streak/mesoderm (Bry 
positive) induction.  Later on, Gouon-Evans et al. (2006) showed that ESC 
cultures were enriched for mesodermal subtypes by the activation of FGF 
signalling by FGF2 treatment, which had previously been established in 
Xenopus (Fletcher & Harland 2008).  Recently, Craft et al. (2013) showed that 
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using a 3-phase ESC/EB protocol including mesoderm induction by activation of 
Activin A/Nodal and canonical Wnt and simultaneous inhibition of BMP 
signalling by Noggin, efficiently enriched for a mesoderm-derived population 
with chondrogenic potential.  
  
Hence, the objectives of this chapter are: firstly, to establish and optimise the 
early steps of ESC differentiation of mesoderm towards both chondrocyte and 
osteoblast differentiation; secondly, to investigate the molecular profile during 
mesoderm induction (phase I) and mesoderm enrichment (phase II) phases; 
and thirdly, to investigate the role of the inhibition of ROCK on mesoderm 
enrichment and on both cartilage and bone lineage specification.    
 
3.2 Methods  
 
For ESCs differentiation towards mesoderm, a serum free, 3-phase ES/EB 
differentiation culture model was employed, using specific recombinant growth 
factors (Activin A, Wnt3a and Noggin) as indicated in chapter 2 section 2.1.3.  
Briefly, in the absence of LIF, ESCs form EBs in suspension cultures.  In the 
first phase (phase I), EBs were cultured in mesoderm induction media 
containing (9 ng/ml) Activin A, Wnt3a (25ng/ml), and Noggin (100 ng/ml) for 1 or 
2 days.  In the second phase (phase II), EBs were cultured in mesoderm 
enrichment media containing FGF2 (10ng/ml) for 3 days.  The role of ROCK 
inhibition was analysed in phase II by using the ROCK inhibitor Y27632 (10uM).  
Analysis was undertaken by monitoring morphological changes and molecular 
analysis of genes representing mesodermal subpopulations (paraxial and lateral 
plate mesoderm), cartilage and bone lineages, using RT-PCR and qPCR.  This 
was followed by functional differentiation analysis of chondrocyte and osteoblast 
differentiation, which was assessed by histochemical staining, Alcian blue (AB) 
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3.3 Results 
 
3.3.1 Morphological analysis of directed ESC differentiation via generation 
of Embryoid bodies (EBs)  
 
During the 3-phase differentiation process, cells undergo specific morphological 
changes.  Prior to differentiation, the undifferentiated ESCs (CCE cell line) grew 
in feeder-independent conditions as colonies (Fig. 3.1B), showing a typical ESC 
morphology with a large nucleus to cytoplasm ratio (Fig. 3.1C).  ESCs 
committed for differentiation formed EBs in a suspension culture in the 
presence of induction medium (phase I) (Fig. 3.1D,E).  After that EBs were 
dissociated and re-aggregated in suspension cultures to reform EBs again 
(phase II) (Fig. 3.1F-I).  In phase III, cells exhibited a typically fibroblastic 
appearance when plated as single cells in a monolayer culture (Fig. 3.1 J,K).  
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3.3.2 Optimisation of the mesoderm induction period (phase I)  
 
In this project, the 3-phase ES/EB culture model was first optimised to 
investigate the differentiation of the specific CCE ESC line towards both the 
cartilage and bone lineages simultaneously.  For this reason, the differentiation 
of ESCs towards both cartilage and bone lineages was examined using the 
same mesoderm induction cocktail and 1-day mesoderm induction period as 
used by Craft et al. (2013), compared to a longer, 2-day induction period (Fig, 
3.2 A,B).  
The Alcian blue and ALP staining results from the 1-day mesoderm induction 
period (2-3d) showed negative Alcian blue staining (Fig. 3.2C) but positive ALP 
staining (Fig. 3.2E).  These results suggest that the CCE ESCs differentiated 
primarily toward the osteogenic rather than the chondrogenic lineage under 
these conditions.   
On the other hand, the results from the 2-day mesoderm induction period (2d-
4d) showed positive staining for both Alcian blue (Fig. 3.2D) and ALP (Fig. 
3.2F), representing differentiation towards both the chondrogenic and 
osteogenic lineages simultaneously.  As the aim of this project was to study the 
effect of ROCK inhibition on both cartilage and bone lineage development, all 
experiments for the remainder of project were performed using a 2-day 
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Figure 3.2: The effect of a 1-day verses 2-day mesoderm induction phase 
(phase I) on the chondrogenic and osteogenic differentiation of ESCs.  
ECSs were cultured in mesoderm induction media for 1 day (A) or 2 days (B), 
then re-plated for mesoderm enrichment for 3 days followed by re-plating in a 
monolayer culture for differentiation. Cultures were fixed after 2 weeks for 
staining.  Representative image of Alcian blue stained monolayers: (C) from a 
1-day (1D) and (D) from a 2-day (2D) mesoderm induction period.  
Representative image of ALP stained monolayers: (E) from a 1-day and (F) 
from a 2-day mesoderm induction period.  The data are representative from 3 
independent experiments.  Scale bar: 100 µm. 
 
3.3.3 Molecular analysis of 2-day mesoderm induction phase (phase I) 
 
Monitoring mesoderm induction entailed analysing the expression of Brachury 
(Bry), which is a definitive marker for primitive streak and early mesoderm.  A 
time course analysis (Fig. 3.3A) using RT-PCR showed that Bry expression was 
first detected between 2-4d of induction and this was maintained up to 6d (Fig. 
3.3B).  Further characterisation in detail using qPCR showed a ~ 8-fold increase 
in Bry expression compared to control 2d cultures (Fig.3.3C).  This suggests 
that under the used induction conditions ESCs are committed to express the 
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Figure 3.3: The expression of Brachyury (Bry) at the primitive streak/mesoderm 
induction phase (phase I).   
A) A scheme showing the time points of each differentiation phase. RNA was 
extracted from 0d (undifferentiated ESCs), 2d (prior to mesoderm induction), 4d 
(after mesoderm induction), 5d and 6d mesoderm-induced EBs. B) RT-PCR 
analysis of Bry expression after 2-day (2-4d), 3-day (2-5d) and 4-day (2-6d) 
induction periods. C) Quantitative PCR analysis of Bry expression after a 2-day 
mesoderm induction.  Data indicate mean ± SD (triplicates) from a 
representative experiment of 3 independent experiments (paired student t-test; * 
p < 0.05, 4d vs 2d).   
 
To further confirm ESC differentiation towards mesoderm, qPCR analysis 
showed a 2-fold down regulation in the expression of Oct-4 (Pou5f1) 
(pluripotency marker) and Sox17 (endoderm marker) at the mesoderm induction 
phase (phase I) (Fig. 3.4).  These results suggest that ESCs differentiated 
towards the mesodermal lineage that was distinct from the endoderm lineages 








Figure 3.4: The expression of Oct4 (pluripotency marker) and Sox17 (endoderm 
marker) at the mesoderm induction phase (phase I).  
Quantitative PCR analysis of Oct-4 and Sox17 expression at the mesoderm 
induction phase (phase I). Data indicate mean ± SD (triplicates) from a 
representative experiment of 3 independent experiments (paired student’s t-
test;  * p < 0.05, 4d vs 2d). 
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3.3.4 Molecular analysis of mesodermal subpopulation (paraxial and 
lateral plate mesoderm) marker gene expression  
 
Following the differentiation of ESCs to a mesoderm population expressing Bry, 
first it was investigated whether a further 3d FGF2 treatment phase (Fig. 3.5A) 
would enrich for the differentiation of Bry positive mesoderm population, as 
FGF2 been known to maintain mesoderm expression (Fletcher & Harland 
2008).  Quantitative PCR analysis of Bry expression showed a 2.5-fold increase 
in Bry expression in 7d cultures compared to 4d cultures (Fig. 3.5B).  This was 
accompanied by a 3.7-fold reduction in Oct-4 expression in 7d cultures in 
comparison to 4d cultures (Fig. 3.5B).  Therefore, the additional 3d treatment 
with FGF2 during mesoderm enrichment phase further increased the proportion 







Figure 3.5: The effect of the mesoderm enrichment phase (phase II) on Bry and 
Oct-4 expression. 
Quantitative PCR analysis of Bry and Oct4 gene expression during mesoderm 
induction (phase I) and mesoderm enrichment (phase II) phases of 
differentiation.  Data indicate mean ± SD (triplicates) from a representative 
experiment of 3 independent experiments (paired student’s t-test; * p < 0.05, 2d 
vs 7d and 4d vs 7d). 
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It was next investigated whether the 3d FGF2 treatment in the mesoderm 
enrichment phase (phase II) led to paraxial mesoderm formation and 
differentiated towards somitic mesoderm, from which cartilage and bone 
develop.  Therefore, the expression of (Pdgfrα, Tbx6 and Msgn1) that are 
expressed during paraxial mesoderm and somite development were analysed 
by qPCR.   Culture of cells in FGF2 for 3 days (4-7d) in phase II caused a 7.5-
fold increase in Pdgfrα expression, as well as a 6-fold and a ~2-fold increase in 
the expression of Tbx6 and Msgn1 expression, respectively compared to 2d 
and 4d cultures (Fig. 3.6).  These results suggest that FGF2 treatment enriched 
for paraxial/pre-somitic mesoderm differentiation at the mesoderm enrichment 
phase (phase II).   
Figure 3.6: The expression of paraxial mesoderm markers at the mesoderm 
enrichment phase (phase II).  
Quantitative PCR analysis of Pdgfrα, Tbx6 and Msgn1 (paraxial mesoderm/pre-
somitic markers) expression at the mesoderm induction (phase I) and 
mesoderm enrichment (phase II) phases of differentiation. Data indicate mean ± 
SD (triplicates) from a representative experiment of 3 independent experiments  
(paired student’s t-test; * p < 0.05, 2d vs 7d and 4d vs 7d). 
 
Further investigation was then conducted on the expression of additional 
paraxial/pre-somitic/somitic mesoderm markers, such as Tcf15, Tbx18, Nkx3.2, 
Tbx6, Pax1, Msgn1 and Meox1.  The results showed a significant increase in 
the expression of all markers at 7d compared to 4d cultures (Fig. 3.7B).  These 
results further confirm that FGF2 treatment enriched for paraxial mesoderm 
differentiation. 
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Figure 3.7: The expression of paraxial mesoderm, pre-somitic and somitic 
markers at the mesoderm enrichment phase (phase II).  
Quantitative PCR analysis of the paraxial mesoderm/pre-somitic/somitic 
markers Tcf15, Tbx18, Nkx3.2, Tbx6, Pax1, Msgn and Meox1 at the mesoderm 
induction phase (phase II).  Data indicate mean ± SD (triplicates) from a 
representative experiment of 3 independent experiments (paired student’s t-
test; * p < 0.05, 4d vs 7d). 
 
During development, cartilage and bone originate not only from paraxial 
mesoderm but also from lateral plate mesoderm, which is the origin of limb bud 
mesenchyme (chapter 1, section 1.3.3). Therefore, it was subsequently 
investigated whether the 3-day FGF2 treatment in the mesoderm enrichment 
phase (phase II) differentiated the cells to lateral plate mesoderm lineage.  
Quantitative PCR results showed an upregulation in the expression of Flk-1, 
Foxf1a, Mesp1 and Prrx1 at 7d compared to 4d cultures (Fig. 3.8), suggesting 
that FGF2 treatment stimulated the differentiation of lateral plate mesoderm at 
the mesoderm enrichment phase (phase II). 
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Figure 3.8: The expression of lateral plate mesoderm markers at the mesoderm 
enrichment phase (phase II).  
Quantitative PCR analysis of lateral plate mesoderm marker expression (Flk-1, 
Foxf1a, Mesp1, Prrx1) at the mesoderm induction phase (phase II).  Data 
indicate mean ± SD (triplicates) from a representative experiment of 3 
independent experiments  (paired student’s t-test; * p < 0.05, 4d vs 7d). 
 
It was then necessary to confirm the specificity of mesoderm enrichment by 
investigating the expression of more posterior primitive streak markers. Semi-
quantitative PCR analysis showed the lack of haematopoietic mesoderm 
(Gata1) and cardiac mesoderm (Nkx2.5) marker expression (Pevny et al. 1991; 
Komuro & Izumo 1993) during differentiation whilst also confirming again the 
decrease in expression of the pluripotency marker, Nanog, and activation of Bry 
and Flk-1 expression (Fig. 3.9). These results suggest that the mesoderm 
induction and enrichment conditions were sufficient for expression of the 
paraxial and lateral plate mesoderm subpopulations from where cartilage and 
bone are thought to arise.  
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Figure 3.9: The expression of cardiac and haematopoietic markers at the 
mesoderm induction (phase I) and mesoderm enrichment phases (phase II).  
A semi-quantitative PCR analysis of Nanog, Bry, Pdgfrα, Flk-1, Nkx2.5 (cardiac 
marker) and Gata1 (haematopoietic marker) expression at the mesoderm 
induction (phase I) and mesoderm enrichment phase (phase II).  Data are from 
a representative experiment from 3 independent experiments.   
 
3.3.5 Chondrogenic and osteogenic lineage specification at the mesoderm 
enrichment phase (phase II) 
 
During embryonic development, cartilage and bone differentiation are controlled 
by the expression of key transcription factors (Lefebvre et al. 1997; Smits et al. 
2001; Otto et al. 1997; Nakashima et al. 2002).  To investigate the changes in 
expression of chondrogenic and osteogenic transcription factors during the 
mesoderm enrichment phase, the expression of Sox9 and Sox5 was analysed 
for cartilage differentiation, and Runx2 and Osx for bone differentiation.  The 
results showed a significant increase in the expression of both cartilage and 
bone markers compared to 4d cultures (Fig. 3.10).  Therefore, these results 
suggest that the cells at the end of the mesoderm enrichment phase (phase II) 
have both chondrogenic and osteogenic potentials, i.e. containing cells 
representing a bi-potential chondro-osteoprogenitor population, or separate 
populations.  The potential of these cells to differentiate further into 
chondrocytes and osteoblasts, respectively, will be investigated in vitro and in 
vivo next chapters 4, 6, and 7, respectively.  
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Figure 3.10: The expression of both chondrogenic and osteogenic lineage 
transcription factors at the mesoderm induction phase (phase II).  
Quantitative PCR analysis of (A) Chondrogenic marker (Sox9 and Sox5) and 
(B) Osteogenic marker (Runx2 and Osx) expression at the mesoderm 
enrichment phase (phase II).  Data indicate mean ± SD (triplicates) from a 
representative experiment of 3 independent experiments (paired student’s t-
test; * p < 0.05, 4d vs 7d). 
 
3.3.6 Effect of ROCK inhibition on paraxial and lateral plate markers 
expression during the mesoderm enrichment phase (phase II). 
 
To explore the effect of ROCK inhibition on ESC-derived mesoderm 
commitment towards the chondrogenic and/or osteogenic lineages, first the 
effect of ROCK inhibition on paraxial and lateral plate mesoderm marker gene 
expression was investigated. To this end, cells were cultured in FGF2 for 3 days 
(4d-7d) in the presence and absence of the ROCK inhibitor Y27632 (Fig.3.11A).  
The results showed that Y27632-treatment led to a significant increase in the 
expression of Pdgfrα, Tcf15, Tbx18, Pax1, Msgn1 and Tbx6 compared to 4d 
cultures (Fig.3.11B), while Pax1 expression was reduced upon Y27632 
treatment at 7d (7d+Y) compared to 4d cultures (Fig.3.11B).  In addition, in 
comparison to Y27632-untreated cultures (7d-Y), Y27632 treatment (7d+Y) 
demonstrated a downregulation in the expression of all genes except Meox1, 
whereby Y27632 treatment showed no effect on its expression compared to 
Y27632-untreated cultures (7d-Y) (Fig. 3.11B).  These results suggest that 
Mesoderm enrichment phase (phase II) 
- 103 - 
inhibition of ROCK signalling directed the differentiation of ESC-derived 
mesoderm towards paraxial mesoderm population at reduced levels. Thus, it 


























Figure 3.11: Effect of ROCK inhibition on the expression of paraxial mesoderm 
markers at the mesoderm enrichment phase (phase II).  
Quantitative PCR analysis of the paraxial mesoderm marker genes, Pdgfrα, 
Tcf15, Tbx18, Nkx3.2, Tbx6, Pax1, Msgn1 and Meox1, at the mesoderm 
enrichment phase (phase II) (4d-7d) in the presence and absence of Y27632 
(±Y).  Data indicate mean ± SD (triplicates) from a representative experiment of 
3 independent experiments (* p < 0.05, (unpaired student’s t-test; 7d-Y vs 
7d+Y) and (paired student’s t-test; 4d vs 7d+Y). 
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Furthermore, analysis of Flk-1, Foxf1a, Mesp1 and Prx1 expression was 
conducted to find out whether ROCK inhibition also affects the expression of 
lateral plate mesoderm markers. The results showed that Y27632 treatment 
upregulated the expression of both Flk-1 and Prx1 at 7d compared to 4d 
cultures, while Y27632 treatment had no effect on the expression of either 
Mesp1 or Foxf1a at the same time point (Fig. 3.12).  In addition, in comparison 
to Y27632-untreated cultures (7d-Y), Y27632 treatment demonstrated that 
Y27632 treatment (7d+Y) downregulated the expression of all tested lateral 
plate mesoderm markers (Flk-1, Foxf1a and Mesp1) compared to untreated 
cultures (7d-Y) (Fig. 3.12).  These results suggest that inhibition of the ROCK 
pathway may be differentiating the ESC-derived mesoderm towards a 
distinctive mesoderm population with reduced lateral plate mesoderm marker 
























Figure 3.12: Effect of ROCK inhibition on the expression of lateral plate 
mesoderm markers at the mesoderm enrichment phase (phase II).  
Quantitative PCR analysis of the lateral plate mesoderm marker genes, Flk-1, 
Foxf1a, Mesp1 and Prx1 at the mesoderm enrichment (phase II).  Data indicate 
mean ± SD (triplicates) from a representative experiment of 3 independent 
experiments (* p < 0.05 (unpaired student’s t-test; 7d-Y vs 7d +Y) and (paired 
student’s t-test; 4d vs 7d+Y). 
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3.3.7 Effect of ROCK inhibition on the expression of cartilage and bone 
transcription factors at the mesoderm enrichment phase (phase II) 
 
To further investigate the effect of ROCK inhibition on ESC-derived mesoderm 
commitment towards the chondrogenic and osteogenic lineages, cartilage and 
bone lineage transcription factors were also assessed following addition of 
Y27632 to the mesoderm enrichment phase for 3 days (4-7d).  The result 
revealed that Y27632 treatment (7d+Y) upregulated both cartilage and bone 
markers when compared to 4d cultures (Fig. 3.13A).  In contrast, when 
compared to Y27632-untreated cultures (7d-Y), results demonstrated that 
Y27632 treatment downregulated Sox9 and Osx expression while upregulating 
Sox5 expression by more than 2-fold (Fig. 3.13A).  Sox9 expression was also 
verified at the protein level, revealing a strong immunofluorescence staining in 
Y27632-untreated cells compared to treated cells (Fig. 3.13B), suggesting that 
ROCK inhibition attenuated chondrogenic and osteogenic lineage commitment 
at the mesoderm enrichment phase (phase II).  Taken together the results 
suggest that inhibition of ROCK signalling enriches for both chondrogenic and 
osteogenic lineages at the mesoderm enrichment phase, however, this 
enrichment is at a lower level than under basal conditions.  
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Figure 3.13: The effect of ROCK inhibition on the expression of chondrogenic 
and osteogenic transcription factors at the mesoderm enrichment phase (phase 
II).  
Quantitative PCR analysis of (A) chondrogenic markers  (Sox9 and Sox5) and 
(B) osteogenic markers (Runx2 and Osx). Data indicate mean ± SD (triplicates) 
from a representative experiment of 3 independent experiments (* p < 0.05,   
(unpaired student’s t-test; 7d-Y vs 7d+Y) and (paired student’s t-test; 4d vs 7d 
+Y). (B) Immunofluorescence staining following cytospin, showing Sox9 
expression in Y27632-treated and untreated cultures at the mesoderm 
enrichment phase (phase II).   Images are from a representative image from 
one experiment. Scale bar: 100um. 
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In this chapter, the objective was to investigate the role of inhibiting ROCK 
signalling during the mesoderm enrichment phase (phase II) on both sum-
mesoderm and cartilage/bone specification.  This was achieved in four steps. 
The first step was optimisation of the kinetics of primitive streak induction in the 
specific ESC line used in this study, followed by differentiation towards the 
cartilage and bone lineages.  Secondly, the expression of primitive streak and 
mesodermal markers during the mesoderm induction (phase I) and enrichment 
(phase II) phases was investigated.  Thirdly, at phase II, the cartilage and bone 
lineages specification potential was investigated.  Fourthly, the effect of 
inhibiting the ROCK pathway on both mesodermal subpopulations and cartilage 
and bone-specific lineage markers was investigated.   
The findings suggest that the mesoderm enrichment phase enriched for the 
expression of both paraxial and lateral plate sub-mesodermal populations, 
expressing both cartilage and bone transcription factors.  In addition, the 
inhibition of ROCK signalling at phase II directed ESC-derived mesoderm 
differentiation towards a distinctive paraxial and lateral plate sub-mesoderm 
populations.  Moreover, ROCK signalling inhibition directed ESC-derived 
mesoderm differentiation towards a distinctive chondrogenic and osteogenic 
populations by differentially regulating the expression of paraxial/lateral plate 
mesoderm and cartilage/ bone transcription factors, suggesting that ROCK 
signalling might be a key modulator in the commitment of mesodermal-derived 
chondro-osteoprogenitor progenitor populations.  These findings will be further 
discussed in the following sections.  
3.4.1 Mesoderm induction (Phase I: 2-4d)  
 
A 3-phase ES/EB culture model has been published by our collaborator recently 
for mesoderm-derived chondrogenic differentiation (Craft et al. 2013).  In this 
project, this differentiation protocol was optimised for the differentiation of the 
CCE cell line towards both the chondrogenic and osteogenic lineages 
simultaneously.  This was achieved by using the same induction cocktail of 
growth factors, but extending the mesoderm induction to a 2-day instead of a 1-
day period, and this was evident by the histochemical staining for cartilage and 
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bone.  Mesoderm induction was confirmed by Bry expression, which is a 
primitive streak and early mesoderm marker (Wilkinson 1990; Yamaguchi et al. 
1999; Kahle et al. 2010). 
It is well-established that the concentration of Activin can direct primitive streak 
development towards mesodermal and endodermal lineages representative of 
posterior and anterior primitive streak (Green et al. 1992; Kubo et al. 2004).  
The induction protocol used here was sufficient for generating a mesodermal 
population that is predicted to give rise to mesenchymal cell types in cartilage 
and bone (discussed later on).  This was demonstrated in several ways.  First, 
the pluripotency gene, Oct-4 (Nichols et al. 1998) was downregulated after 
mesoderm induction (at 4d) and then further after mesoderm enrichment (at 7d) 
phases of differentiation.  Second, under the same conditions, Sox17 an 
endoderm marker (Kanai-Azuma et al. 2002) was downregulated at 4d.  Third, 
haematopoietic and cardiac markers were also not expressed at 4d and 7d, as 
shown by GATA1 and Nkx2.5 markers (Pevny et al. 1991; Komuro & Izumo 
1993; Chen & Schwartz 1995).  The lack of GATA1 and Nkx2.5 gene 
expression was likely due to inhibition of BMP signalling with Noggin, since it is 
known that BMP signalling is important for haematopoiesis differentiation 
(Johansson & Wiles 1995; Sumi et al. 2008; Nostro et al. 2011).  Indeed, a 
preliminary experiment confirmed haematopoietic (osteoclasts) and cardiac 
lineages (beating cardiomyocytes) in CCE cells when BMP was used in the 
induction phase (phase I: 2-4d) rather than Noggin (personal communication).  
Taken together, the induction conditions appear to be sufficient for further 
enrichment and differentiation of cartilage and bone lineages.  
3.4.2 Mesoderm enrichment (Phase II: 4-7d)  
 
Cartilage and bone largely develop from two mesodermal subpopulations, 
paraxial mesoderm and lateral plate mesoderm. Axial bone develops from 
paraxial mesoderm while appendicular bone develops from lateral plate 
mesoderm (Olsen et al. 2000; Zhang et al. 2009; Keller & Nieden 2011).  In this 
project, Bry-expressing differentiated cells expressed paraxial mesoderm by the 
expression of Pdgfrα at the mesoderm enrichment phase (phase II).  Pdgfrα is 
expressed in paraxial mesoderm and somites (Orr-Urtreger et al. 1992; 
Takakura et al. 1997).  In addition, cells in phase II expressed pre-somitic 
markers such as Tbx6 and Msgn1, which are also downstream markers of Wnt 
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signalling (Chalamalasetty et al. 2011).  The paraxial mesoderm population in 
phase II was further marked by expression of genes required for temporal 
development of somites/sclerotome, such as Tcf15, Tbx18, Meox1, Pax1 and 
Nkx3.2.  During development, paraxial mesoderm segments into somites (Tam 
& Tan 1992; Kulesa & Fraser 2002b), which are marked by upregulation of 
Tcf15 and Tbx18 somitic mesoderm markers (Burgess et al. 1996; Bussen et al. 
2004; Singh et al. 2005).  Furthermore, specification of the sclerotome is 
marked by the expression of Meox1 (Mankoo et al. 2003; Rodrigo et al. 2004), 
Pax1 (Dietrich et al. 1993; Rodrigo 2003) and Nkx3.2 (also known as Bapx1) 
(Tribioli et al. 1997; Tribioli & Lufkin 1999).  
In addition, during phase II, the mesodermal population expressed Flk-1 
together with Pdgfrα. Flk-1 is expressed in lateral plate mesoderm that gives 
rise to somatopleuric mesoderm, the origin of limb bud chondrogenic 
mesenchymal cells (Lawson et al. 1991; Yamaguchi et al. 1993; Kabrun et al. 
1997; Kinder et al. 1999) as it is expressed in the haematopietic mesoderm 
(Takakura et al. 1997). The lateral plate mesoderm population in phase II was 
further marked by the expression of other lateral plate mesoderm markers such 
as Mesp1 (Saga et al. 1996; Chan et al. 2013) and Foxf1a (Chang & Ho 2001; 
Ormestad et al. 2004) as well as Prx1, which is expressed during limb bud 
development (Martin et al. 1995; Martin & Olson 2000).   
 
At the mesoderm enrichment phase (phase II), both Sox9 and Sox5 gene 
expression were upregulated (Lefebvre et al. 2001), suggesting commitment 
towards the chondrogenic lineage.  In addition, the immunofluorescence 
staining confirmed Sox9 expression at the protein level.  Sox9 is a key 
transcription factor marking chondrogenic commitment and differentiation (Bi et 
al. 1999).    Furthermore, Sox9 expression is not only a chondrogenic marker, 
but also a chondro-osteoprogenitor population marker (Akiyama et al. 2002; 
Akiyama et al. 2005).  Therefore, expression of Sox9 at the mesoderm 
enrichment phase (phase II) could also be suggestive of the presence of an 
osteogenic population.  Thus, osteoblast transcription factors were also 
investigated in phase II.    
 
The expression of both Runx2 and Osterix were upregulated at phase II.  Runx2 
is a key transcription factor (Komori et al. 1997; Otto et al. 1997) and Osterix is 
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a downstream marker for osteogenic commitment and differentiation 
(Nakashima et al. 2002).  Osterix expression suggests that the cells are at a 
more committed stage of osteogenic differentiation.  Runx2 expression might 
have been due in part to the presence of FGF2 during the enrichment phase, as 
FGF2 is known to induce Runx2 expression (Montero et al. 2000).   
 
Although Runx2 and Osterix expression are important regulators in the 
commitment of MSCs towards bone differentiation, they are also expressed in 
chondrocytes.  Runx2 and Osterix expression was shown to be important in the 
late stages of chondrocyte differentiation and hypertrophy (Inada et al. 1999; 
Kim et al. 1999; Komori 2005; Oh et al. 2012).  Therefore, their expression in 
phase II supports the presence of a chondro-osteoprogenitor population.  
 
There are two additional possibilities that could contribute to enriching for the 
differentiation of a chondrogenic population during the mesoderm enrichment 
phase. First, the culture model used, rely on culturing cells in a suspension 
form. This might have contributed to directing cells towards chondrogenesis by 
mimicking the condensation stage, which is an essential step during cartilage 
development (Hall & Miyake 2000).  Second, in the mesoderm enrichment 
phase, cultures were supplemented with FGF2 for 3 days.  FGF2 signalling is 
known to be essential during skeletal development, particularly in limb bud 
development (Savage et al. 1993; Fallon et al. 1994; Yu & Ornitz 2008).  In 
support of the differentiation of mesoderm towards limb bud mesenchyme, was 
the expression of Prx1 and a preliminary experiment conducted to culture cells 
in FGF2 only in phase III, showed that the chondrocyte nodules generated had 
a morphology that resembled chondrocyte nodules produced in limb bud 
micromass cultures (Sui et al. 2003) (data not shown).  These results suggest 
that the differentiation culture conditions may resemble the signals 
characteristic of limb bud chondrocyte differentiation. 
In conclusion, the mesoderm enrichment phase (phase II) differentiated the 
ESC-derived mesoderm towards a bi-potential chondro-osteoprogenitor 
population.   
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3.4.3 ROCK inhibition differentially regulates sub-mesodermal and 
chondro-osteoprogenitor populations at the mesoderm enrichment 
phase (phase II) 
 
Investigating the role of ROCK inhibition at an intermediate developmental 
stage, such as the mesoderm enrichment phase in ESCs is done here for the 
first time.   Inhibition of ROCK signalling at phase II upregulated the expression 
of paraxial markers (except Pax1), suggesting differentiation of cells towards 
the axial bone lineage.  In addition, Flk-1 (a lateral plate mesoderm marker) and 
Prx1 (a limb bud marker) were also upregulated upon ROCK inhibition with no 
effect on the other lateral plate markers tested (Mesp1 and Foxf1a), which 
represent appendicular bone differentiation.  This might suggest that ROCK 
inhibition directed the differentiation towards somite/sclerotome more than 
somatic/limb bud mesoderm development.  Interestingly, in comparison to 
ROCK untreated cultures (7d-Y), ROCK inhibition showed a general 
downregulation of all mesoderm markers, suggesting that ROCK inhibition 
differentially regulated both paraxial and lateral plate mesoderm sub-mesoderm 
markers at the mesoderm enrichment phase (Phase II: 4-7d). 
Moreover, the ROCK inhibition directed the differentiation of ESC-derived 
mesoderm towards a chondro-osteoprogenitor population by unregulating the 
expression of Sox9 and Sox5 as well as Runx2 and Osx.  Interestingly, 
however, ROCK inhibition (7d+Y), in comparison to ROCK unexposed cultures 
(7d-Y), led to downregulation of Sox9 and Osx expression.  In addition, Sox9 
was weakly expressed at the protein level compared to Y27632-untreated 
cultures, which correlated with the mRNA expression.  The weak expression 
may suggest reduced Sox9 activity upon ROCK inhibition.  However, 
quantification of Sox9 activity is required to confirm this observation on a larger 
sample size.  The complex effects of ROCK inhibition on Sox9 activity has been 
reported in other studies, with differential effects being explained by the effects 
of culture model used, 2 verses 3-dimensional cultures (Woods et al. 2005; 
Woods & Beier 2006). Woods et al. (2006) reported that even when Sox9 
expression was upregulated, the expression of Sox9 down stream targets, Col II 
and aggrecan was downregulated in micromass culture, linked to the reduction 
in Sox5 and Sox6 expressions.  In this project, the cells were cultured in a 
suspension form for 3 days. 
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ROCK inhibition, (7d+Y vs 7d-Y), upregulated Sox5 expression and had no 
effect on Runx2 expression.  These results might indicate that ROCK inhibition 
signalling primes the differentiation towards cartilage over bone lineage.  
Other studies reported a role of RhoA/ROCK in the commitment of hMSC to the 
osteogenic lineage.  McBeath et al., (2004) showed by using micropatterned 
surfaces that activation of Rho/ROCK signalling stimulated osteogenesis and 
upregulated the osteogenic markers Runx2 and ALP. In addition, cells infected 
with an adenovirus encoding constitutively active RhoA stimulated osteogenesis 
in unspread cells while infection with adenovirus encoding constitutively active 
ROCK induced the osteogenesis irrespective of cell shape.  On the contrary, 
Meyers et al. (2005) reported using a modeled microgravity culture model, that 
transfecting hMSCs with an adenovirus containing constitutively-active RhoA 
inhibited osteogenic differentiation. However, this study did not investigate if 
there is a role for the downstream effector, ROCK, on osteoblast differentiation.  
Interestingly, in the context of haematopoietic differentiation, Chen et al 
(Abstract published in ISSCR, 2013), demonstrated that ROCK inhibition using 
Y27632 in ESCs harbouring a Flk1 reporter gene, is a strong inducer of Flk-1 
expressing cells and upregulated posterior primitive streak and haematopoietic 
markers, suggesting that ROCK signalling can modulate mesodermal cell 
commitment towards the haematopoietic lineage.   
In summary, ROCK inhibition in the mesoderm enrichment phase (phase II) 
proved to differentially regulate the differentiation of ESC-derived mesoderm 
towards a distinctive chondro-osteoprogenitor population. In addition, ROCK 
inhibition might be a key in modulating chondrogenic over osteogenic potential 
when compared to ROCK unexposed cultures.  Further kinetic gene expression 
analysis of cartilage and bone markers would be helpful in understanding the 
maturity stage of the cells before differentiating them in phase III as well as the 
downstream signalling factors controlling cartilage and bone differentiation at 
the mesoderm enrichment phase (phase II).  In addition, quantification of the 
percentage of progenitors expressing cartilage and bone specific markers by 
FACS, or using cells that are GPF-labeled will provide further data on the 
efficiency of the differentiation protocol.  The effect of ROCK inhibition on the 
functional potential in vitro and in vivo will be interesting to explore since the 
cells proved to be primed towards the chondrogenic and osteogenic lineages at 
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the molecular level. This will be investigated further in the next chapters 
(chapter 4 for in vitro cartilage differentiation, chapter 6 for in vitro bone 
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Chapter 4 Effect of phase-specific ROCK inhibition on the 




Monolayer differentiation phase (phase III): chondrogenesis 
- 115 - 
4.1  Introduction  
 
Chondrocyte differentiation undergoes a multi–stage cellular process that 
involves proliferation, differentiation and ends with maturation. During 
embryonic development of endochondral bone, cartilage formation includes 
several stages, whereby mesenchymal cells undergo condensation followed by 
chondrocyte differentiation (chondrogenesis), which is then replaced by 
osteoblasts (osteogenesis) (Hall & Miyake 2000; Olsen et al. 2000; Goldring et 
al. 2006; Zhang et al. 2009; Lefebvre & Bhattaram 2010).  Chondroctyes are the 
only cellular component in cartilage (Pitsillides & Beier 2011). Chondrogenesis 
is a multistep process controlled by morphological and molecular changes 
(chapter 1, section1.4.11.5).   
Cartilage is composed of chondrocytes, specific proteoglycans such as 
aggrecan and characteristic exracellular matrix proteins. These components are 
altered during the process of chondrocyte differentiation and maturation.  
Differentiated chondrocytes are characterised by a round or polygonal 
morphology that secret collagen type II (herein, Col II) and aggrecan (herein, 
Acan), while hypertrophic chondrocytes are enlarged cells and secret collagen 
type X (herein, Col X) (Hall & Miyake 2000; Hartmann 2009; Raggatt & 
Partridge 2010; Keller & Nieden 2011; Pitsillides & Beier 2011).   
Small GTPAse signalling has been shown to influence chondrogenesis (Beier & 
Loeser 2010) in terms of lineage commitment (Gao et al. 2010), chondrogenic 
gene marker expression, differentiation and maturation (Wang, Woods, Sabari, 
Pagnotta, L. Stanton, et al. 2004; Woods et al. 2005; Woods & Beier 2006; 
Woods, Wang, Dupuis, et al. 2007; Kumar & Lassar 2009; Appleton et al. 2010; 
Haudenschild et al. 2010; Kim et al. 2012; Dy et al. 2012; Furumatsu et al. 
2013).  Specifically, the role of Rho/ROCK signalling in chondrogenesis appears 
to be complex.  Several reports have suggested a positive role for Rho/ROCK 
signalling in chondrogenic commitment and differentiation (Woods et al. 2005; 
Tew & Hardingham 2006; Woods & Beier 2006),  
While others have shown the contrary, in particular, using the Y27632 chemical 
inhibitor (Woods & Beier 2006).   This may be due to several possibilities, such 
as culture conditions (e.g. 2- versus 3-dimensional cultures), cell origin and the 
stage of cell development during the differentiation process. Thus, the exact 
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mechanism of ROCK signalling in regulating chondrogenic development is not 
yet clear and unravelling the complexity of this signalling pathway in 
chondrogenic differentiation has been an interest in the field of musculoskeletal 
diseases such as osteoarthritis.  Therefore, establishing an ES/EB, step-wise, 
mESC mesoderm differentiation model system (discussed in chapter 3) allows 
for a controlled and defined method for dissecting and further understanding of 
the molecular events occurring during development of cartilage, in particular, 
specification and differentiation.  Thus, this chapter will investigate the effect of 
ROCK inhibition, specifically at two developmental stages: the mesoderm 
enrichment phase (phase II) and the differentiation phase (phase III). 
4.2 Methods 
 
The 3 phase ES/EB differentiation model system (discussed in chapter 3, 
Fig.3.1) was used, which included mesoderm induction (phase I) followed by 
the mesoderm enrichment phase (phase II) then a monolayer differentiation 
phase (phase III) (details in chapter 2, Fig.2.1).   In the differentiation (phase III), 
cells were re-plated as single cells at a density of 10,000 cells/6mm well in a 
monolayer culture containing chondrogenic media supplemented with 100ng/ml 
BMP4 and 10ng/ml FGF2.  
To test the effects of ROCK inhibition, Y27632 was added at specific time points 
during differentiation, as will be shown in each section.  Cultures were fixed 
after 2 weeks. Analysis was undertaken by monitoring the morphological 
changes of the cells during the culture period and quantification of Alcian blue 
staining of chondrocyte nodules, an indicator of sulphated glycosaminoglycans, 
which is an established marker of chondrogenesis.  Gene expression analysis 
of chondrogenic markers was performed by qPCR at several time points during 
differentiation, specifically at 4, 7, 14 and 21d. 
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4.3 Results 
    
4.3.1 Chondrogenic differentiation of ESC–derived mesoderm  
 
In chapter 3, molecular analysis showed that both Sox9 and Sox5 were 
upregulated after culturing cells in FGF2 for 3 days in the mesoderm enrichment 
phase (phase II) (chapter 3, Fig. 3.10).  Hence, during the monolayer 
differentiation phase (phase III), the chondrogenic potential of the cells 
generated from the mesoderm enrichment phase (phase II) was examined by 
differentiating them in chondrogenic media (table 2.3) as shown in the timeline 
(Fig. 4.1A). 
Firstly, analysis of morphological changes revealed that chondrocyte nodule 
formation appeared after 1 week of culture in chondrogenic media.  After 
another week in culture, chondrocyte cells developed into 3-dimensional, 
cobblestone-like chondrocyte nodules (Fig. 4.1B-E).  The chondrocyte nodules 
produced an extracellular matrix proteoglycan that stained positively with Alcian 
blue (Fig. 4.1F-I).  Further evidence confirming the presence of chondrocytes 
was gained by investigating the expression of type II collagen protein.  
Immunofluorescence analysis demonstrated that differentiated chondrocyte 
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Figure 4.1: Chondrogenic differentiation of ESCs-derived mesoderm in the 
monolayer differentiation phase (phase III). 
A) A differentiation scheme showing the timing of chondrogenic differentiation.  
Cells were cultured in chondrogenic media (FGF2 (10 ng/ml), BMP4 
(100ng/ml)).  Monolayer cultures were fixed after 2 weeks for analysis.  B-E) 
Phase-contrast and bright-field images of monolayer cultures showing typical 
cartilage nodules with rounded chondrocyte morphology. F-I) Alcian blue 
staining of chondrocyte nodules showing chondrocyte cells surrounded by an 
Alcian blue positive ECM. J,K) Collagen type II immunofluorescence staining of 
chondrocyte nodules.  All images are from 21d cultures and from representative 
wells (n= 11 experiments). Scale bars: 10um. 
 
 
Molecular analysis of the cultures after 2 weeks of differentiation (7-21d) (Fig. 
4.2A) showed an upregulation of Sox9 expression at 14d compared to 7d 
cultures, which was then downregulated at 21d, the end of the differentiation 
period compared to 14d cultures. On the other hand, no differences were found 
in Col II expression in 14d and 7d cultures, whilst its expression was then 
upregulated at the end of the differentiation at 21d compared to 14d cultures.  
The hypertrophic chondrocyte marker type X collagen (Col X) was expressed, 
however, at a negligible level compared to Sox9 and Col II expression (Fig. 
4.2B). Col X expression was slightly upregulated at 14d compared to 7d 
cultures and then downregulated at 21d of differentiation compared to 14d 
cultures.  Collectively, the results suggest that mesoderm-derived ESCs can 
differentiate efficiently towards the chondrogenic lineage. 
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Figure 4.2: Expression of chondrogenic markers after 2 weeks in the monolayer 
differentiation phase (phase III). 
A) The differentiation scheme showing in pink boxes the time points at which 
RNA was extracted during the differentiation at 4, 7, 14 and 21d.  B) 
Quantitative PCR analysis of chondrogenic markers gene expression (Sox9, 
Col II, and Col X). The insert shows a magnification of Col X expression. Data 
indicate mean ± SD (triplicates) from a representative experiment of 3 




4.3.2 Effect of ROCK inhibition during the mesoderm enrichment phase 
(phase II) on chondrogenic differentiation 
 
In chapter 3, Y27632 treatment during the mesoderm enrichment phase (phase 
II) illustrated a differential effect on the expression of the chondrogenic 
transcription factors (Sox9 and Sox5) compared to the Y27632-untreated 
cultures (Fig.3.13).  To further investigate the functional potential of the 
generated cells, cells were cultured in the absence and presence of Y27632 in 
phase II, followed by culture in chondrogenic media in the absence of Y27632 
for 2 further weeks (Fig. 4.3A).  Analysis of the morphological changes in 
culture revealed that chondrocyte nodules were observed in both Y27632-
treated and untreated monolayer cultures after 1 week in chondrogenic media, 
and this was clearly evident following Alcian blue staining (Fig. 4.3B).  However, 
quantification of nodule formation following Alcian blue staining showed a  3-fold 
increase in the percentage of Alcian blue positive nodules in Y27632-treated 
cultures, 
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compared to untreated cultures (Fig. 4.3C).  This increase was verified by 
quantification of the Alcian blue staining following solubilisation (Fig. 4.3D).  
These results suggest that short-term inhibition of ROCK signalling in phase II 
(4-7d) induced chondrogenic differentiation afterwards in phase III (7-21d) in the 




Figure 4.3: The effect of temporal ROCK inhibition in phase II on chondrogenic 
differentiation of ESC-derived mesoderm. 
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.   In phase III, cells were cultured in chondrogenic 
media for 2 weeks then fixed for analysis.  B) Representative images of Alcian 
blue stained wells from 3 independent experiments.  C) The percentage of 
Alcian blue-positive nodule area was counted manually using the point-counting 
method.  D) Alcian blue staining was solubilised and quantified by measuring 
absorbance at 630 nm.  Data indicate mean ± SD (triplicates) from a 
representative experiment of 3 independent experiments (paired student’s t-
test; * p < 0.05). 
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Subsequently, molecular analysis of (14d) cultures (Fig. 4.4B, green bars) 
confirmed the cellular effects demonstrated with Y27632 (+Y) treatment through 
the upregulation of the expression of Sox9 and Acan compared to the untreated 
cultures (-Y).  Meanwhile, there were no differences in the expression of either 
Col II or Col X in Y27632-treated cultures (+Y), compared to the untreated 
cultures (-Y) (Fig. 4.4B, green bars).  On the other hand, analysis of (21d) 
cultures (Fig. 4.4B, blue bars), showed that Y27632 treatment (+Y) upregulated 
all four chondrogenic genes in comparison to the untreated cultures (-Y).   
Moreover, analysis of Y27632-untreated cultures (-Y) at (21d) revealed that all 
genes were downregulated by the end of the differentiation phase compared to 
(14d) cultures (Fig. 4.4B, -Y14d vs -Y21d).  Interestingly, however, Col II 
expression at 21d, in the absence of Y27632 (-Y), showed a substantial 
increase compared to 14d cultures (Fig. 4.4B, -Y14d vs -Y21d). Similarly, 
Y27632-treatment also showed similar pattern (Fig. 4.4B, +Y14d vs +Y21d) 
These results suggest that ROCK signalling inhibition at the mesoderm 
enrichment phase (phase II) enhanced chondrogenesis at the mRNA level.  In 
addition, ROCK signalling inhibition in phase II seems to direct the 
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Figure 4.4: The effect of ROCK inhibition in phase II on the expression of 
chondrogenic markers in phase III. 
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.  In phase III of differentiation, RNA was extracted at 2 
time points during the differentiation; at 14d (after 1 week in the differentiation 
phase) and at 21d (after 2 weeks in the differentiation phase). ±Y represents 
treatment with Y27632 during phase II. B) Quantitative PCR analysis of 
chondrogenic marker expression (Sox9, Acan, Col II, and Col X).  Data indicate 
mean ± SD (triplicates) (n=2 for 14d) and (n=3 for 21d)(paired student’s t-test; * 
p < 0.05). 
 
 
4.3.3  Effect of ROCK inhibition in both phases II and III on chondrogenic 
differentiation  
 
Following the results from the previous section, further investigation was 
conducted on whether inhibiting ROCK continuously in both phases II and III (4-
21d) would influence chondrogenic differentiation.   For this reason, cells in 
phase II were cultured in both the absence and presence of Y27632, followed 
by culture in chondrogenic media, this time in the presence of Y27632 for a 
further 2 weeks (Fig. 4.5A).   Quantification of Alcian blue staining at this stage 
demonstrated a 7.2-fold increase in the percentage of Alcian blue positive
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nodules, and Alcian blue solubilisation quantification confirmed this increase 
(Fig. 4.5B-D).  This indicates that the long-term inhibition of ROCK signalling 
during both the mesoderm enrichment and differentiation phases (4-21d), not 
only induced but also enhanced the chondrogenic differentiation of mesoderm 































Figure 4.5: The effect of continuous Y27632 exposure in phases II and III on 
chondrocyte nodule quantification and GAG synthesis. 
 
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.  In phase III, cells were cultured in chondrogenic 
media for 2 weeks then fixed for analysis.  B) Representative images of Alcian 
blue stained wells from 3-5 independent experiments.  C) The percentage of 
Alcian blue-positive nodule area was counted manually using the point-counting 
method.  D) Alcian blue staining was then solubilised and quantified by 
measuring absorbance at 630 nm.  Data indicate mean ± SD (triplicates) from a 
representative experiment of 3 independent experiments (paired student’s t-
test; * p < 0.05). 
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Quantitative PCR analysis was then performed for chondrogenic markers 
expression at (14d) cultures and (21d) cultures from temporal (-/+) and 
continuous Y27632 treatment (+/+) as shown in the time line (Fig. 4.6A), in this 
section for the simplicity of presentation, temporal (7-21d) cultures will be 
defined as (-Y) and continues cultures will be defined as (+Y).   
The results showed at 14d of differentiation, that Y27632 treatment upregulated 
Sox9, Acan and Col X expression with no effect on Col II expression in 
comparison to Y27632-untreated cultures (Fig. 4.6B, green bars, -Y14d vs 
+Y14d). Interestingly, qPCR analysis of 21d cultures showed that Y27632 
treatment upregulated both Col II and Col X with no effect Sox9 expression and 
a slight, but significant downregulation in Acan expression compared to 
Y27632-untreated cultures (Fig. 4.6B, blue bars, -Y21d vs +Y21d).   Analysis of 
Y27632-untreated cultures revealed a downregulation in Sox9 expression with 
no effect on Acan, Col II, and Col X expressions by the end of the differentiation 
phase (21d) compared to (14d) cultures  (Fig. 4.6B, -Y14d vs-Y21d). While 
upon Y27632 addition, no effect was shown on Sox9 and Acan expression by 
the end of the differentiation phase, however, Col II Col X expression was 
upregulated compared to 14d cultures (Fig. 4.6B, +Y14d vs +Y21d).  
These results supported the observation that long-term exposure to ROCK 
inhibition in both phases II and III (4-21d) stimulated the differentiation of a 
distinctive chondrogenic population with an enhanced hypertrophic chondrocyte 
differentiation potential at the mRNA level in comparison to short-term ROCK 
inhibition exposure in phase III only. 
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Figure 4.6: The effect of continuous Y27632 exposure in phases II and III on 
chondrogenic marker expression  
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.  In phase III of differentiation, RNA was extracted at 2 
time points during the differentiation; at 14d (after 1 week in the differentiation 
phase) and at 21d (after 2 weeks in the differentiation phase). ±Y represents 
treatment with Y27632 during phase II.  B) Quantitative PCR analysis of 
chondrogenic markers expression (Sox9, Acan, Col II, and Col X).   Data 
indicate mean ± SD (triplicates) (n=2 for 14d) and (n=3 for 21d)(paired student’s 
t-test; * p < 0.05).  
 
Summarising the effects of ROCK inhibition across the different Y27632 
treatment protocols (Fig. 4.7A), the results show that only a 3-day pulse of 
Y27632 treatment during the mesoderm enrichment phase (phase II: 4-7d), 
increased Col II and Col x expression by a 3-fold and 83-fold, respectively (Fig. 
4.7B,C; -/- vs +/-).  Moreover, continuous exposure to Y27632 during both the 
mesoderm enrichment and differentiation phases (phase II and III: 4-21d) 
showed a 4-fold and 250-fold increase in both genes, suggesting further 
enhanced cartilage differentiation (Fig. 4.7B,C; -/- vs +/+).  However, temporal 
Y27632 treatment during the differentiation phase III alone (7-21d) showed a 2-
fold reduction in Col II expression, suggesting that late exposure was not 
sufficient to stimulate chondrogenesis and may even inhibit it (Fig. 4.7B,C; -/- vs 
-/+). In parallel, Col X expression was increased by 35-fold, but at very low 
Monolayer differentiation phase (phase III): chondrogenesis 
- 127 - 
levels.  Taken together, the findings reveal that inhibition of ROCK starting from 
the early mesodermal stage is sufficient to stimulate chondrogenic 
differentiation of ESC derived mesoderm. Therefore, ROCK inhibition in phase 
II is the key in inducing chondrogenesis and continous ROCK inhibition 





















Figure 4.7: Summary of the effects of temporal ROCK inhibition on Col II and 
Col X gene expression.    
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.  B) Representative images of Alcian blue stained 
wells from 2 independent experiments.   C) RNA was extracted at 21d for 
analysis of chondrogenic marker expression (Col II, Col X) using qPCR.  Data 
indicate mean ± SD (triplicates) from an experiment other than previously 
shown (one-way ANOVA test; * p < 0.05). 
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4.4 Discussion  
 
This chapter has demonstrated, in a serum free, 3-phase ES/EB culture model, 
an effective directed differentiation of ESC-derived mesoderm towards 
chondrocytes. In addition, the chondrgenic effect of ROCK signalling inhibtion 
proved to be a   phase-specific  effect.  Temporal ROCK inhbition (+/-) during 
the mesoderm enrichment phase was shown to be the key in driving the 
chondrogenic differentiation of ESC-derived mesoderm.  Furthermore, 
continous ROCK inhibition in both the mesoderm enrichment phase and 
differentiation phase (+/+) proved to enhance the chondrogenic differentiation 
towards hypertrophic cartilage.  Therefore, a short-term ROCK inhibition, 
specifically at the mesoderm enrchment phase (+/-) may have a distinctive role 
in influencing cartilage specification,  differentiation, and maturation.   
The functional consequences for chondrogenesis were analysed systematically 
here by testing the effects of short, temporal Y27632 exposure in phase II only 
(+/-), followed by phase III chondrogenic differentiation in the absence or 
presence of the ROCK inhibitor.  This will be discussed further in the following 
sections.  
As mentioned in the introduction, the inhibition of Rho/ROCK signalling showed 
controversial results in terms of its role in chondrogenic differentiation, 
explained by the possibility of a cell context dependent effect (Woods et al. 
2005; Woods & Beier 2006).  This may be due to several possibilities, such as 
culture conditions (e.g. 2- versus 3-dimensional cultures), cell origin, and the 
stage of cell development during the differentiation process. It was proved that 
by using our 3-phase differentiation culture model, the role of ROCK inhibition 
on chondrogenic differentiation could be addressed through a defined and 
controlled approach, by analysing the ROCK signalling inhibition effect in two 
developmental stages: mesoderm enrichment (phase II) and the differentiation 
phase (phase III), which will be further discussed in the following sections.
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4.4.1 Temporal ROCK inhibition (4-7d)  
 
A short pre-exposure to ROCK inhibitor during the mesoderm enrichment phase 
(+/-) led to the induction of chondrogenesis later in the differentiation phase 
(Phase III) in the absence of further ROCK inhibition.  The significant, 3-fold 
increase in the percentage of Alcian blue-positive nodules suggested that 
exposing cells to a short pulse of ROCK inhibitor at the mesoderm enrichment 
phase (+/-) might have targeted early chondrogenic precursors.  In addition, 
Alcian blue dye extraction and measurement of absorbance confirmed the 
sulphated glycosaminoglycan synthesis.   
Additionally, as described in the previous chapter (Chapter 3), expression 
profiling during the mesoderm enrichment phase (Phase II) proved that the cells 
generated were primed towards chondrogenesis.  The 3-day FGF2 treatment 
enriched the cell population towards paraxial and lateral plate mesoderm as 
well as for chondrogenesis as measured by gene expression, and ROCK 
inhibition modulated the expression profile of both populations.  The results 
showed that both pre-chondrogenic mesoderm markers such as Nkx3.2, and 
Prx1 (chapter 3) (Leussink et al. 1995; Rodrigo 2003) and Sox genes (Sox9 and 
Sox5) expression were upregulated prior to the differentiation phase (phase III).   
Several studies demonstrated the chondrogenic effect of ROCK signalling 
inhibition in different cell context. Woods et al. (2005) reported that ROCK 
inhibition, using Y27632, showed round cell morphology, increased 
glycosaminoglycan synthesis, but did not increase the number of condensed 
Alcian blue positive nodules in limb micromass cultures and primary cell 
monolayer cultures. In our culture model, the actual number of nodules was not 
counted individually as this could not be done in an unbiased way.  Instead the 
percentage of Alcian blue positive area was quantified according to clustering of 
the nodules as they reached the end of the differentiation. However, it would be 
interesting to quantify the effect of ROCK inhibition on chondrogenic precursors 
number during the differentiation period. In addition, Tew and Hardingham 
(2006) reported that ROCK signalling prevented dedifferentiation of articular 
chondrocytes phenotype when cells cultured in a monolayer form.   
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Furthermore, using a similar ESC culture system, Craft et al (2013) reported the 
differentiation of mesoderm-derived chondrocytes whereby the mesoderm 
induction media was supplemented with ROCK inhibitor Y27632.  
In this project, the presence of ROCK inhibitor-sensitive cells generated from 
the mesoderm enrichment phase (phase II) was further evident at the molecular 
level when cultures were analysed at the differentiation phase (Phase III), 
showing an upregulation of chondrogenic marker expression.   The analysis of 
one-week and two-weeks cultures expressed Sox9 and Acan, suggesting the 
existence of chondrogenic progenitors at this stage of differentiation that 
responded positively to ROCK inhibition.  The molecular profile at 21d cultures 
analysis showed the upregulation of Sox9 and Col II expression in the ROCK 
inhibitor treated cultures as well as Col X, but at very low levels. Therefore, 
suggesting the advancement in the maturation of the cultures under the 
influence of ROCK inhibition.   
Similarly, several studies in mouse (Woods et al. 2005; Woods & Beier 2006) 
and human (Haudenschild et al. 2010) cultures have reported that ROCK 
inhibition stimulates Sox9 expression as well as downstream targets, Col II and 
aggrecan.  In the context of human articular cartilage, ROCK inhibition (Y27632) 
showed to activate Sox9 expression (Tew & Hardingham 2006). However, 
differences in the cell culture model showed to influence down stream targets of 
chondrogenic lineage even in the expression of Sox9 (Woods & Beier 2006).   
Furthermore, Woods et al. (2006) reported that Col II and aggrecan expression 
was upregulated in ATDC5 cell line culture and primary cell monolayer cultures 
while downregulated in micromass cultures.  
Surprisingly, short-term exposure to ROCK inhibition, this time in phase III only 
(7-21d), had no effect on chondrocyte differentiation and maybe even inhibited it 
slightly.  The expression of Col II and Col X was very low in comparison to their 
expression when ROCK was inhibited only in phase II (4-7d) or inhibited in both 
phases II and III (4-21d).  This effect may suggest that exposing cells to the 
ROCK inhibitor at phase III may be too late to stimulate the ROCK-sensitive 
populations or chondrogenic progenitors compared to exposing the cells to the 
ROCK inhibitor in phase II.  This could be explained by the expression analysis 
of the mesoderm enrichment phase (phase II)  (chapter 3), which showed that 
ROCK inhibitor-untreated cultures (7d-Y) expressed higher transcript levels of 
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mesoderm gene markers as well as cartilage and bone gene markers compared 
to ROCK inhibitor-treated cultures (7d+Y). Therefore, suggesting that ROCK-
inhibited cultures might be at a different stage of mesoderm development 
compared to ROCK treated cultures.  In conclusion, under the culture conditions 
used in this project, temporal ROCK inhibition in phase III only (7-21d) is not 
recommended for further studying of chondrogenesis. 
4.4.2 Continuous ROCK inhibition (4-21d) 
 
In contrast to the short-term effects of ROCK inhibition in the mesoderm 
enrichment phase (Phase II: 4-7d) on chondrogenic differentiation, the current 
study also proved that continuous ROCK inhibition in both phases II and III not 
only induced chondrogenesis, but also enhanced it towards hypertrophy.  This 
was evident by the significant 7.2-fold increase in Alcian blue-positive nodule 
area as well as in the upregulation in expression of Col II and Col X.  
Interestingly, the effect of ROCK inhibition on chondrocyte hypertrophy 
demonstrated under our culture conditions corresponded with that shown by 
Wang et al. (2004). It was demonstrated that ROCK inhibition accelerated 
hypertrophic differentiation of chondrocytes in both the ATDC5 cell line and 
primary chondrocytes micromass cultures. This was confirmed by upregulation 
in the expression of both Col X and BSP as well as an increase in both ALP 
activity and mineralisation of cultures.  
 Indeed, our serum-free culture model could be a good foundation for future 
study of chondrocyte differentiation, in particular, hypertrophy and chondrogenic 
maturation, especially on the effect of ROCK inhibition signalling.  Therefore, 
further studies of chondrogenic differentiation using the 3-phase differentiation 
model with continuous ROCK inhibition could pave the way for further 
understanding of molecular mechanisms downstream of ROCK inhibition 
signalling, which may contribute to driving and regulating chondrocyte 
differentiation and expansion.  
Comparing the effects of short-term exposure to ROCK inhibition, (+/-) or (-/+), 
to continuous exposure to ROCK inhibition (+/+) showed the greatest increase 
in both chondrocyte positive nodule areas in the expression of both Col II and 
Col X chondrogenic markers.   
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Indeed, the chondrogenic differentiation observed upon ROCK inhibition led to 
an efficient differentiation of chondrocytes covering up to ~95% of culture area.  
In human ESC cultures, Oldershaw et al. 2010 reported, in 3 cell lines, an 
efficient differentiation of chondrocyte that comprised 74-97% of Sox9 
expressing cells, using a serum free, 3 stage differentiation model.  However, 
they did not show functional differentiation of the generated cells. Therefore, in 
the current study it will be interesting to examine the percentage of Sox9 
expressing cells in the cultures prior to the chondrogenic differentiation stage. 
In summary, using the novel culture conditions and the 3-phase culture model, 
the results in this chapter proved for the first time a temporal effect of ROCK 
signalling on mesoderm-derived chondrogenesis by using ROCK inhibitor 
(Y27632).  It was proven that pre-exposing cells to ROCK inhibition in the 
mesoderm enrichment phase (+/-) was the driving force in the induction of 
chondrogenesis, which was demonstrated by functional analysis in the 
differentiation phase (-/+). In addition, continuous exposure to ROCK inhibition 
during the mesoderm enrichment and differentiation phases (+/+) advanced the 
chondrogenic differentiation towards hypertrophy.  Therefore, it will be 
interesting to examine the in vivo potential of the differentiated cells and their 
ability to generate a stable articular or growth plate-like cartilage phenotype. 
Thus, this protocol for cartilage differentiation could be then translated to human 
ESCs and iPSCs for the understanding of human diseases such as 
osteoarthritis and skeletal bone growth.  The in vivo potential of the cells will be 
further discussed in chapter 7.   
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Chapter 5  The relationship between FGF2, BMP4 and GDF5 
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5.1 Introduction 
 
In this project, the findings presented in chapter 4 clearly demonstrated that 
phase-specific manipulation of ROCK signalling inhibition enhanced 
chondrogenic differentiation towards hypertrophy.  Therefore, the results 
instigated further examination in two aspects of chondrocyte differentiation (i.e. 
hypertrophic and non-hypertrophic chondrocyte differentiation) and the role of 
ROCK signalling inhibition in this process. However, optimisation of the terminal 
differentiation media was considered first.    
During embryonic development and postnatal life, most bone of the skeleton 
undergoes endochondral ossification, whereby a cartilage template is formed 
which is then replaced by bone (Hall & Miyake 2000; Olsen et al. 2000; Goldring 
et al. 2006; Mackie et al. 2008; Long & Ornitz 2013b).  In the long bones of the 
limbs, such as the femur and humerus, chondrocytes undergo cycles of 
proliferation, hypertrophy and apoptosis.  Chondrocytes closest to the end of 
long bones, proliferate (called resting chondrocytes).  After that, they undergo 
accelerated proliferation and form characteristic columns of cells for longitudinal 
bone growth. Finally, cells reach a terminal differentiation phase prior to matrix 
calcification, at which hypertrophic chondrocytes develop, which are 
characterised by an increase in cell volume, secretion of the extracellular matrix 
protein, Col X, and expression of Matrix Metalloproteinase 13 (MMP13), ALP, 
Runx2 and Ihh. This provides the setting for blood vessel invasion and bone 
mineralisation (Inada et al. 1999; Long et al. 2001a; Jacenko et al. 2001; 
Kronenberg 2003; Lefebvre & Smits 2005; Goldring et al. 2006; Hidaka & 
Goldring 2008).  Chondrocyte hypertrophy is a critical stage at which a 
transition occurs from chondrogenesis to osteogenesis (Goldring et al. 2006; N. 
S. Hwang et al. 2007; Solomon et al. 2008).    
FGF signalling has been known for its mitogenic effect on different cell types, 
including chondrocytes (Solchaga et al. 2005; Chiou et al. 2006), however, it 
may also exhibit differential effects on chondrogenic proliferation and 
hypertrophy (Yoon et al. 2006; Sahni et al. 1999).  FGF2, in particular, has been 
shown in several studies to stimulate proliferation while inhibiting hypertrophic 
differentiation in cultures of rat rib growth plate chondrocytes (Wroblewski & 
Edwall-Arvidsson 1995) and in micromass cultures of rabbit rib cells (Kato & 
Iwamoto 1990).  
Monolayer differentiation phase (phase III): FGF2/BMP4/Y27632 
- 135 - 
In contrast to chondrocytes in the growth plate, chondrocytes in the joint 
surfaces are required to maintain the integrity of articular cartilage and are 
characterised by specialised ECM consisting primarily of collagen type II (Col 
II), aggrecan (Acan) (Hidaka & Goldring 2008; Pitsillides & Beier 2011), and 
marked by the expression of various markers such as GDF5 (previously known 
as BMP14 in humans), which is a member of the TGFβ superfamily (Storm et 
al. 1994; Settle et al. 2003; Archer et al. 2003; Pacifici et al. 2006; Iwamoto et 
al. 2007; Khan et al. 2007) and lubricin (Prg4) (Flannery et al. 1999; 
Schumacher et al. 1999).   
Recently, manipulation of BMP4 and GDF5 signalling has been shown to 
specify ESC-derived mesoderm towards hypertrophic and non-hypertrophic 
(articular-like) chondrocytes (Craft et al. 2013).  Therefore, establishing an 
ES/EB, step-wise, mESC mesoderm differentiation model system (discussed in 
chapter 3) allows for a controlled and defined method for dissecting and further 
understanding the role of ROCK inhibition in directing chondrocyte 
differentiation towards distinct chondrocyte populations that are either 
hypertrophic or non-hypertrophic.  
In the previous chapter (chapter 4), the finding demonstrated that a phase-
specific manipulation of ROCK signalling inhibition enhanced chondrogenic 
differentiation towards hypertrophy; however, that occurred under the influence 
of both FGF2 and BMP4 signalling which were established as the basal 
differentiation conditions.  In light of the potential opposing roles of FGF in 
regulating proliferation and differentiation, further inquiry was conducted into 
whether manipulating FGF2, in particular its duration of treatment under the 
culture conditions used in this project, could further influence the amount and 
type of cartilage formed in vitro (i.e. hypertrophic maturation) of ESC-derived 
mesoderm. In addition, it was investigated whether ROCK inhibition together 
with BMP4 or GDF5 signalling would influence ESC-derived mesoderm towards 
hypertrophic and non-hypertrophic (articular-like) chondrocytes. 
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The 3-phase ESC/EB differentiation model system as discussed in chapter 3 
was also applied here. The same protocol was followed as was used for the 
chondrogenic differentiation studies described in chapter 4, whereby the 
chondrogenic media contained BMP4 (100ng/ml), FGF2 (10ng/ml).  Exposure 
to FGF2 was either for the entire culture duration (herein, defined as continuous 
FGF2) or removed after 1 week of differentiation (at 14d) (herein, defined as 
temporal FGF2).  Furthermore, under temporal FGF2 culture conditions, BMP4 
was replaced by GDF5 (30ug/ml) as will be described later in this chapter.  
To test the effects of ROCK inhibition, Y27632 (10mM) was added to the 
cultures, as will be shown in each section.  Cultures were fixed after 2 weeks 
and analysis was undertaken by monitoring the morphological changes of cells 
in culture, quantification of Alcian blue positive nodule areas, Col X 
immunofluorescence staining as well as H&E with Alcian blue staining.  
Molecular analysis of chondrogenic marker gene expression Sox9, Col II, Col X 
and Prg4 was also performed by qPCR. 
5.3 Results 
 
5.3.1 The effect of ROCK inhibition and temporal FGF2 on chondrogenic 
differentiation and maturation 
 
In chapter 4, it was demonstrated that phase-specific ROCK inhibition 
stimulated chondrogenesis and continuous exposure to ROCK inhibition 
enhanced this effect, as evidenced by an increase in the percentage of 
chondrogenic nodules and upregulation of chondrogenic gene expression, 
including Col X, the hypertrophic chondrocyte marker.   All the former results 
were obtained from continuous use for 2 weeks of a chondrogenic medium 
containing FGF2 and BMP4.  Recognising that long-term treatment with FGF2 
might not provide the optimal balance between proliferation and differentiation 
led us to investigate the chondrogenic potential of cells when cultured in FGF2 
alone, or in combination with BMP4 (Fig. 5.1A). 
Alcian blue staining results showed, in comparison to control cultures (Fig. 
5.1B,E,F), cultures treated with FGF2 only showed a significant reduction in 
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Alcian blue staining (Fig. 5.1C,G,H).  In addition, BMP4 only cultures showed a 
visible increase in Alcian blue staining (Fig. 5.1D,I,J).  These results suggest 
that FGF2 inhibits while BMP4 signalling stimulates chondrogenesis.  However, 
observations of cells during the culture period showed that FGF2 cultures 
reached confluency earlier than BMP4 cultures (observational data), suggesting 
that FGF signalling is required for initial stage proliferation and/or expansion of 














Figure 5.1: Effect of FGF2 and BMP4 either alone or in combination on 
chondrogenic differentiation. 
A) A differentiation scheme showing the timing of factors additional to the 
culture media in phases II and III. In phase II, cells were cultured in FGF2 and 
Y27632. Then in phase III, cells were cultured in chondrogenic media 
containing FGF2 and BMP4 (either alone or in combination) in the further 
presence of Y27632 for 2 further weeks then fixed for analysis. B) Images of 
Alcian blue stained wells and (E&F) microscopic images from cultures treated 
with combined FGF2 and BMP4. C) Images of Alcian blue stained wells and 
(G&H) microscopic images from cultures treated with FGF2 only.  D) Images of 
Alcian blue stained wells and (I&J) microscopic images from cultures treated 
with BMP4 only.  All images are from one representative experiment of 2 
independent experiments.  Scale bars: 100 µm. 
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Based on the findings in Figure 5.1, demonstrating that FGF2 is required for 
initial stage proliferation and/or expansion of chondrogenic precursors and 
continuous treatment in FGF2 inhibited chondrogenic differentiation of ESC-
derived mesoderm, it was investigated whether temporal exposure to FGF2 
during the monolayer differentiation phase (phase III) could influence the 
amount and type of cartilage formed in vitro, and whether ROCK inhibition 
during the mesoderm enrichment phase (phase II: 4-7d) would influence this 
process.  
As shown in Fig. 5.2A, in these experiments cells were first cultured in phase II 
in the presence or absence of Y27632 followed by differentiation (phase III) in 
the continued presence of Y27632.  Cells were cultured in the continuous 
presence of FGF2 and BMP4 as control cultures (defined as continuous FGF2), 
and compared to cultures where FGF2 was removed after one week of culture 
(defined as temporal FGF2) (Fig.5.2A).   
At the morphological level, in temporal FGF2 cultures, the Y27632-treated 
cultures showed large round cells that resembled hypertrophic chondrocytes 
compared to Y27632-untreated cultures (Fig. 5.2B&C). Moreover, the 
hypertrophic chondrocyte morphology was further confirmed by analysis of 
histological sections of fixed cultured tissue (Fig. 5.2D) and at the protein level 
by immunofluorescence for Col X (Fig. 5.2E).  
Staining differentiated monolayer cultures with Alcian blue followed by 
quantification showed, under continuous FGF2 culture conditions, a 4-fold 
increase in GAG production in Y27632-treated cultures (+YC) compared to 
untreated cultures (-YC) (Fig. 5.2F&G, blue bars).  Under temporal FGF2 culture 
conditions, Y27632-treated cultures (+YT) showed a slightly higher, ~5-fold 
increase in GAG production compared to untreated cultures (+YT) (Fig. 5.2F&G, 
green bars). These results suggest that the stimulatory effect of the ROCK 
signalling inhibition during phase II was enhanced slightly by temporal FGF 
signalling compared to continuous treatment. The results also confirm the 
importance of ROCK signalling inhibition during phase II, since there were no 
differences in temporal versus continuous FGF2 treatment in the absence of 
ROCK inhibition.   
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Figure 5.2: The effect of ROCK inhibition and temporal FGF2 on chondrogenic 
differentiation. 
A) A differentiation scheme showing the timing of factors additional to the 
culture media in phases II and III. In phase II, cells were cultured in the 
presence of absence of Y27632.  In phase III, cells were cultured in presence of 
FGF2, BMP4, and Y27632. FGF2 was removed from the medium either at 14d 
(temporal, labelled Temp.FGF2) or at 21d (continuous, labelled contin. FGF2) 
while cells were cultured in continuous presence of BMP4 for 21d.  B&C) Alcian 
blue stained monolayers showing larger and rounder hypertrophic chondrocyte 
morphology in Y27632-treated compared to untreated cultures.  D) A cross-
section of a monolayer stained with H & E and Alcian blue showing abundant 
extracellular matrix and large round chondrocyte morphology.  E) Collagen type 
X immunofluorescence staining of a monolayer.  F) Alcian blue stained wells 
were solubilised for quantification.  G) Alcian blue staining of monolayers from 
temporal and continuous FGF2 cultures treated in the presence and absence of 
Y27632. Data indicate mean ±SD (triplicates) of one experiment (paired student 
t-test; *p<0.05). (±Yc:  indicate continuous FGF2),(±YT: indicate temporal FGF2).    
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Subsequently, molecular analysis demonstrated under continuous FGF2 culture 
conditions that Y27632 treatment (+YC) did not have any effects on Sox9 
expression; however, it led to a 10-fold increase in both Col II and Col X 
expression compared to untreated cultures (-YC) (Fig. 5.3, blue bars).  
Interestingly, in temporal FGF2 culture conditions, Y27632 treatment (+YT) 
upregulated Sox9 expression by 1.6-fold with a 10.5-fold and a 30-fold increase 
in the expression of Col II and Col X, respectively compared to untreated 
cultures (-YT) (Fig. 5.3, green bars).  These results suggest that ROCK 
signalling inhibition together with temporal FGF2 signalling enhanced both 
chondrogenic precursors and mature chondrocyte differentiation.  
Interestingly, in the absence of Y27632, temporal FGF2 cultures (Fig. 5.3; -YT, 
green bars) did not have an effect on Sox9 expression, however, there was an 
upregulation of Col II and Col X expression in comparison to continuous FGF2 
cultures (Fig. 5.3; -YC, blue bars).   Therefore, the results confirm the Alcian 
blue staining (Fig. 5.2G) and the importance of ROCK inhibition during phase II 
in the stimulation of chondrogenic differentiation, in particular, in promoting 
chondrogenic or maybe chondro-osteoprecursor differentiation, since there 
were no differences in temporal vs continuous FGF2 treatment in the absence 













Figure 5.3: The effect of ROCK inhibition and temporal FGF2 on  chondrogenic 
gene expression. 
RNA was extracted from continuous and temporal FGF2 cultures from Y27632 
treated (+Y) and untreated (-Y) cultures for qPCR analysis of chondrogenic 
marker gene expression, Sox9, Col II and Col X.  Data indicate mean ±SD from 
one representative experiment from 2 independent experiments  (paired student 
t-test; *p< 0.05) (±Yc: continuous FGF2), (±YT: temporal FGF2). 
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5.3.2 The effect of ROCK inhibition and GDF5 on chondrogenic 
differentiation and maturation.   
 
In the previous section it was demonstrated that Y27632 treatment in temporal 
FGF2 culture conditions enhanced chondrocyte maturation towards 
hypertrophy.  Hatakeyama et al. (2004) and Craft et al. (2013) reported that 
BMP4 and GDF5 controlled the hypertrophic and non-hypertrophic 
differentiation of chondrocytes in E11.5 mouse micromass cultures and ESC 
cultures, respectively.  Therefore, in this project, it was investigated whether 
manipulation of BMP4 and GDF5 would influence chondrogenic differentiation 
(i.e. hypertrophic vs non-hypertrophic chondrocytes) and whether inhibition of 
ROCK would have an effect on either condition.  Therefore, cells were cultured 
in the presence of either BMP4 or GDF5 in phase III.  FGF2 was removed after 
1 week of culture and an analysis of cultures was performed after another one 
week in culture (Fig. 5.4A).  
Cultures treated with GDF5 reached confluence in 4 days and chondrocyte 
nodule formation developed more rapidly in GDF5 cultures compared to BMP4 
cultures (data not shown).  At the morphological level, GDF5 cultures showed 
distinctive tightly packed, chondrocyte nodules (Fig. 5.4B) and the Y27632-
treated cultures resulted in very large 3-dimensional nodules (Fig. 5.4C) that 
showed increased matrix deposition/GAG synthesis, as measured by 
quantification of Alcian blue staining, in comparison to the untreated cultures 
(±YG)(Fig. 5.4D&E, pink bars). Therefore, the results suggest that GDF5 
signalling stimulated chondrogenic differentiation and aggregation and inhibition 
of ROCK signalling enhanced it.   
In comparison to BMP4 cultures, there were clear differences in morphology 
and distribution of chondrocyte nodules between BMP4 (Fig. 5.2B&C) and 
GDF5 cultures (Fig. 5.4B&C).  The Alcian blue quantification results showed 
that in the absence of Y27632 in phase II, GDF5 cultures (-YG) showed a 
significant increase in GAG production compared to BMP4 cultures (-YB) (Fig. 
5.4D&E), suggesting that GDF5 signalling enriched the number of chondrocyte 
nodules more than BMP4 signalling.   
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While upon the addition of Y27632 in phase II, GDF5 cultures (+YG) showed no 
significant differences from BMP4 cultures (+YB) (Fig. 5.4D&E), although the 
distribution of nodules were markedly different.  
Taken together, ROCK inhibition during the mesoderm enrichment phase 
enhanced the chondrogenic effects of both BMP4 and GDF5.  However, in 
contrast to BMP4, GDF5 signalling stimulated the number of chondrocyte 
nodules even without ROCK inhibition in phase II.  Despite the dramatic 
differences in chondrocyte nodule morphology and distribution in GDF5 versus 
BMP4 cultures, total matrix accumulation was similar, suggesting that there 
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Figure 5.4: The differences between BMP4 and GDF5 signalling in ROCK –
dependent chondrogenic differentiation. 
A) A differentiation scheme showing the timing of the addition/removal of factors 
in the culture media in phases II and III.  In phase II, cells were cultured in FGF2 
and Y27632. Then in phase III, cells were cultured in the presence of FGF2 and 
Y27632 with either BMP4 or GDF5 for 2 weeks, whilst at 14d, FGF2 was 
removed.  B&C).  B&C) Alcian blue stained monolayers from GDF5 cultures 
cultured in the absence (B) or presence (C) of Y27632 during phase II.   D) 
Alcian blue stained wells were solubilised for quantification. E) Images of Alcian 
blue stained  monolayers from BMP4 ±Y27632 (green box) and GDF5(pink box) 
cultures. Data indicate mean ±SD (triplicates) from one experiment 
(triplicates)(paired student t-test;*p<0.05) (±YB: BMP4), (±YG:  GDF5).  
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To further analyse the effect of both Y27632 and GDF5 treatment on 
chondrogenic differentiation, preliminary molecular analysis of chondrogenic 
marker gene expression was undertaken after a short culture period of 1 wk and 
was compared to BMP4-treated cultures.  The results revealed that in Y27632-
treated cultures, BMP4 (+YB) stimulated Acan and Col X expression as shown 
earlier (Chapter 4, Fig. 4.6B) and additionally, stimulated the articular cartilage 
marker Prg4/Lubricin compared to Y27632 untreated cultures (-YB) (Fig. 5.5A).  
However, in the presence of GDF5 (+YG), there was a downregulation in Acan 
and Col X expression but an upregulation of Prg4/Lubricin compared to 
untreated cultures (-YG) (Fig. 5.5B). These preliminary results suggest that 
GDF5 and ROCK signalling might interact to drive chondrogenic differentiation 














Figure 5.5: The effects of BMP4 and GDF5 on chondrogenic gene expression. 
RNA was extracted at 14d from the (A) BMP4 and (B) GDF5 cultures that were 
Y27632 treated (+Y) or untreated (-Y) in phase II.  qPCR analysis was 
performed for the chondrogenic marker genes Acan, Col X (hypertrophic 
chondrocyte marker) and Prg4 (articular chondrocyte marker).  Data indicate 
mean ±SD from one representative experiment from one experiment (paired 
student t-test;  *p< 0.05). 
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In this chapter, two aspects of chondrogenic differentiation have been 
examined. First, the finding in chapter 4 that the effect of phase–specific 
inhibition of ROCK signalling could enhance chondrogenic maturation and 
hypertrophy, as evidenced by Col X, prompted further optimisation and 
characterisation of these populations.   
The chondrogenic differentiation media used so far contained FGF2 and BMP4, 
based on developmental studies for limb and endochondral growth plate 
development which showed distinct and sometimes antagonistic effects of FGF 
signalling on chondrocyte lineage commitment, proliferation and differentiation 
(Yoon et al. 2006; Sahni et al. 1999).  Several studies have reported that FGF2 
stimulates proliferation while inhibiting hypertrophic differentiation in cultures of 
rat rib growth plate chondrocytes (Wroblewski & Edwall-Arvidsson 1995), and  
in micromass of rabbit rib cells (Kato & Iwamoto 1990).  Therefore, it was 
reasoned that continuous exposure of the ESC-derived chondrocytes to FGF2, 
despite the presence of BMP4, might not provide the optimal conditions for 
cartilage differentiation in the ESC/EB culture system used in this project.  
Hence, the hypothesis was that the effects of ROCK inhibition might be better 
documented under optimal differentiation.   
The time period of FGF signalling was shown to be critical and the stimulatory 
effect of ROCK inhibition on chondrogenesis was enhanced by the withdrawal 
of FGF signalling at the latter stages of chondrocyte differentiation. Temporal 
FGF2 signalling enhanced the chondrogenic maturation effect of ROCK 
signalling inhibition, as evidenced by matrix deposition and Col II, Col X gene 
expression.  However, the importance of ROCK signalling inhibition during 
phase II was shown to be its role in promotion of chondrogenic or perhaps 
chondro-osteoprogenitor differentiation, regardless of the duration of exposure 
to FGF2 signalling.  Other reports have shown that ROCK inhibition stimulates 
Sox9 expression (as discussed in chapter 4); however, there have been no 
reports on the effect of temporal FGF and phase–specific ROCK signalling 
inhibition, which is unique to this project. 
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The preliminary results from culturing cells in GDF5 demonstrate that the 
culture conditions could be manipulated by BMP4 and GDF5 signalling to 
recapitulate hypertrophic and non-hypertrophic chondrocyte differentiation, 
respectively. The improved culture conditions (i.e. temporal FGF2 exposure) 
were used for assessing the effects of GDF5 as a potential inducer of an 
articular cartilage phenotype.   ROCK signalling inhibition combined with GDF5 
signalling stimulated a chondrogenic population with distinctive morphology, 
enhanced matrix deposition, and articular–like gene expression, demonstrated 
by the upregulation of Prg4/Lubricin expression and the downregulation of Col X 
expression compared to ROCK signalling inhibition when combined with BMP4 
signalling.  Gene expression was performed on a 1-week culture, and further 
experiments looking at longer-term cultures will determine whether GDF 
cultures can maintain a stable articular/non-hypertrophic phenotype.   
These outcomes were consistent with the findings reported previously using 
different culture models (Hatakeyama et al. 2004; Craft et al. 2013).  
Hatakeyama et al. (2004), which showed, in micromass cultures of E11.5 cells, 
a differences in chondrocyte morphology between GDF5 and BMP4-stimulated 
chondrocyte nodules. In addition, in a mESC, serum free culture, Craft et al. 
(2013) demonstrated similar differences in chondrocyte morphology in cells 
cultured in BMP4 and GDF5, whereby GDF5 upregulated Prg4 expression and 
low levels of Col X expression were found in comparison to BMP4 cultures.   
It seems that inhibition of ROCK signalling, in particular during the mesoderm 
enrichment phase (+/-), induced hypertrophic chondrocyte differentiation in the 
presence of BMP4 combined specifically with temporal FGF2 signalling.  In 
addition, independently of FGF2 signalling, ROCKsignalling inhibition seems to 
enrich for chondrogenic and/or chondro-osteoprogenitor cells. Finally, ROCK 
signalling inhibition together with GDF5, but not with BMP4 signalling, might be 
inducing a differentiation programme that resembles a non-hypertrophic 
(articular-like) chondrocyte differentiation.  
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Consequently, access to enriched populations of hypertrophic and non-
hypertrophic chondrocytes developed by manipulation of FGF2, BMP4 or GDF5 
together with stage-specific ROCK inhibition will provide insights into molecular 
events regulating both hypertrophic and non-hypertrophic differentiation under 
the influence of the ROCK pathway and their potential future use in tissue 
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Chapter 6 Effect of ROCK inhibition on osteogenic   
differentiation of ESC-derived mesoderm 
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6.1 Part A 
6.2 Introduction 
 
During embryonic development of endochondral bone, a cartilage template is 
formed which is then replace by bone (Hall & Miyake 2000; Olsen et al. 2000; 
Goldring et al. 2006; Long & Ornitz 2013b).   Bone as a tissue is composed of 3 
cell types; osteoblasts (bone-forming cells), osteocytes (terminally differentiated 
osteoblasts engulfed in mineralized bone matrix), and osteoclasts (bone-
resorbing cells).  Osteoblasts secrete extracellular matrix, which consists of 
mineral (hydroxyapatite), collagen (predominantly collagen type I (herein Col I)), 
water, noncollagenous proteins, and lipids in decreasing proportion 
(Boskey&Robey 2013).  Bone formation (osteogenesis) is a multistep process 
that is controlled by a cascade of molecular events (Karsenty et al. 2009).  
Small GTPAse signalling has been shown to influence osteogenesis, in terms 
of: lineage commitment (McBeath et al. 2004), osteogenesis marker gene 
expression, differentiation and maturation (Ohnaka et al. 2001; McBeath et al. 
2004; Harmey et al. 2004; Yoshikawa et al. 2009; Khatiwala et al. 2009; Prowse 
et al. 2013).  Specifically, the role of Rho/ROCK signalling in osteogenesis 
appears to be complex.  Several reports have suggested a positive role for 
Rho/ROCK signalling in osteogenesis commitment and differentiation (McBeath 
et al. 2004; Meyers et al. 2005; Khatiwala et al. 2009; Arnsdorf et al. 2009). 
However, others have shown the contrary, specifically using the Y27632 
chemical inhibitor (Ohnaka et al. 2001; Harmey et al. 2004; Kanazawa et al. 
2009; Yoshikawa et al. 2009; Prowse et al. 2013).   
The effect of ROCK signalling on osteogenesis had been investigated in our lab 
(Harmey et al. 2004).  In primary mouse calvarial osteoblast cultures, our 
laboratory has shown that the inhibition of ROCK signalling positively influenced 
the differentiation and maturation of primary osteoblast cells and while 
activation of Rho by the Pasteurella Multocida Toxin (PMT), led to a decrease in 
osteoblast differentiation, suggesting a role of Rho/ROCK in osteoblast 
differentiation.  Interestingly, the Harmey et al. (2004) study pointed out that the 
effect of ROCK inhibition was dependent on the differentiation stage of the cells 
and of nodule formation, suggesting that ROCK may be targeting the 
differentiation of osteoblast precursors rather than matrix deposition and 
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mineralisation.  Collectively, these studies highlighted the complexity of ROCK 
signalling, which may be further explained by several possibilities, such as 
species differences, culture conditions (e.g. 2D versus 3D cultures), cell origin 
and the stage of cell development during the differentiation process.  Thus, the 
exact mechanism of ROCK signalling in regulating osteogenic development is 
not yet clear and unravelling the complexity of this signalling pathway in 
osteogenic differentiation has been an interest in the field of musculoskeletal 
diseases such as osteoarthritis.  Therefore, establishing an ESC/EB, step-wise, 
mESC mesoderm differentiation model system (discussed in chapter 3) allows 
for a controlled and defined method for dissecting and further understanding of 
the molecular events occurring during development of bone, in particular, 
specification and differentiation.  Thus, this chapter will investigate the effect of 
ROCK inhibition, specifically at two developmental stages: the mesoderm 
enrichment phase (phase II) and the differentiation phase (phase III). 
6.3  Methods 
 
The 3-phase ESC/EB differentiation model system as discussed in chapter 3 
was also applied here. The same protocol was followed as was used for the 
chondrogenic differentiation studies described in chapter 4, except that in phase 
III, cells were re-plated as single cells in a monolayer culture in osteogenic 
media (OM) containing 50ug/ml Ascorbic Acid (AA), 10mM β-glycerophosphate 
(β-GP), 10-7M Dexamethasone, 100ng/ml BMP4 and 10ng/ml FGF2.  To test 
ROCK inhibition, 10mM Y27632 was added to the cultures, as will be shown in 
each section.  Cultures were fixed after 2, 3, or 4 weeks and analysis was 
undertaken by monitoring the morphological changes of cells in culture, as well 
as quantification of ALP positive nodule areas, and assessment of 
mineralisation by von Kossa staining.  Molecular analysis of osteogenic marker 
gene expression (Runx2, Osx, ALP, BSP and OC) was also performed by 
qPCR. 
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6.4 Results 
6.4.1 Osteogenic differentiation of ESC-derived mesoderm 
 
In chapter 3, molecular analysis showed that both Runx2 and Osx were 
upregulated after culturing cells in FGF2 for 3 days during the mesoderm 
enrichment phase (phase II) (chapter 3, Fig. 3.10).  Therefore, the next step 
was to examine whether cells generated at phase II had the functional potential 
to differentiate towards the osteogenic lineage, when cultured in osteogenic 
media in the monolayer differentiation phase (phase III) (Fig. 6.1A).   
Firstly, morphological analysis under basal osteogenic media conditions 
indicated that cells started to cluster and form 3-D nodules by 21d and were 
positively stained with ALP (Fig. 6.1B-E), with a distinctive cuboidal morphology 
(Fig. 6.1D,E).  In addition, the cells expressed collagen type I protein when 
assessed by immunofluorescence staining (Fig. 6.1F,G).  Interestingly, although 
collagen type 1 was expressed, there were no signs of mineralisation at this 
period of differentiation, i.e. after 2 wks of differentiation.  These results implied 
that ESC-derived mesoderm differentiated towards the osteogenic lineage, but 
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Figure 6.1: Osteogenic differentiation of ESC-derived mesoderm in the 
monolayer differentiation phase (phase III). 
A) A differentiation scheme showing the timing of osteogenic monolayer 
differentiation.  In phase III, cells were cultured in osteogenic media (FGF2 
(10ng/ml), BMP4 (100ng/ml), Dex. (10-7M), β-GP (10mM).  Monolayer cultures 
were fixed after 2 weeks for analysis. B,C) ALP staining of osteoblast nodule 
areas. D,E) Images of  3-D osteoblast nodules showing typical cuboidal 
morphology of osteoblast cells.  F,G) Collagen type I immunofluorescence 
staining of osteoblast nodules, insert (F; negative control) insert (G; cells 
stained with Dapi).  All images were from representative wells from 10 
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Molecular analysis of cultures at (21d) of differentiation (Fig. 6.2A) showed a 
significant upregulation of Runx2, Osx, and ALP expression compared to 
cultures prior to the beginning of monolayer differentiation i.e. at 7d (Fig. 6.2B).  
Collectively, these results suggested that ESC-derived mesoderm was able to 













Figure 6.2:  Expression of osteogenic markers after 2 weeks in the monolayer 
differentiation phase (phase III).  
A) A differentiation scheme showing cells cultured in the absence of Y27632 in 
phases II and III, then cultured in osteogenic media in phase III.   RNA was 
extracted at two time points (pink box) during the differentiation period: 7d and 
21d.  B) Quantitative PCR analysis of osteogenic marker gene expression 
(Runx2, Osx and ALP). Data indicate mean ±SD (triplicate samples), from one 
representative experiment of 3 independent experiments.  Data indicate mean ± 
SD (triplicates) from a representative experiment of 3 independent experiments 
(paired student’s t-test; * p < 0.05, 7d vs 21d). 
 
6.4.2 Effect of ROCK inhibition in the mesoderm enrichment phase (phase 
II) on osteogenic differentiation 
 
In chapter 3, Y27632 treatment in the mesoderm enrichment phase (phase II) 
illustrated a differential effect on expression of osteogenic transcription factors 
(Runx2 and Osx) compared to the untreated cultures.  Y27632 treatment did not 
affect Runx2 expression, however, it downregulated expression of Osx (Fig. 
3.13A).  To further investigate the functional potential of the Y27632-treated 
cells, cells were re-plated in phase III in osteogenic media and then cultured for 
a further 2 weeks (Fig. 6.3A). Quantification of ALP-positive nodule areas 
indicated that treatment with Y27632 during phase II alone significantly 
decreased the ALP positive areas compared to Y27632 untreated cultures  (Fig. 
6.3B&C). 
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Subsequently, at the molecular level, qPCR analysis indicated that Y27632 
treatment downregulated expression of Osx, ALP, BSP while it did not have an 
effect on the expression of Runx2 and OC (Fig. 6.3D).  These results advocate 
that inhibition of ROCK signalling at the mesoderm enrichment phase (4-7d) 
inhibited osteogenic differentiation of ESC derived mesoderm in the 
differentiation phase (7-21d).  
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Figure 6.3: Effect of ROCK inhibition in phase II on osteogenic differentiation of 
ESC-derived mesoderm. 
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.  In phase III, cells were cultured in osteogenic media 
for 2 weeks.  B) Representative images of ALP stained monolayers from 3 
independent experiments. C) Quantification of ALP positive nodule areas. D) 
Quantitative PCR analysis of osteoblast-specific markers, Runx2, Osx, ALP, 
BSP and OC at 21d of differentiation. Data indicate mean ± SD (triplicates) from 
a representative experiment of 3 independent experiments (paired student’s t-
test; * p < 0.05). 
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6.4.3 Effect of ROCK inhibition in both phases II and III on osteogenic 
differentiation  
 
Following on from the results of the previous section, it was then investigated 
whether prolonged ROCK inhibition would influence osteogenic differentiation.  
In phase II, cells were cultured in the presence and absence of Y27632.  Then 
in phase III, cells were cultured in osteogenic media, however, this time cells 
would be cultured in the presence of Y27632 for 2 weeks (Fig. 6.4A).  
Quantification of ALP staining demonstrated a 1.4 fold increase in ALP positive 
nodule areas when cells treated with continuous Y27632 in comparison to the 
control (Fig. 6.4B,C).  In parallel, continuous Y27632 treatment showed an 
upregulation of mature osteogenic markers (BSP), while it showed no effect on 
(Runx2, Osx, ALP and OC) compared to the control cultures (Fig.4D).  These 
results indicated that the continuous inhibition of ROCK signalling in both 
phases (4-21d) had stimulated osteogenic differentiation of ESC-derived 
mesoderm and possibly had directed the differentiation towards maturation. 
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Figure 6.4:  Effect of continuous ROCK inhibition in both phase II and III on 
osteogenic differentiation of ESC- derived mesoderm. 
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.  In phase III, cells were cultured in osteogenic media 
for 2 weeks.  B) Representative images of ALP-stained monolayers from 3 
independent experiments.  C) Quantification of ALP-positive nodule areas.  D) 
Quantitative PCR analysis of osteoblast-specific markers (Runx2, Osx, ALP, 
BSP and OC) at 21d of differentiation. Data indicate mean ±SD (triplicate 
samples), from one representative experiment of 3 independent experiments. 
Data indicate mean ± SD (triplicates) from a representative experiment of 3 
independent experiments (paired student’s t-test; * p < 0.05). 
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Summarising all four treatment groups together (Fig. 6.5A), ALP staining results 
showed a 2-fold increase in ALP positive areas in continuous Y27632-treated 
cultures compared to untreated cultures (-/- vs +/+), followed by a 1.4-fold 
increase in cultures exposed to a temporal Y27632 treatment in phase III only 
(7-21d) compared to untreated cultures (-/- vs -/+). Interestingly, temporal 
Y27632 treatment in phase II only caused a slight but significant decrease in 
ALP positive areas compared to untreated cultures (-/- vs +/-) (Fig. 6.5B&C).   
These results confirmed that temporal inhibition of ROCK signalling in phase III 
(-/+) is the key in inducing osteogenesis, and continuous ROCK signalling 
inhibition (+/+) enhanced the differentiation and maturation processes. These 
results suggest a developmental phase-specific effect of ROCK signalling 
inhibition on osteogenic differentiation.  
Moreover, BSP expression results proved that continuous Y27632 treatment 
(+/+) and temporal Y27632 treatment in phase III only (-/+) upregulated BSP 
expression by 6-fold and 5-fold respectively, compared to untreated cultures.  
By contrast, Y27632 treatment in phase II only (+/-) showed a significant 3-fold 
reduction in BSP expression compared to untreated cultures (-/-) (Fig. 6.5D). 
Taken together, and in comparison to the chondrogenic effect of Y27632 
treatment seen in chapter 4 (Fig. 4.7), it seems that ROCK inhibition in phase II 
(+/-) differentially affects chondrogenic and osteogenic differentiation, and 
continuous ROCK inhibition (+/+) directs towards chondrocyte hypertrophy and 
further osteoblast maturation.  
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Figure 6.5: Effect of stage-specific ROCK inhibition in phases II and III on 
osteogenic differentiation of ESC-derived mesoderm. 
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III. In phase III, cells were cultured in osteogenic media 
for 2 weeks.  B) Representative images of ALP-stained monolayers from 2 
independent experiments. C) Quantification of ALP-positive nodule areas. D) 
Quantitative PCR analysis of osteoblast specific markers, BSP at 21d of 
differentiation. Data indicate mean ± SD (triplicates) from a representative 
experiment of 3 independent experiments (one-way ANOVA; * p < 0.05). 
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In the first part of this chapter (partA), it was demonstrated that the serum-free, 
3-phase ESC/EB model system effectively directed ESCs towards osteoblast 
differentiation.  As mentioned in the introduction, the effect of ROCK signalling 
on osteogenesis is complex, and according to cell types derived from different 
species, the differentiation stage of the cells, and culture conditions, all of which 
could influence the role of Rho-ROCK signalling.   The use of the ESC/EB 
differentiation protocol (chapter 3) enabled the role of ROCK inhibition on 
osteoblast differentiation to be addressed in a defined and controlled manner, 
by analysing the effects of ROCK inhibition at two developmental stages: 
mesoderm enrichment (phase II) and differentiation phases (phase III). 
Herein, it was proved that temporal ROCK inhibition indeed has a 
developmental phase-specific effect on osteogenic differentiation.  When ROCK 
was inhibited during the mesoderm enrichment phase only (4-7d), osteogenesis 
was not induced.   However, when ROCK was inhibited, either during the 
differentiation phase only (-/+) or continuously in both phases (+/+), 
osteogenesis was induced.  These findings will be discussed further in the 
following sections.  
Upon temporal/short-term inhibition of ROCK signalling in phase II only (+/-), 
there was a reduction in the percentage of ALP positive nodule areas and this 
was accompanied by a downregulation in the expression of Osx, ALP and BSP.  
Similar results were shown in other reports (McBeath et al. 2004; Khatiala et 
al.2009; Arnsdorf et al. 2009).  The McBeath et al. (2004) study demonstrated 
that RhoA/ROCK signalling is required for osteogenic differentiation of hMSC 
and that ROCK is downstream of both cell shape and soluble factors.  
Expressing constitutively active RhoA in un-spread cells led to an osteogenic 
fate while spread cells differentiated to an adipogenic fate, suggesting an effect 
of cell shape in the osteogenic effect of RhoA. However, constitutively active 
Rho effector, ROCK, induced osteogenesis in both round and spread cells, 
independently of cell shape and Y27632 showed the opposite effect.  
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Therefore, supporting the importance of ROCK signalling in the osteogenic 
differentiation of hMSCs. Therefore, it could be speculated that the inhibitory 
effect of ROCK on osteogenesis seen in our cultures may suggest that the cells 
generated from exposing phase II cultures to ROCK inhibition (+/-) could have 
been in a MSC-like stage and therefore had responded negatively to ROCK 
inhibition.  Alternatively, as phase II cultures are non-adherent aggregates, the 
consequences of cell shape cannot be ruled out. 
In contrast to the short-term effects of ROCK inhibition in phase II (+/-) on long-
term osteoblast differentiation, it was demonstrated that continuous ROCK 
inhibition, in both phases (+/+), stimulated osteogenesis which was manifested 
by the increase in the ALP-positive nodule area and tended towards an 
upregulation of bone specific markers (Runx2, ALP) while significant increase in 
BSP expression.  This positive ROCK inhibition effect on osteogenesis in phase 
III was also verified when ROCK was temporally inhibited in phase III only (-/+).   
These results confirm that ROCK inhibition in phase III is responsible for 
inducing osteogenesis from ESC-derived mesoderm.  
These stimulatory results of ROCK inhibition on osteogenesis correspond with 
other studies where ROCK inhibition stimulated osteogenesis in pre-osteoblast 
cultures which might represent more committed cells (Harmey et al. 2004; 
Yoshikawa et al. 2009; Prowse et al. 2013).  Harmey et al. (2004) demonstrated 
that inhibition of Rho (using C3 transferase) and ROCK (using Y27632 or HA-
1077) led to stimulation of osteoblast differentiation and mineralisation, as 
shown by an increase in bone nodule formation and up regulation of ALP and 
OC gene expression.  Further, this study pointed out that the effect of ROCK 
inhibition was dependent on the differentiation stage of the cells, i.e. the stage 
of nodule formation and treatment with ROCK inhibitors may be targeting the 
differentiation of osteoblast precursors rather than matrix deposition and 
mineralisation as analysed by ALP quantification.   
Similarly, Yoshikawa et al. (2009) proved that ROCK inhibition using Y27632 
stimulated osteogenesis both in vivo and in vitro.  Initially, it was demonstrated 
that Y27632 treatment increased osteogenesis by upregulation of ALP and OC 
expression and increased nodule formation compared to the untreated cultures.   
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Further, the osteogenic effect of ROCK inhibition was confirmed by using a 
constitutively active ROCK mutant and a dominant-negative ROCK construct in 
mesenchymal ST2 cells.  This stimulatory effect was also reproduced in human 
primary osteoblast cultures using a different ROCK inhibitor, Hydroxyfasudil 
(Ohnaka et al. 2001).  Therefore, the results of our study could suggest that the 
cells in phase III are at a pre-osteoblast-like stage of development, and hence 
responded positively to ROCK inhibition.  
On the molecular level, the osteogenic effect of ROCK inhibition in the 
differentiation phase (phase III) was linked to BMP signalling (Harmey et al. 
2004; Yoshikawa et al. 2009).  This was demonstrated by correlation of the 
upregulation of ALP and OC expression in Y27632 treated cultures with the 
upregulation of BMP4 expression using qPCR and Northern blot analyses. In 
addition, Yoshikawa et al. 2009 demonstrated that ROCK inhibition stimulated 
ectopic bone formation in the presence of BMP2 in the implanted collagen 
composite, therefore, suggesting the cooperation between ROCK and BMP 
signalling in inducting osteogenesis.   
 Similarly, Hydroxyfasudil upregulated BMP2 expression in MC3T3 cultures 
(Kanazawa et al. 2009).  In addition, other reports have proven the association 
of ROCK inhibition with the BMP pathway by the use of other classes of ROCK 
pharmacological inhibitors such as statins, which are 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors (Ohnaka et al. 2001; Kanazawa et 
al. 2009). Both studies demonstrated that the enhancement of BMP2 and OCN 
mRNA expression in osteoblasts is induced by hydroxyfasudil using hMSC 
(Ohnaka et al. 2001) and MC3T3 cultures (Kanazawa et al. 2009).  Therefore, 
the mechanism of osteogenesis in our culture conditions could be related to 
BMP signalling, especially as the osteogenic media is supplemented with 
BMP4, yet the exact mechanisms and downstream pathways that might be 
activated following ROCK inhibition are not yet known and require further 
investigation.   
Moreover, the stage-specific effect of ROCK inhibition on osteogenic 
differentiation of ESC-derived mesoderm could be explained in part by the 
expression studies preformed during the mesoderm enrichment phase (phase 
II: 4t-7d) (chapter3). The findings proved that cells exposed to ROCK inhibitor at 
phase II (4-7d) expressed markers of a bi-potential chondro-osteoprogenitor 
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population as well as paraxial and lateral plate mesoderm markers. However, 
when comparing cultures untreated and treated with ROCK inhibitor, ROCK 
inhibition at phase II (+/-) proved to differentially affect the differentiation 
mesoderm and chondro-osteoprogenitor population.  
Collectively, this suggests that the generated populations (i.e. exposed to 
ROCK inhibitor (4-7d)) might respond differently upon subsequent long-term 
differentiation (7-21d); and indeed there were differences, as discussed in this 
chapter and in chapter 4 for chondrogenesis. Taken together, it seems that 
there is a preferential effect of ROCK inhibition in phase II (+/-) towards 
chondrogenic over osteogenic differentiation, at least according to 
histochemical analysis.  These interesting results, however, require further 
analysis of both cartilage and bone specific gene markers expression for 
confirmation.   
Findings from long-term/continuous ROCK inhibition in both phases II and III 
(+/+) enhanced chondrocyte hypertrophy as demonstrated in (chapter 4) and 
led to advancement in osteoblast differentiation, thereby mimicking a growth 
plate differentiation process. In addition, BSP expression analysis showed 
similar pattern under both chondrogenic and osteogenic media conditions (data 
not shown).  BSP is not only expressed during bone differentiation, but it is also 
expressed in hypertrophic chondrocytes (Chen et al. 1991; Barnes et al. 2002; 
Gerstenfeld & Shapiro 1996).  Thus, it is speculated that the cells generated 
after a 2-week differentiation phase (phase III: 7-21d) could be at a specific 
stage that might represent an endochondral ossification process of bone 
formation where cells might be at the transition stage between late stages of 
chondrocyte differentiation and hypertrophy and early osteogenic differentiation. 
The in vivo potential of cells will further verify this speculation (chapter 7).   
In summary, based on ALP staining quantification and gene expression analysis 
in this section, it is established that that ROCK inhibition modulates ESC-
derived mesoderm differentiation to osteoblast in a phase-specific manner.   
The use of the ESC/EB differentiation protocol enabled us to address the role of 
ROCK inhibition in a defined and controlled manner, by analysing the effects of 
ROCK inhibition at two developmental stages: mesoderm enrichment (phase II) 
and differentiation phases (phase III).  The inhibition of ROCK in the 
differentiation phase showed to be the key stage for the anabolic effect on 
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bone, while ROCK inhibition in the mesoderm enrichment phase showed the 
contrary.  Furthermore, the findings here in this chapter and in combination with 
findings in chapter 4 and 5, strongly suggest that long-term ROCK inhibition 
manipulation directs the maturation of chondrocytes and osteoblasts, possibly 
mimicking endochondral ossification.  The ability of the osteoblasts to mature 
further and attain full mineralisation in vitro - which is a characteristic of 
functional bone tissue - will be interesting to investigate further and this will be 
discussed in the next part of this chapter (part 6.B).   
In conclusion, this is the first evidence for the osteogenic differentiation from 
ESC-derived mesoderm using the novel 3-phase, serum-free ES/EB 
differentiation system.  In addition, appreciating the influence of the 
developmental stage of cells on the osteogenic effect of ROCK signalling may 
pave the way for further comprehensive understanding of the molecular events 
regulating the ROCK pathway and provide future consideration for potential 
therapeutic targets for metabolic diseases characterised by bone loss such as 









Monolayer differentiation phase (phase III): osteogenesis 
- 165 - 
 




During bone formation, in order for bone tissue to become functional, it 
undergoes a stage of mineralisation to strengthen the collagen composite of 
bone. This provides mechanical resistance to bone and serve as a source of 
calcium, phosphate, and magnesium ions for mineral homeostasis (Boskey & 
Robey 2013).  In the context of in vitro differentiation, ascorbic acid (AA), β-
glycerophosphate (β-GP) and Dexamethasone are well-established as being 
essential for differentiation and to induce mineralisation in vitro in rodent pre-
osteoblastic cultures (Bellows et al. 1990) as well as in human MSC 
differentiation and mESCs/hESCs cultures (Buttery et al. 2001; Phillips et al. 
2001; zur Nieden et al. 2003; Duplomb et al. 2007; Brown et al. 2009; Hwang et 
al. 2013).  The majority of osteogenic differentiation experiments performed in 
the past have been conducted in serum-containing cultures.  
However, in the serum-free culture system used here, the data presented until 
this point of the thesis, demonstrated that the use of these osteogenic factors 
had not triggered mineralisation during the differentiation phase, at least with 
the growth factor combinations and time course applied in these experiments.  
As this is a unique and novel serum-free system, it is possible that it lacks some 
osteoblast-specific inducing or cooperating factors for full osteoblast 
differentiation.  
The model system used in this project made it possible to test several aspects 
of enhancing osteogenic differentiation towards mineralisation in a defined way 
and at a specific time points during the differentiation process.  Thus, the next 
step was to test several additional conditions in an attempt to drive the ESC-
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6.8 Methods 
  
Briefly, the conditions tested were as follows:  (1) extending the culture period to 
4 weeks under the same media conditions; (2) supplementing the osteogenic 
media with batch-tested serum (FCS) or known osteogenic factors such as 
vitamin D3, Wnt3a, Hedgehog signalling agonists, low concentration of β-
glycerophosphate; (3) culturing cells in FGF2 and BMP4 either separately or in 
combination; (4) culturing cells using a temporal FGF2 exposure; (5) re-plating 
differentiated osteoblasts in the presence of specific factors for an additional 
phase of differentiation/maturation under temporal FGF2 conditions.  The effect 
of ROCK inhibition during the mesoderm enrichment phase (phase II) as well as 
during differentiation (phase III) was assessed in the context of the different 
culture conditions as indicated below. 
6.9 Results 
 
6.9.1  Extending the differentiation culture period  
  
The original standard culture period used for osteogenic differentiation in phase 
III was 2 weeks (7-21d).  It was therefore investigated whether simply extending 
the culture period for an additional 2 weeks (35d) would promote mineralisation.   
In the first instance, this was tested in the continuous presence of Y27632 as 
this had been shown in the first part of this chapter (partA), to maximise 
osteogenic differentiation and gene expression.  Thus, cells were treated with 
Y27632 in phase II, and subsequently, in phase III, cells were cultured in 
osteogenic media containing Y27632 for a total of 28d (Fig. 6.6A).  Following 
ALP and von Kossa staining, the results showed positive ALP staining (Fig. 
6.6B), however, no signs of mineralisation were evident after von Kossa 
staining (Fig. 6.6C&D).  These results indicated that simply extending the 
culture period with the standard osteogenic media conditions to a total of 35d 
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Figure 6.6: Extending the culture period (total 35d) does not induce osteoblast 
mineralisation.  
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.  In phase III, cells were cultured in osteogenic media 
then fixed at 21d or 35 for ALP and von Kossa staining. B) Images of 
monolayers co-stained with ALP and von Kossa (triplicate wells).  C,D) 
Representative images of monolayers after von Kossa staining showing 3D 
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6.9.2 Addition of batch tested serum (FCS) to the osteogenic culture 
media 
  
The second approach undertaken to test the osteoblast mineralisation potential 
was to culture cells in a medium containing serum, acknowledging that serum-
free cultures may have removed essential components required for 
mineralisation.  As above, cells were cultured in phase II in the presence of 
Y27632, and in phase III cells were cultured in osteogenic media containing 
Y27632 for 28d, and additionally, FCS that was batch-tested for osteogenesis 
was added at three different concentrations, 10%, 1% and 0.1% (Fig. 6.7A).  
The results revealed that cells cultured with 10% and 1% FCS were stimulated 
to proliferate more rapidly and reached confluence faster than cultures with 
0.1% FCS or serum-free. During monolayer culture, 10% FCS showed an 
overgrowth of cells (not nodules) during the monolayer culture (Fig. 6.7B, 
arrow).  While cultures in 0.1% FCS appeared to be able to differentiate 
compared to 10 and 1% serum cultures (Fig. 6.7H), although to a lesser extent 
than the serum-free control cultures, with no visible nodules present (Fig. 6.7D) 
as in the serum-free cultures (Fig. 6.7I). Long-term culture for 28d clearly did 
not enhance osteogenesis and mineralisation, and, in fact, addition of FCS 
markedly inhibited differentiation, which was evident in the FCS dose-
dependent decrease in ALP staining compared to the control, serum-free 
culture (Fig. 6.7F-I).  Together, these results implied that simply adding FCS 
was not sufficient to induce mineralisation; rather, serum negatively regulated 
osteogenic differentiation. 
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Figure 6.7: Effect of serum on osteogenic differentiation of ESC-derived 
mesoderm.   
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phase II and III.  In phase III, cells were cultured in osteogenic media 
in the absence and presence of batch tested FCS at 10%, 1% or 0.1%) for 3 
weeks. B-E) Microscopic images of monolayers prior to staining showing; 
overgrowth of monolayer in 10% serum supplemented culture presented by 
dark areas (arrow) and clear nodule formation in serum-free cultures compared 
to 1% and 0.1% serum-supplemented cultures.  F-I) Images of ALP stained 
monolayers.  All images are from representative well from one experiment 
(triplicate wells).  Scale bars: 100 µm. 
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6.9.3  Addition of osteogenic inducing factors to the osteogenic culture 
media 
 
Another approach for testing osteoblast differentiation and mineralisation of 
osteoblasts was to take a candidate approach and test supplementation of the 
culture media during differentiation phase III with growth factors that had been 
shown to control bone formation.  The effects of the following were tested:  (1) 
Hedgehog signalling (Hh), a known inducer of osteoblast differentiation (Long et 
al. 2001b; Long et al. 2004; St-Jacques et al. 1999), by using a potent 
stimulator of Hh signalling, a Smoothened Agonist (SAG), which activates the 
Hh receptor Smoothened in a ligand-independent way (Chen et al. 2002);  (b) 
Canonical Wnt signalling, which is known to control osteogenesis in both the 
embryonic and postnatal stages  (Johnson et al. 2004; Hartmann 2009; Clevers 
& Nusse 2012).  This was tested by the addition of Wnt3a to stimulate canonical 
Wnt signalling, hypothesising an induction in osteogenic differentiation;  (3) 
Vitamin D3, which has been shown to enhance the osteogenic differentiation 
and mineralisation of ESC-derived cultures in full FCS conditions (zur Nieden et 
al. 2003). This was tested by the addition of 1,25-dihydroxyvitamin D3 (VitD3);  
(4) a lower concentration of β-GP (2mM) instead of the commonly used dose of 
10mM, which has been associated with poor osteoblast viability and dystrophic 
mineralisation (Orriss et al. 2007).  
Cells were cultured in the presence of Y27632 in phase II, and subsequently in 
phase III in osteogenic media containing Y27632, and each of the test factors 
individually until d28 (Fig. 6.8A).  The results revealed that after 28d of culture, 
all conditions displayed positive ALP staining (Fig. 6.8B-F), yet there were no 
signs of mineralisation following von Kossa staining (Fig. 6.8G-K).  Interestingly, 
VitD3 cultures showed a slight reduction in ALP staining compared to control 
cultures (Fig. 6.8D,I).  These preliminary studies suggested that none of the 
factors tested seemed to stimulate further maturation and mineralisation under 
these experimental conditions and therefore no further characterisation was 
carried out at this time. 
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Figure 6.8: Effect of supplementing osteogenic media with known osteogenic 
inducing factors on osteoblast mineralisation.  
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.  In phase III, cells were cultured in osteogenic media 
supplemented with one of the following osteogenic factors: β-GP (2mM), VitD3 
(10-8M), SAG (100nM), Wnt3a (10ng/ml).  Cultures were fixed after 3 weeks for 
staining. B-F) ALP staining of monolayers. G-K)  Microscopic images of 
monolayers after ALP and von Kossa staining.  All images are from a 
representative well from one experiment (triplicate wells). Scale bars: 100 µm. 
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6.9.4 Effect of FGF2 on osteogenic differentiation 
 
Besides being important as a mitogenic factor, FGF2 signalling is also known to 
regulate osteoblast differentiation (Marie et al. 2012; Yu & Ornitz 2008; Dorey & 
Amaya 2010; Degnin et al. 2010).  Notably, knock out studies have shown that 
loss of FGF2 causes inhibition of bone formation and reduction in bone mass 
(Montero et al. 2000).  In addition, overexpression of FGF2 induces 
achondroplasia and shortening of long bone formation (Coffin et al. 1995).  The 
mechanism of FGF2 in controlling osteogenesis can be multifaceted: the effects 
of FGF2 have been reported to either affect osteoblast proliferation or 
differentiation, depending on the developmental stage within the osteoblast 
lineage (Yu 2003; Fakhry et al. 2005).  A large body of evidence supports the 
notion that FGF2 is important for proliferation, but can also inhibit osteoblast 
differentiation (Debiais & Hott 1998; Fakhry et al. 2005; Dailey et al. 2005).   
In this project, the initial serum-free conditions for the differentiation phase 
(phase III) were carried out in the presence of both FGF2 and BMP in the 
culture media.  It was thus questioned whether the presence of FGF2 could 
negatively affect osteoblast differentiation.  Therefore it was decided to test the 
effects of culturing cells for 2 weeks in FGF2 and BMP4, either alone or in 
combination (Fig. 6.9A). 
Results revealed that culturing cells only in FGF2 for 2 weeks inhibited 
osteogenesis compared to control, which was evident by the weak ALP staining 
(Fig. 6.9C,G,H).    On the other hand, cells cultured only in BMP4 (Fig. 6.9D,I,J) 
presented similar ALP staining results to those that had been cultured in a 
combination of BMP4 and FGF2 (Fig. 6.9B,E,F).   Furthermore, it was observed 
that FGF2 culture attained confluency earlier than BMP4 only cultures (data not 
shown), suggesting that FGF2 assisted in proliferation of the cells beyond those 
of BMP4 signalling. 
The results further indicated that continuous FGF2 treatment inhibited 
osteogenic differentiation of ESCs.  Nevertheless, it was still required at the 
early stages of differentiation of the cells in order for them to proliferate.  
Moreover, BMP4 separately or in conjunction with FGF2 did not induce 
osteoblast mineralisation. 
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Figure 6.9: Effects of FGF2 and BMP4, either alone or in combination, on 
osteogenic differentiation. 
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.   In phase III, cells were cultured in osteogenic media 
supplemented with either FGF2 or BMP4 alone, or in combination, then fixed 
after 3 weeks for staining.  B-D) ALP staining of monolayers.  E-J) Images of 
monolayers after ALP and von Kossa staining.  All images are from a 
representative well from one experiment (triplicate wells).  Scale bars: 100 µm. 
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6.10 Effect of FGF2 and BMP4 on primary calvaria osteoblast 
differentiation 
  
Subsequently the role of FGF2 and BMP4 was investigated by using an 
independent differentiation system such as primary mouse calvaria, which is an 
established, well-known in vitro culture model for the differentiation and 
mineralisation of osteoblasts.  Primary murine calvarial osteoblasts were 
cultured in differentiation media, which consisted of AA and β-GP, in both the 
presence and absence of batch-tested serum.  The differentiation medium was 
then supplemented with BMP4 or a combination of BMP4 and FGF2 for 2 
weeks. 
In osteogenic media containing serum, BMP4-treated cultures stimulated both 
ALP staining and mineralisation by von Kossa staining (Fig. 6.10B).  The 
addition of FGF2 to BMP4 cultures showed a marked inhibition of ALP activity 
and von Kossa staining compared to BMP4-treated cultures (Fig. 6.10C), 
indicating that FGF2 signalling inhibits both differentiation and mineralisation of 
primary calvarial osteoblasts.    
A comparison with ESC cultures was attempted by differentiating primary 
osteoblasts in serum free conditions to interpret better the effects of BMP4 and 
FGF2.  Whilst cells cultured in serum-free medium (control culture) failed to 
differentiate into ALP-positive cells (Fig. 6.10D).  BMP4-treated cultures 
displayed some ALP staining, signifying that even in serum-free conditions, 
BMP4 alone can stimulate some ALP activity, albeit minimally (Fig. 6.10E).  
However, cultures treated with both FGF2 and BMP4 displayed a marked 
increase in ALP staining, but no mineralisation as assessed by von Kossa 
staining (Fig. 6.10F).   
This suggests that FGF2 is very important for stimulating the differentiation of 
primary calvaria osteoblasts, although whether this is due to proliferation or 
survival is not known.  Nevertheless, this provides independent evidence that 
FGF2 is required for survival and/or proliferation of osteogenic cells, as was 
also suggested for ESC-derived osteoblasts and indeed chondrocytes. 
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Figure 6.10: Effect of FGF2 and BMP4 on osteogenic differentiation of POB in 
serum and serum-free media.  
Primary mouse calvarial osteoblasts were cultured in either serum (A-C) or 
serum- free media (D-F) supplemented with (AA and β-GP) in the presence of 
either (BMP4) or (BMP4 and FGF2) as indicated for 2 weeks.  Cultures were 
then fixed and co-stained with ALP and von Kossa.  All images are from a 
representative well from one experiment (triplicate wells). 
 
6.11 Long-term culture following re-plating of differentiated 
osteogenic cells 
  
The results from the previous section were then used to probe whether re-
plating end-stage cultures might provide a trigger for further differentiation and 
mineralisation.  This was done under conditions of temporal instead of 
continuous FGF2 treatment, which was shown in the previous section to inhibit 
osteogenesis in a continuous exposure approach (Fig. 6.9 and 6.10). Therefore, 
cells treated in the absence or presence of Y27632 in phase II were cultured 
subsequently in Phase III in osteogenic media with Y27632, followed by 
removal of FGF2 after 1 week.  After a further week, cells were dissociated and 
re-plated as single cells in osteogenic media containing Y27632 and BMP4, and 
this was designated Phase IV (Fig. 6.11A).  
Morphological analysis demonstrated that osteogenic differentiation under a 
temporal FGF2 protocol generated osteoblast nodules  (Fig. 6.11B&C), showing 
similar morphology to osteoblast cells differentiated under continuous FGF2 
conditions (Fig. 6.11 B&C).  Quantification of ALP positive nodule areas at 21d 
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percentage of ALP positive nodule areas compared to untreated cultures (Fig. 
6.11D&E).  Remarkably, following re-plating (phase IV), Y27632 pre-treated 
cultures began to show mineral deposits after reaching confluence when 
assessed by von Kossa staining at 28d (i.e. after one week of differentiation) 
(Fig.6.11H,J,L) compared to Y27632 not pre-treated cultures (Fig. 6.11G,I,K).  
These results implied that ROCK inhibition in phase II stimulated osteoblast 
mineralisation after re-plating when pre-cultured in temporal FGF2 conditions. 
Therefore, it was established that differentiated osteoblast had the capacity to 
mineralise and attain a functional stage once cultured in temporal FGF2 and re-
plated. 
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Figure 6.11:  Effect of temporal FGF2 and ROCK inhibition on osteogenic 
differentiation after re-plating.  
A) A differentiation scheme showing the timing of Y27632 addition to the culture 
media in phases II and III.   In phase III, cells were cultured in osteogenic media 
supplemented with Y27632. FGF2 was removed from media at 14d.  Some 
cultures were then fixed at 21d for staining and others were re-plated at 21d in a 
48 well plate and fixed at 28d for staining.  B,C) Microscopic images of ALP 
stained monolayers. D) Quantification ALP staining. E) ALP staining of 
monolayers.  F) Co-staining of monolayer with ALP and von Kossa.  F-H) 
Microscopic images of ALP stained monolayer, showing mineralisation in 
(+Y27632 cultures).  I-L) Microscopic images of von Kossa stained monolayers, 
showing mineralisation in both (±Y27632 cultures).  All images are from one of 
2 representative experiments.  Scale bars: 100 µm.  Data indicate mean ± SD 
(triplicates) from a representative experiment of 2 independent experiments 
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6.12 Discussion  
 
In this section, it was demonstrated by ALP and von Kossa staining, that 
osteogenic cultures could produce mineralised matrix after further manipulation, 
mainly by extension of the culture period following re-plating of the cells.  More 
importantly, this was enhanced by the inhibition of ROCK in phase II 
(mesoderm enrichment phase).  
Mineralisation of osteoblast matrix has been demonstrated in mESC 
differentiation cultures (zur Nieden et al. 2003; Kawaguchi et al. 2005;Hwang et 
al., 2006)  as well as in hESCs  (Sottile et al. 2003; Vats et al. 2006; Shimko et 
al. 2004; Heng et al. 2004; Evans et al. 2009; Bielby et al. 2004; Handschel et 
al. 2010).  All previous studies were undertaken in a serum containing 
osteogenic media.  Furthermore, (Alfred et al. 2010) demonstrated 
mineralisation of mESC-derived osteoblast cultures in serum-free conditions, 
however, cells were exposed to serum, albeit in a bioreactor, at earlier stages of 
differentiation. 
In this project, using the ESC/EB model, it was demonstrated that culturing 
ESC-derived mesoderm in osteogenic media for 2 weeks did not produce any 
signs of mineralisation based on morphology and von Kossa staining.  
Therefore, it was hypothesised that this could be due to several possibilities, 
such as factors related to exposure time, dose, growth factor interaction during 
culturing period, lack of mineralising inducing factors (serum, Wnt3a, SAG, 
VD3), culture duration, mineralisation inhibitors, cell line, developmental stage of 
cells, and species type (Davis & Zur Nieden 2008; Lin & Hankenson 2011c).  
These factors will be discussed in the following sections.  
Given the advantages of the serum-free culture system, it was possible to 
perform preliminary experiments to examine a few of these causes, including 
duration of culture period, culturing in the presence of well-known osteogenic 
inducing factors (Wnt3a, SAG, VD3), low doses of β-GP and serum (FCS), 
FGF2 exposure time during culture and re-plating.   On examination of these 
factors, it was possible to determine that ESC-derived mesoderm had the 
capacity to mineralise only when cultured in temporal FGF2 and then re-plated 
in osteogenic culture for 1 week.    
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Initially, osteogenic differentiation was carried out for two weeks during the 
differentiation phase (phase III; 7to21d). During this period, no mineralisation of 
the osteoblast nodules was observed.   Previous studies of both murine and 
human ESCs showed mineralisation of osteoblast cultures within a period of 3 
to 4 weeks in osteogenic media (zur Nieden et al. 2003; Bourne et al. 2004).  
Therefore, in this project, the culture period was then further lengthened by an 
additional two weeks, using the same osteogenic media (FGF2, BMP4, Dex, 
AA, β-GP).  However, this still did not instigate mineralisation, and it is indeed 
possible that even longer culture periods beyond four weeks might be 
necessary, as the re-plating studies (as will be discussed later) seemed to 
provide conditions for allowing the mineralisation potential of the cultures to be 
realised. 
Supplementing osteogenic media (in the continuous presence of FGF2 and 
BMP4) with the following osteogenic factors: Wnt3a, SAG, and VD3, 
unfortunately, did not induce mineralisation and even showed a slight reduction 
in cultures supplemented with vitamin D3 and FCS (10%, 1%).  These 
unexpected negative ALP staining results could be due to the causes 
suggested earlier, including exposure time and dose of the osteogenic factors, 
in particular, the combination of FGF2 and BMP4, mineralisation inhibitors, 
developmental stage of cells, (Davis & Zur Nieden 2008; Lin & Hankenson 
2011b).  Zur Nieden et al. (2005) had demonstrated that osteogenic 
differentiation of ESCs was affected by both the exposure time and a 
combination of different osteogenic factors.  They demonstrated that the time of 
BMP2 exposure influenced the osteogenic differentiation and that the 
combination of BMP2 with vitamin D3 did not produce the same osteogenic 
effect as Vitamin D3 alone.  They also pointed out that Vitamin  D3 rescued the 
osteogenic phenotype when added to the culture at a later time point during the 
differentiation period.  Vitamin D3 was shown to induce mineralisation of ESC 
cultures during a period of (27-34d). 
Additionally, β-GP is normally added to osteogenic media as a source for 
inorganic phosphate production.  In previous studies, the β-GP concentration 
used normally in osteogenic media (10mM) has been shown to negatively affect 
mineralisation of pre-osteoblast cultures (Orriss et al. 2007).  During the testing 
of our cultures, a 2mM β-GP dose and 10mM β-GP in the osteogenic media 
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produced no signs of osteoblast mineralisation. Therefore, at least in these 
culture conditions, the possibility of the effect of β-GP concentration on 
mineralisation of osteogenic cultures was ruled out.  
The following osteogenic factors (Wnt3a, SAG, and vitamin D3) were tested 
separately in an osteogenic media, however, the osteogenic media contained 
BMP4, Dex, β-GP, AA, and in the presence of Y27632. The presence of 
multiple factors in the media may have caused opposing interactions and 
affected the results.   In addition, cultures were continuously exposed to FGF2; 
which had been demonstrated (as discussed later) to inhibit osteogenesis. 
Therefore, the combination of several factors at this particular time point and 
under the influence of ROCK inhibition may have induced opposing interactions.  
During this project, ESC-derived mesoderm in osteogenic media containing AA, 
β-GP, Dex, BMP4 and FGF2 was used in continuous culture (i.e. for two weeks) 
as the basal culture conditions.  Interestingly, however, it was proved that the 
continuous presence of FGF2 in osteogenic media inhibited osteogenesis when 
these cells were exposed to FGF2 for 2 weeks.  A one-week pulse of FGF2 was 
adequate to induce osteogenesis and ROCK inhibition maximised the 
osteogenic differentiation.  
The effect of temporal FGF on osteogenesis corresponds with other studies that 
support the belief that the effect of FGF2 on osteogenesis is not only dependent 
on the developmental stage of osteoblast, but is also dependent on the duration 
of exposure to FGF2.  Prolonged FGF2 exposure inhibits osteoblast 
mineralisation, while short exposure was shown to have the reverse effect 
(Kalajzic, et al. 2003; Fakhry et al. 2005; Ling et al. 2006).   
The effect of ROCK inhibition could be explained by its stimulatory effect on 
osteogenic precursors.  Harmey et al. (2004) demonstrated that ROCK 
inhibition using Y27632 stimulates the osteogenic differentiation in primary 
mouse calvaria osteoblastc cultures by affecting the differentiation of osteoblast 
precursors rather than matrix deposition and mineralisation.  This was evident 
by the increase in the number of ALP expressing cells leading to enhanced 
nodule formation and earlier mineralisation.  Thus, the manifestation of 
mineralisation using our culture model could be because cells were exposed to 
temporal FGF2 for one week during phase III.  Cells were then re-plated in 
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osteogenic media, which may have enhanced the proliferation potential of 
previously quiescent cells or stimulated the selective differentiation of pre-
osteoblasts that was enhanced by ROCK inhibition.  
The mineral deposits were localised to the osteoblast nodules, suggesting that 
this could be physiological instead of ectopic mineralisation caused by the 
addition of β-GP to the culture medium.  To further establish that this 
mineralisation is due to a physiological process, it is suggested that further 
analysis is undertaken, using FTIR and TEM to study calcium and phosphate 
levels in the mineralisation process (Gentleman et al. 2009). 
Taken together, it was established that osteoblast cultures could mature and 
mineralise in vitro.  The unique and novel serum-free system used in this project 
provided the possibility to test several aspects of enhancing osteogenic 
differentiation towards mineralisation in a defined way and at a specific time and 
examine the role of ROCK inhibition. Based on morphology and von Kossa 
staining, it was demonstrated that re-plating cells after culturing in temporal 
FGF2 conditions was the only method that produced mineralisation of 
osteoblast and this was enhanced by the control of ROCK inhibition in phase II 
(mesoderm enrichment phase). Thus, these findings demonstrate that through 
the stage specific manipulation of appropriate signalling pathways it possible to 
generate distinct populations of mESC-derived osteoblasts that are able to 
generate growth plate-like cells in vitro, the in vivo potential of the generated 
cells (i.e. replating) would be interesting to evaluate and compare to the basal 
conditions (i.e. without plating) in future studies.    
 
In conclusion, this is the first evidence showing osteogenic differentiation and 
maturation from ESC-derived mesoderm using this novel 3-phase, serum-free 
ESC/EB differentiation system used in this project.  Understating the molecular 
mechanisms regulating this differentiation at the different development stages 
(i.e. mesoderm enrichment, differentiations, and replating phases) may shed 
light on the molecular role ROCK pathway possess in bone development and 
disease.  Furthermore, access to a highly enriched population of osteoblasts at 
different developmental stags (i.e. progenitors or differentiated cells) will provide 
a basis for pursuing cell-based therapy for bone disease in cases of bone loss.
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Chapter 7 In vivo evaluation of the chondrogenic and 
osteogenic potential of ESC-derived mesoderm: Effect of 
ROCK inhibition  
 
In vivo differentiation   
- 183 - 
7.1 Introduction 
 
ESCs are considered an attractive cell source for studying the in vitro 
differentiation of specific cell types in a directed and controlled differentiation 
approach under appropriate manipulation of specific signalling pathways 
(Gadue et al. 2005; Murry & Keller 2008). The ability of ESCs to differentiate 
into any cell type from the three germ layers allows for the use of these cells for 
tissue replacement and regeneration therapy (Murry & Keller 2008; Irion et al. 
2008).   However, a major obstacle in the use of ESCs for this purpose is the 
ability to control and direct their differentiation efficiently so as to prevent 
potential undifferentiated ESCs from spontaneous differentiation and teratoma 
formation in vivo (Yamanaka et al. 2008).   
In this project, as shown in previous chapters (chapters 4, 5, and 6), the 3 
phases differentiation culture model directed the differentiation of ESC-derived 
mesoderm to cartilage and bone lineages in vitro that was accompanied by 
sequential expression of chondrogenic and osteogenic specific markers 
expression.  However, whether these populations harbour any differentiation 
potential in an in vivo context is not known.   
This chapter describes the preliminary proof-of-concept experiments that were 
performed to investigate whether ESC-derived chondrogenic/osteogenic cells 
could form tissue in vivo.  Since the step-wise approach provides different 
stages of differentiation, the focus of this project was on two specific cell 
populations:  (1) Cells derived directly from the mesoderm enrichment phase 
(phase II) that had already expressed cartilage and bone transcription factors, 
and (2) cells derived after the differentiation phase (phase III).  In addition, 
based on the clear effect that ROCK inhibition had during both phases, further 
investigations were carried out to determine whether ROCK inhibition would 
influence the in vivo behaviour of these cells.  
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7.2 Methods 
 
To investigate the in vivo potential of differentiated cells, cells were harvested 
from two developmental phases in our model:  the mesoderm enrichment phase 
(phase II) and the monolayer differentiation phase (phase III).  Firstly, at the 
mesoderm enrichment phase (phase II), cells were harvested from 7d cultures. 
These were then transplanted under the kidney capsule of adult 
immunocompromised (SCID) mice, in the form of aggregates or as a single cell 
suspension in matrigel.  Matrigel was then transplanted without cells as a 
control.  In addition, ROCK inhibitor-treated cultures were also investigated by 
the transplantation of Y27632-treated cultures. Secondly, at the differentiation 
phase (phase III), monolayers from 21d cultures, which gone through an 
osteogenic differentiation period in osteogenic media, were harvested and 
transplanted under the kidney capsule of SCID mice.  ROCK inhibitor treated 
cultures were also investigated by specifically transplanting cells exposed to 
ROCK inhibitor at phase III only (7-21d) and cells exposed to ROCK inhibitor 
continuously (4-21d) in osteogenic media.  For analysis, mice were sacrificed 
after periods of 1 and 3 weeks. Kidney samples were harvested, fixed, and 
processed for histochemical analysis using H & E with Alcian blue staining.  All 
in vivo procedures were performed according to Home Office guidelines. 
7.3 Results  
 
7.3.1 Effect of ROCK inhibition on the in vivo potential of ESC-derived 
mesoderm at the mesoderm  (phase II)  
 
As described in chapter 3, the molecular analysis at the mesoderm enrichment 
phase (phase II) indicated that cells expressed key transcription factors for both 
chondrogenic (Sox9, Sox5) and osteogenic lineages (Runx2, Osx) at the end of 
the reaggregation culture period (4-7d).  Under basal conditions, the expression 
of these genes is required for the initiation and differentiation of both cartilage 
and bone lineages (chapter 1, section 1.5).  Therefore, to determine whether 
the early mesoderm-derived chondro-osteoprogenitor cells generated in phase 
II would have the capacity to generate cartilage and/or bone tissue in vivo, the 
generated aggregates were transplanted under the kidney capsule of SICD 
mice.  Thus, cells were cultured for 3 days in FGF2 (phase II, 4-7d) and the 
generated aggregates were transplanted under the kidney capsule and left for 3 
weeks (Fig. 7.1A).   
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The results demonstrated that the transplanted aggregates/cells had developed 
a tumour (Fig. 7.1B). Hematoxylin-eosin staining (H&E) analysis confirmed the 
formation of various tissues originating from the 3 germ layers (endoderm, 
ectoderm, and mesoderm), including gut-like epithelial tissue (gland), epidermal 
tissue (keratin), cartilage, and bone cell in the developed tumour on the site of 
transplantation in the kidney capsule (Fig. 7.1E&G). This suggested that cells 
still retained the pluripotent characteristic and had capacity to differentiate to 
cells from the three germ layers, indicating undifferentiated ESCs.  Therefore, it 
is clear that cells generated at the mesoderm enrichment phase (phase II) of 
ESC/EB differentiation are tumorigenic and not fully differentiated.  
As demonstrated in chapter 3, Y27632 treatment in the mesoderm enrichment 
phase (phase II: 4-7d), led to upregulation in the expression of both 
chondrogenic (Sox9 and Sox5) and osteogenic (Runx2 and Osx) gene 
expression.  Therefore, priming the ESC-derived mesoderm cells differentiation 
towards chondrogenic and/or osteogenic lineages.  In addition, other reports 
revealed that inhibition of ROCK signalling was linked to counteracting tumour 
progression and metastasis. ROCK signalling acts on actin cytoskeleton 
stabilisation and supporting actin-myosin contraction as well as the anti-
angiogenic effect of ROCK inhibition (Itoh et al. 1999; Liu et al. 2009; Morgan-
Fisher et al. 2013). Thus, understanding the role of ROCK inhibition effect on 
differentiation and anti-tumorigenic effect allowed to speculate whether ROCK 
inhibition would have a role in controlling the in vivo potential of 7d aggregates 
transplanted cells.    
Therefore, to determine whether the early mesodermal-derived chondro-
oteoprogenitor cells generated in ROCK inhibitor treated cultures, in phase II, 
would have the capacity to generate cartilage and/or bone tissue in vivo, the 
generated aggregates were transplanted under the kidney capsule of SICD 
mice.  Hence, in phase II, cells were cultured in FGF2 in the presence and 
absence of Y27632.  After 3 days in culture, at 7d, generated aggregates from 
both Y27632-treated and un-treated cultures were transplanted under the 
kidney capsule and left for 3 weeks (Fig. 7.1A).   
Surprisingly, under macroscopic examination upon dissection and based on 
gross appearance, transplanted aggregates/cells from Y27632-treated (Fig. 
7.1C) the tumours formed from Y27632-treated cultures appeared to be smaller 
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than tumours formed from Y27632 untreated cultures (n=4/5) (Fig. 7.1B&C), 
although the sizes were not quantified.  No growths were observed in control 
matrigel grafts (Fig. 7.1D).  Histological examination after H&E staining 
indicated the formation of cell types of the three germ layers in tumours derived 
from both Y27632-untreated (Fig. 7.1E&F) and Y27632-treated cultures (Fig. 
7.1G&H). The tissues contained: gut-like epithelial tissue (e), epidermal tissue 
(keratin)(k), bone cell types (b), which are formed from the three germ layers, 
endoderm, ectoderm, and mesoderm, respectively.  These results suggest that 
ROCK inhibition reduced the size of the developed tumour.   
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Figure 7.1: Effect of ROCK inhibition on the in vivo potential of cells generated 
from the mesoderm enrichment phase (phase II). 
A) A differentiation scheme showing the timing at which cells were harvested for 
transplantation. In phase II, cells were cultured in the presence and absence of 
Y27632.  Then after 3 days in culture (at 7d), cells were harvested and 
transplanted under the kidney capsule of adult immunocompromised (SCID) 
mice, in the form of aggregates or as single cells in matrigel suspension, and 
left in situ for a further 4 weeks and then harvested for analysis.  Harvested 
kidneys from both Y27632-untreated (B) and Y27632-treated (C) transplanted 
cells showing teratoma lesions (arrows) that developed at the site of cell 
implantation.  D) Image of control harvested kidney, where matrigel alone was 
transplanted, without cells. Histological section of tumour tissue harvested from 
kidney sample of transplanted Y27632-untreated monolayer (E&F) and Y27632-
treated monolayer (G&H) stained with H&E and Alcian blue showing in arrows 
the differentiation of cell types from the three germ layers (ectoderm, 
mesoderm, and endoderm), including ectoderm component; epiderm tissue.  
Squamous epithelium showing a keratin deposition pattern (k), mesodermal 
components, and bone (b), and endoderm gut-like structures lined with 
mucinous epithelium  (e) are indicated. Data are from a representative 
experiment from 5 independent experiments.  Scale bars:  100um. 
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7.3.2     Effect of ROCK inhibition on the in vivo potential of cells 
generated from the monolayer differentiation phase (phase III) 
 
Given that the transplantation of cells generated from the mesoderm enrichment 
phase (phase II) displayed teratoma formation, the next step was to examine 
the in vivo potential of cells, which had undergone the third phase of 
differentiation (phase III: 7-21d) in the 3-phase model.   Cells pre-treated with 
Y27632 or not pre-treated were cultured for 2 weeks in osteogenic 
differentiation media in the presence of Y27632 (Fig. 7.2A).  The monolayers 
were then transplanted under the kidney capsule of adult immunocompromised 
(SCID) mice for 1 to 3 weeks. 
Macroscopic analysis upon dissection revealed small white lesions on the 
surface of the kidney samples at the site of transplantation that were hard in 
texture when palpated, suggesting possible mineralisation (Fig. 7.2B&C).  
Histological analysis after H&E staining revealed the formation of bone tissue in 
the grafts (n=2).  A time-course of bone development was carried out on grafts 
after only 1 week in vivo.  Histological analysis showed the presence of 
cartilaginous tissue containing cells with typical round, chondrocyte morphology, 
which were surrounded by extracellular matrix that was stained intensely with 
Alcian blue in Y27632-treated samples (Fig. 7.2D-F). 
Examination of the cartilage tissue after a further two weeks in vivo suggested 
that chondrocyte tissue was replaced by bone tissue in Y27632-treated  
samples (Fig. 7.2H). Therefore, transplanted phase III cells cultured in 
osteogenic media had undergone a temporal, endochondral ossification-type 
process in vivo.  Furthermore, examination of samples (n=1) confirmed that the 
grafts from the Y27632-treated cultures appeared larger compared to the 
control i.e. untreated samples (Fig. 7.2I&J), although quantification was not 
performed.  Significantly, no teratomas were observed in any of the grafts from 
21d transplanted monolayers obtained from in vitro differentiation cultures 
(phase III: 7-21d).  
Histological analysis of the formed bone revealed that it resembled natural 
trabecular bone structure comprising osteoblast-like cells lining bone surfaces 
(OB) and osteocytes (O) embedded within mineralised bone matrix (Fig. 
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7.2H&I).  Some of the cells embedded within the bone matrix were enlarged 
and were associated with Alcian blue-stained matrix, resembling hypertrophic 
chondrocytes (HC), suggesting an endochondral ossification type of bone 
formation (Fig. 7.2H&I). In addition, the grafts were vascularised, which showed 
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Figure 7.2: Effect of ROCK inhibition on the in vivo potential of cells generated 
from the differentiation phase (phase III). 
A) A differentiation scheme showing the timing at which cells were harvested for 
transplantation. In phase III, cells were cultured in the presence and absence of 
Y27632 in osteogenic media.  Then, after 2 weeks in culture (at 21d), cells were 
harvested and transplanted under the kidney capsule of adult 
immunocompromised mice (SCID), in the form of a monolayer, left in situ for 1-3 
weeks and then harvested for analysis.  Harvested kidneys from both Y27632-
untreated (B) and Y27632-treated (C) transplanted cells showing white lesions 
that developed at the site of cell implantation (arrows).   Histological sections of 
tissue stained with H&E and Alcian Blue showing the formation of chondrocyte 
cells with abundant Alcian Blue-positive matrix lying on top of kidney tissue 
formed after 1 week in vivo from Y27632-treated (D-F).  After a 3-week in situ, 
section showing bone replacing cartilage tissue, resembling natural trabecular 
bone structure in Y27632-untreated monolayer (G) and Y27632-treated 
monolayer (H).  I&J) Higher magnifications of the images in (H) showing a 
bone-like island compromising osteoblast-like cells lining bone surfaces (OB) 
and osteocytes (O) embedded within mineralised bone matrix, some of the cells 
embedded within the bone matrix were enlarged and were associated with 
Alcian blue-stained matrix, resembling hypertrophic chondrocytes (HC). 
Vascularisation showing collection of blood cells (red blood cells (BC) 
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7.4 Discussion  
 
In this chapter, the preliminary proof-of-concept experiments proved the 
efficiency of the 3-phase, serum free ESC/EB differentiation in vitro culture 
model, whereby ESC-derived chondrogenic/osteogenic cells developed in vitro, 
specifically at the differentiation phase (phase III), which were cultured in 
osteogenic media, had the potential to form bone tissue in vivo. The formed 
bone tissue recapitulated embryonic development of the endochondral bone 
ossification process, which was characterised by the formation of a chondrocyte 
tissue, after 1 week in vivo, that was replaced by bone tissue after further 2 
weeks.  
 Moreover, inhibition of ROCK signalling during the in vitro differentiation phase 
seemed to enhance in vivo osteogenic differentiation.  Although several studies 
in the literature (chapter 1, section 1.10.2) have reported the efficiency of in vitro 
differentiation culture models for cartilage and/or bone in both mouse and 
human ESCs, as proven by expression analysis and flow cytometry analysis, 
yet fewer studies have carried out further functional analysis to investigate the 
in vivo potential of the generated cells. This emphasises the importance of 
translating the findings reported in chapters 4-6 of this project, to an in vivo 
context, which provides evidence for the in vivo functionality of in vitro 
differentiated cells.  
The advantages provided by the step-wise, 3-developmental phase culture 
model used in this project allowed examination of the in vivo potential of 
different populations generated, at different time points during differentiation, i.e. 
early and late stages of differentiation. Herein, the two time points tested were 
the mesoderm enrichment phase (phase II) and the differentiation phase (phase 
III), 7d and 21d cultures, respectively.   
The molecular profile results discussed in chapter 3 proved that during the 
mesoderm enrichment phase (phase II: 4-7d), the cells were primed towards 
differentiation towards both chondrogenic and osteogenic lineages.  The 3-day 
FGF2 treatment (reaggregation) upregulated the key transcription factors for 
both cartilage and bone lineages (Sox9 and Sox5) and (Runx2 and Osx), 
respectively. In addition, molecular profiles of gene expression of pluripotent 
markers showed a reduction in Oct-4 expression in two consecutive phases 
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ofESC differentiation (i.e. mesoderm induction and enrichment phase), 
suggesting progression of cell differentiation and gradual reduction in the 
pluripotency genes characteristic of ESCs.  However, transplanted 
reaggregates/cells from 7d cultures demonstrated tumorigenic potential, 
suggesting that the population still contained some undifferentiated ESCs. 
Thus, the differentiation conditions during the mesoderm enrichment phase 
(phase II) proved to be too heterogeneous and sub-optimal for cells to form 
cartilage or bone tissue in vivo.   
Surprisingly, although ROCK inhibitor treated-cells demonstrated tumorigenic 
capacity, ROCK inhibition seemed to reduce the ESC capacity of the 
transplanted cells, as evidenced by gross examination of the tumour (n=4/5).  
Thus, ROCK inhibition might influence differentiation of ESCs.  Several studies 
have reported the in vivo effects of ROCK inhibition on tumorigenesis whereby 
ROCK inhibition using Y27632 prevented tumour invasion and metastasis, 
explained by counteracting activation of ROCK, which acts on actin 
cytoskeleton stabilisation and supporting actin-myosin contraction as well as 
through the anti-angiogenic effect of ROCK inhibition (Croft et al. 2004; Somlyo 
et al. 2003; Rath & Olson 2012). Further quantification is needed of the size of 
tumours generated from ROCK inhibitor treated and untreated tumour samples. 
Subsequently, in vitro functional analysis of cells generated at 21d of culture 
during the differentiation phase (phase III) was conducted to direct ESCs 
towards both chondrogenic and osteogenic differentiation. Chondrogenic 
differentiation was proven to acquire hypertrophic chondrocyte characteristics 
as demonstrated in (chapters 4 and 5). On the other hand, osteogenic 
differentiation exhibited mineralisation after further manipulation of the culture 
conditions and prolonged culturing (i.e. after temporal FGF2 exposure and re-
plating, defined as phase IV: 21-28d) as shown in chapter 6.  Therefore, given 
that the differentiation culture model used in this project is a serum-free model, 
this suggests that optimal conditions had not yet been met in the in vitro 
cultures.  Thus, cells from the osteogenic media, at 21d of culture, were 
selected in order to prove their functionality in an in vivo environment.  
Transplantation of these cells clearly demonstrated ectopic bone formation and 
a lack of tumour formation in both the absence and presence of the ROCK 
inhibitor cultures. Moreover, analysis of samples from one experiment 
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suggested that bone formation in ROCK inhibited samples appeared to be 
enhanced; as this was not measured, further experimentation and quantification 
may add valuable information to the anabolic effect seen with ROCK inhibition 
treatment. Even though, these results support the osteogenic and mineralisation 
potential of the cells demonstrated in chapter 6, whereby exposure to ROCK 
inhibition, specifically in phase III, enhanced osteogenic differentiation and 
advanced it towards mineralisation after prolonged culturing (chapter 6).   
Previous in vivo studies findings support the anabolic effect of ROCK.  
Yoshikawa et al. (2009) demonstrated in mice that continuous delivery of ROCK 
inhibition using Y27632 enhanced ectopic bone formation when induced by 
rhBMP-2 impregnated into an atelocollagen carrier. Therefore, based on these 
studies and our preliminary study it could be speculated that ROCK inhibition 
during in vivo differentiation of cells might have advanced the cells for further 
differentiation down the osteogenic pathway.  A methodical time-course study of 
xenograft development from ESC-derived osteogenic cells would address this. 
Interestingly, the boney tissue formed in vivo demonstrated a bone formation 
that was reminiscent of an endochondral ossification process, as cells formed 
chondrogenic tissue early, after 1 week of transplantation, which was then 
replaced by bone after 3 weeks.  Therefore, the differentiation culture model 
used in this project was proven to provide completely defined conditions for 
osteogenic differentiation, both in vitro and in vivo.  This is perhaps expected, 
as the cultures that were grafted were a mixed cell population containing cells 
with both chondrogenic and osteogenic potential (see also chapters 4-6).  
Further studies of more enriched or purified chondrogenic or osteogenic 
populations, either through further optimisation of growth factor conditions, or 
through cell sorting, will be necessary to identify their in vivo potential.  
Nevertheless, this suggests application of an endochondral ossification 
approach for bone regeneration (Craft et al. 2013; Yang et al. 2013), whereby 
an intermediate cartilage formation stage (cartilage phase) is required to prime 
cells for bone formation.  The rationale behind this approach is that 
chondrocytes are able to survive with limited nutrition and oxygen.  Secondly, 
they are able to secrete vascular endothelial growth factor (VEGF) in the 
hypertrophic stage, which is beneficial for blood vessel growth and attraction of 
osteoblast precursors for the initiation of the bone formation stage (Pfander and 
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Gelse 2007).  Thus, mixed chondro-osteoprogenitor populations still provide a 
suitable source for regenerative therapy applications.  Indeed, the mixed 
chondrogenic and osteogenic potentials of transplanted cells has been proven 
in other studies to be beneficial for bone regeneration, based on both ESCs 
(Jukes et al. 2010) and MSCs (Pelttari et al. 2006; Tasso et al. 2009; Tortelli et 
al. 2010; Scotti et al. 2010; Farrell et al. 2009; Farrell et al. 2011).  
In this project, there are several limitations in terms of graft versus host 
contribution.  Tracing the fate of the grafted cells was not performed thus the 
possibility of host cell contribution to the xenograft growth was difficult to 
assess. As the cells used for this project were unlabelled male ESCs, one 
option was to trace the localisation of male Y chromosome sequences by using 
Immunofluorescence in situ hybridization (ImmunoFISH). However, the SCID 
adult mice used in this study were male.  Another better option, which will be 
pursued in future experiments, is the use of a fluorochrome (eg. GFP)-based 
fluorescent protein labelled reporter cell line, where it would be possible to trace 
all ESC derivatives, or trace specifically chondrogenic or osteogenic derivatives.  
Furthermore, the anabolic effect seen in ROCK inhibited samples was 
encouraging in that in vivo results matched the in vitro results; however, further 
analysis of a larger sample size and measuring bone volume would be 
beneficial.  In addition, better optimisation is required to dissect the in vivo 
potential of chondrogenesis versus osteogenesis samples.   Regarding the graft 
site, the in vivo experiments were carried out in the kidney capsule.  Kidney 
capsule implantation, although technically challenging, has been shown to be a 
good model for testing ectopic bone formation, It promotes robust bone growth 
by providing supraphysiologic blood and nutrient resources (Scott et al. 2012).  
Other implantation models, such as intramuscular implantation, have been used 
for BMP in vivo bone formation confirmation experiments. With intramuscular 
transplantation it may be difficult to distinguish host from graft cells due to the 
mixture with muscle satellite cells, specifically if cells are not labelled.  However, 
it proved to be a good model for testing cartilage phenotype stability (Dell’Accio 
et al. 2001; Eltawil et al. 2009).   
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In summary, in vivo ectopic bone formation results confirmed the osteogenic 
differentiation results obtained in vitro in osteogenic media over 2 weeks.  The 
bone tissue was preceded by chondrocyte tissue formation, thus mimicking the 
temporal embryonic development of endochondral ossification.  In addition, 
inhibition of ROCK signalling seemed to enhance bone formation.  These 
results could suggest a promising source of generating osteogenic progenitor 
cells. Further investigation is necessary of the chondrogenic cells differentiated 
from in vivo cultures and optimisation of in vivo conditions for better tracing of 
graft cells.   
In conclusion, further understanding of the effect of ROCK inhibition at the 
cellular and molecular levels could still be promising. The regenerative potential 
of ROCK inhibition could be advanced in the development of future treatments 
and translation of the step-wise ESC/EB culture model to human ESC or iPSC 
model systems.    
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The aim of this project was to investigate the role of ROCK signalling via the 
use of Y27632 ROCK inhibitor, on cartilage and bone lineage specification and 
differentiation by using a novel 3-phase, serum free, ESC/EB differentiation 
model system.  This project established that ROCK inhibition differentially 
regulates ESC-derived mesoderm differentiation to chondrocytes and 
osteoblast in a phase-specific manner i.e mesoderm enrichment (phase II) and 
differentiation phases (phase III).  This was evident based on results from 
histochemical staining quantification and lineage-specific gene expression 
analysis.  
8.1 The mesoderm enrichment phase (phase II) 
 
It has been established that ROCK signalling inhibition may modulate the 
differentiation of intermediate progenitor populations, sub-mesoderm and 
chondro-osteoprogenitor populations. The findings in chapter 3 demonstrate 
that the inhibition of ROCK signalling upregulates the expression of both 
chondrogenic and osteogenic key transcription factors simultaneously, 
suggesting the commitment of ESCs towards the chondrogenic and osteogenic 
lineages (Fig. 3.13 4d vs 7d+Y).  This role of ROCK inhibition at an intermediate 
developmental stage, such as the mesoderm enrichment phase in ESCs is 
done here for the first time and is unique to this project.  
Interestingly, compared to control cultures, ROCK inhibition during the 
mesoderm enrichment phase (phase II) proved to differentially regulate the 
differentiation of ESC-derived mesoderm towards a distinctive chondro-
osteoprogenitor population.  Expression of Sox9 and Osx was downregulated 
and Sox5 expression was upregulated with no effect on Runx2 expression (Fig. 
3.13, 7d-Y vs 7d+Y).  The outcome of this differential effect of ROCK inhibition 
was further investigated by functional in vitro differentiation analysis 
demonstrated in chapter 4 (Fig. 4.3, -/- vs +/-) for chondrogenic differentiation 
and chapter 6 (Fig. 6.3, -/- vs +/-) for osteogenic differentiation. Taken together, 
the results establish that exposure to ROCK inhibitor at the mesoderm 
enrichment phase (-/- vs +/-) differentially induces the chondrogenic over the 
osteogenic lineage as presented in the proposed model (Figure 8.1).   
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Furthermore, the differential effect of ROCK inhibition on chondrogenic and 
osteogenic key transcription factors expression might be linked to the ROCK 
inhibition effect on sub-mesoderm genes profile demonstrated in chapter 3 (Fig. 
3.11 and Fig. 3.12, 7d-Y vs 7d+Y). The results show that inhibition of ROCK 
signalling differentially regulates the expression of paraxial and lateral plate 
mesoderm transcription factors, suggesting that ROCK inhibition might be 
directing ESC differentiation towards a distinctive paraxial and lateral plate sub-
mesoderm populations compared to ROCK inhibitor untreated cultures (7d-Y vs 
7d+Y).  Therefore, supporting the differential effect on cartilage and bone gene 








Figure 8.1: A summary of the effects of the ROCK inhibitor on chondrogenic 
and osteogenic commitment of ESCs at the mesoderm enrichment phase 
(phase II). 
At the mesoderm enrichment phase (phase II), the exposure to ROCK inhibitor 
(+Y27632) upregulated the expression of key transcription factors for both 
chondrogenic (Sox9 and Sox5) and osteogenic (Runx2 and Osx) as the control 
(-Y27632) (data in figure. 3.13). However, ROCK inhibition differentially 
regulated the mentioned transcription factors (data in figure. 3.13), suggesting 
the generation of a distinctive chondrogenic and osteogenic progenitor 
population, a “chondro-osteoprogenitor population “.  Diagram modified from 
Keller 2005.   
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8.2 The differentiation phase (phase III) 
 
In this project it was established, without cell sorting and purification 
approaches, that ROCK signalling modulates the specification and 
differentiation of cartilage and bone from ESC-derived mesoderm. The findings 
in chapters 4 and 6 clearly demonstrate that the exposure to ROCK inhibitor at 
the mesoderm enrichment phase is the key stage for the anabolic effect on 
cartilage (-/- vs +/-) (Fig. 4.7B).   
On the other hand, the exposure to ROCK inhibitor at the differentiation phase 
proved to be the key stage for the anabolic effect on bone (-/- vs -/+) (Fig. 6.5).  
Furthermore, the long-term exposure to ROCK inhibitor further enhanced the 
differentiation of both cartilage and bone (+/+) compared to temporal ROCK 
inhibition (-/+) and basal condition (-/-) (Fig. 4.7, 5.2, and 6.11), respectively, 
evident by the increase in the percentage of Alcian blue or ALP positive nodule 
area and gene expression analysis.  Taken together, these results established 
that the effect of ROCK inhibition on chondrogenic and osteogenic 
differentiation is a phase-specific dependent effect (Fig. 8.2).  
8.2.1 Short-term exposure to ROCK inhibitor 
 
In the context of chondrogenic differentiation, findings in chapter 4 demonstrate 
that Y27632 pre-treatment in phase II (-/- vs +/-) (Fig. 4.3), stimulates a 3-fold 
increase in the percentage of Alcian blue positive nodule and upregulates 
cartilage-specific gene markers expression at 14d of differentiation, suggesting 
the positive influence of inhibiting ROCK signalling on cartilage differentiation.   
These stimulatory results of ROCK inhibition agree with previous studies 
conducted on primary cell cultures and ATDC5 cell lines (Wang et al. 2004; 
Woods et al. 2005; Tew & Hardingham 2006).  On the contrary, the change in 
cell culture model i.e. micromass cultures showed a negative response to 
ROCK inhibition (Woods & Beier 2006), which may indicate that the 
developmental stage of cell differentiation as well as the culture model may 
influence the response of cells to ROCK signalling.  
 
In the context of osteogenic differentiation, findings in chapter 6, demonstrate 
that Y27632 pre-treatment in phase II (-/- vs +/-) (Fig. 6.3 and 6.5), inhibits 
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osteogenic differentiation evident by a significant decrease in the percentage of 
ALP positive nodule area and bone-specific gene markers expression.  Several 
studies have suggested that the developmental state of the cells does influence 
the response to ROCK inhibition (McBeath et al. 2004; Arnsdorf et al. 2009).  
McBeath et al. (2004) reported that ROCK inhibition via Y27632 and 
constitutively active ROCK overexpression in cells decreased osteogenic 
differentiation in hMSCs cultures.  Similarly, Arnsdorf et al. (2009) showed 
similar results in murine C3H10T1/2 cultures upon treatment with Y27632.  
These results have led to the question of whether cells at the differentiation 
phase III (7-21d) could be at a MSC–like state.  
Indeed, it would be interesting to further investigate the expression of the 
standard MSC surface markers in ESC-derived cells, and investigate the 
potential of the cells to differentiate into other cell types of mesodermal/MSC 
origin, such as adipocytes or myocytes (Kopher et al. 2010; Harkness et al. 
2011; Mahmood et al. 2012).  Moreover, further characterisation of the 
generated cell population is also necessary as investigating the kinetics of 
osteogenic gene marker expression and measuring ALP activity during the 
differentiation process would allow for further confirmation of the inhibitory effect 
of ROCK inhibition on osteogenesis at the differentiation phase.   
Taken together, the findings suggest that ROCK inhibition at the mesoderm 
enrichment phase is key in positively regulating chondrogenesis while 
negatively regulating osteogenesis at the molecular and cellular levels. Further 
analysis of the kinetics of gene expression at different time points during the 
differentiation phase (phase III) will be beneficial to investigate further and 
understand the effect of ROCK in a dynamic manner.  




Long-term ROCK inhibition (-/+ vs +/+) (Fig. 4.5 and 4.7) enriched chondrogenic 
differentiation as observed by a 7.2-fold increase in Alcian blue positive nodule 
areas as well as promoting hypertrophic chondrocyte differentiation as 
evidenced by cell morphology and Col X expression.  Interestingly, further 
manipulation of the culture conditions by culturing cells in temporal FGF2 
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demonstrated to act synergistically with ROCK inhibition and further 
enhancement of the hypertrophic phenotype (Fig. 5.2 and 5.3).   
Additionally, it was demonstrated for the first time that ROCK inhibition 
enhances non-hypertrophic chondrocyte differentiation in short-term cultures 
when implementing GDF5 instead of BMP4 signalling.  The effect of GDF5 on 
ESC–derived mesoderm chondrocyte differentiation have been proposed by 
Craft et al. (2013) where the switch between BMP and GDF5 signalling 
influenced the in vitro differentiation of chondrocyte to either hypertrophic or 
non-hypertrophic phenotype.  Therefore, ROCK signalling may play an 
important role in mesoderm specification towards hypertrophic and non-
hypertrophic chondrocytes and this has implications for generating stable 
articular cartilage for potential osteoarthritis applications.  To this end, I have 
been involved in preliminary studies that are show marked differences in the 
ability of BMP4- and GDF5-stimulated chondrocytes to differentiate in vitro in 
specific hydrogel formulations (Toh et al. 2009) (Kania, Bukhary, Grigoriadis). 
8.2.4 Osteogenesis 
 
Findings in chapter 4, 5 and 6, strongly suggest that long-term ROCK inhibition 
(-/+ vs +/+) manipulation increases osteogenic differentiation by 1.4-fold. 
Compared to temporal ROCK inhibition and basal conditions, respectively. In 
addition, it directs the maturation of chondrocytes (Fig. 5.2 and 5.3) and 
osteoblasts (Fig. 6.11), possibly mimicking endochondral ossification.  The 
ability of the osteoblasts to mature further and attain full mineralisation in vitro 
was demonstrated in chapter 6, part B.  This is the first evidence showing 
osteogenic differentiation and maturation from ESC-derived mesoderm using 
this novel 3-phase, serum-free ESC/EB differentiation system used in this 
project. A preliminary experiment was conducted to investigate the potential of 
osteoblasts to reach to functional osteoblasts i.e. mineralisation.  The findings 
described in chapter 6, part B (Fig. 6.11), demonstrate that ROCK inhibition in 
the mesoderm enrichment phase (phase II) enhances the production of 
mineralized matrix of osteoblasts evident by ALP and von Kossa staining. This 
was demonstrated after modification of the culture conditions by culturing cells 
in temporal FGF2 and prolonged culturing followed by replating differentiated 
cells (21d cells).   Therefore, these findings suggest that ROCK inhibition, 
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specifically in the mesoderm enrichment phase (phase II: 4-7d), is the driving 
force for osteoblast mineralisation. 
In the context of osteogenic differentiation, I have performed preliminary 
experiments showing that ESCs cultured in osteogenic media could attach and 
differentiate on osteoconductive hydroxyapatite scaffolds (Daculsi et al. 2013) 
(data not shown). The findings suggested that application of ESC-derived 
osteogenic progenitors could be influential for the future application in bone 
regeneration or repair of bone defects.  The utilisation of different biomaterials 
have been broadly investigated by others in the context of ESC-derived 
chondrogenic and/or osteogenic progenitor cells, in order to direct cell 
differentiation for tissue regeneration and the generation of functional tissue in 
vivo using mESC, hESCs and iPSCs (Hwang et al. 2008; Scott et al. 2012; 
Craft et al. 2013; de Peppo et al. 2013; Teng 2013). However, by using the 
ROCK inhibitor it could provide additional mechanistic insights into whether 














General discussion and future work   











Figure 8.2: A summary of phase-specific effect of ROCK signalling inhibition via 
Y27632 (Y) differentially regulates chondrogenic and osteogenic differentiation 
of ESC-derived mesoderm during the monolayer differentiation phase (phase 
III) 
At the monolayer differentiation phase (phase III), the exposure to the ROCK 
inhibitor either in a short-term exposure (+/-) and (-/+) or a long-term exposure 
(+/+) modulates the differentiation of a putative chondro-osteoprogenitor 
population as marked by quantification of Alcian blue for chondrocytes (c) and 
ALP for osteoblasts (b), and lineage-specific marker expression.  (A) Basal 
conditions (-/-) were shown to differentiate ESC-derived mesoderm to both 
lineages. (B) Short-term exposure to Y27632 at phase II (+/-) showed 
preferential differentiation towards chondrogenic over the osteogenic lineage, 
while (C) short-term exposure to Y27632 at phase III (-/+) showed a preferential 
differentiation towards osteogenic over the chondrogenic lineage (-/+).  (D) 
Long-term exposure to Y27632 at phases II and III (+/+) showed differentiation 
to both lineages, however, long-term exposure to ROCK inhibition directed the 
differentiation towards hypertrophic chondrocytes (data in figure 4.7, 5.2, and 
5.3) and mineralised osteoblast differentiation (data in figure. 6.11). Diagram 
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8.3 In vivo potential of ESC-derived chondrocytes and osteoblasts 
 
In chapter 7, the in vivo potential of the differentiated cells confirmed the 
endochondral ossification potential of the differentiated cells in vitro (Fig. 7.2).   
The implanted differentiated cells from a 21d culture underwent a chondrogenic 
phase of differentiation in the first week of transplantation, which was replaced 
completely by bone tissue after an additional 2 weeks in vivo.  The bone 
formation potential seemed to be enhanced by ROCK inhibition, however, this 
needs further confirmation on a larger number of samples and quantification 
analysis of bone tissue.  In addition, investigating the in vivo potential of cells 
derived from the other temporal ROCK inhibited cultures (i.e +/-) would be 
interesting to further analyse whether the differentiated cells would undergo 
similar differentiation to those tested in chapter 7 (i.e. -/+ and +/+).  
The evidence on whether ectopic bone formation originates from the graft itself 
will require further analysis.  One approach could be by the use of female SCID 
mice as hosts, and investigate the presence of the Y-chromosome marker since 
the CCE cell line is derived from male embryos.  Alternatively, the advancement 
in the use of reporter ESC lines specifically for cartilage or bone lineages would 
provide genetic labeling for better tracing cell lineages.  Such an approach 
would be beneficial to analyse the effects of ROCK inhibition, for example, to 
investigate whether the temporal inhibition of ROCK during the mesoderm 
enrichment phase (+/-) would give rise to progenitors that have either 
endochondral ossification or stable articular cartilage potentials. 
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8.4 Conclusion and future work  
 
For the mesoderm enrichment phase, accessing intermediate populations of 
chondrocyte and osteoblast precursors by using the ROCK inhibitor (Y27632) in 
the novel 3 phase, ESC/EB differentiation culture model, will permit for further 
understanding of the molecular mechanisms regulating cartilage and bone 
differentiation and the downstream events regulated by ROCK signalling.  
Furthermore, analysis by quantification of the percentage of progenitors 
expressing cartilage and bone specific markers such as Sox9 and Runx2 by 
flow cytometry, or using specific ESCs with GFP knocked into specific 
transcription factor loci will provide further data on the efficiency of the 
differentiation protocol and investigate whether ROCK influences this process.  
Moreover, further analysis of the kinetics of cartilage and bone markers gene 
expression at different time points during the mesoderm enrichment phase 
(phase II: 4-7d) would be helpful in understanding the maturity stage of the cells 
before differentiating them in phase III as well as the downstream signalling 
factors controlling cartilage and bone differentiation.  In this regard, we have 
begun to identify ROCK inhibitor-dependent global changes in gene expression 
through microarray analysis during this important mesoderm enrichment phase, 
and it will be interesting to identify novel pathways that might contribute to 
establishing the chondrogenic and osteogenic lineages. 
Whereas in the differentiation phase, through the phase-specific manipulation of 
ROCK signalling pathways it was possible to generate distinct populations of 
ESC-derived chondrocytes and osteoblasts at different developmental stages. 
In addition further manipulation of other signalling pathways such as FGF2 and 
BMP signalling allowed for the generation of growth plate-like cells or articular 
cartilage-like cells in vitro. Ultimately, this will provide insights into further 
understanding and characterisation of embryonic development of both 
mesoderm cartilage and bone progenitors, in particular in response to ROCK 
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In the last few years, several studies have demonstrated that Rho GTPase 
siganlling, including ROCK signalling, can affect cell differentiation through the 
interaction with the cell cytoskeleton, ECM (i.e. in detecting matrix stiffness) and 
cell shape (Shih et al. 2011; Mih et al. 2012).  In addition, ROCK inhibitors, 
specifically Y27632, are now routinely implemented for culturing hESC cultures 
(Claassen et al. 2009; Cortes et al. 2009; Gauthaman et al. 2010; Lai et al. 
2010; Watanabe et al. 2007).  However, the exact mechanisms of ROCK 
inhibitor-dependent effects, in particular on cartilage and bone differentiation is 
not clear and further investigation is necessary to shed light on the downstream 
signalling pathways or regulatory genes that are responsive to ROCK signalling.  
Ultimately, these will identify novel pathways that might contribute to regulating 
chondrogenic and osteogenic lineages, especially at the early developmental 
stages represented by the novel ESC differentiation model system used in this 
project.  
The translation of this novel ESC differentiation model system from mouse 
ESCs to human ESCs or iPSC model systems would be an essential next step 
for this research.  The advantage being is the accessibility it offers to progenitor 
cells, either chondrogenic or osteogenic, specifically through ROCK signalling 
manipulation may provide the generation of distinctive chondrogenic and/or 
osteogenic progenitors for tissue replacement therapy, for the treatment of bone 
and/or cartilage defects such as osteoporosis and osteoarthritis.  Therefore, 
provide a biological means for further understanding the mechanisms of 
cartilage and bone development in healthy and diseased cells using a cell-
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